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Tuberculosis
Tuberculosis (TB) is as old as mankind but still far from defeated. Typical tuberculosis 
decay was already found in the spines of well preserved Egyptian mummies [1]. 
Currently, about four millennia later, still about 1,6 million people are killed by this 
infectious disease yearly [2]. Although effective antituberculosis treatment has 
been available throughout the world for over half a century, the impact of treatment, 
particularly in the developing world, has been much less than might have been 
expected [3]. Therefore, it is anticipated that TB will remain a major public health 
problem for the years to come. New strategies to strengthen the fight against this 
old disease are warranted. 
Etiology, transmission and  pathogenesis
The main causative organism of tuberculosis, Mycobacterium	tuberculosis, was only 
discovered in 1882. It usually attacks the lungs but it can also affect the central 
nervous system, the lymphatic system, the spine and other organs. In pulmonary 
tuberculosis, cavities filled with white necrotic material may appear. During active 
disease, some of these cavities are joined to the air passages of bronchi and the necrotic 
material, which contains living bacteria, can be coughed up. Therefore, pulmonary 
TB patients can infect other persons with the tuberculosis bacterium by expelling 
infectious aerosol droplets while coughing, sneezing or talking. Extrapulmonary TB is 
not contagious, but may co-exist with contagious pulmonary TB. 
In most patients, infection with M.	 tuberculosis results in asymptomatic latent TB 
infection (LTBI), which should be discerned from the disease	 tuberculosis. However, 
LTBI can lead to the active disease tuberculosis. Approximately ten percent of the 
healthy people infected with M.	 tuberculosis will eventually develop TB [4, 5]. The 
risk of developing TB appears to disappear exponentially during the first few years 
after infection [6]. The most important factor that determines whether infection will 
progress to disease, is the adequacy of the host’s immune response to the presence 
of M.	 tuberculosis. The presence of diseases such as diabetes, malignancies and, 
of course, human immunodeficiency virus (HIV), is therefore associated with the 
development of the disease tuberculosis [6]. Tuberculosis is a poverty related infectious 
disease: its morbidity and mortality are strengthened by poverty, malnutrition and 
overpopulation. 
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Symptomology and diagnostics 
When latent tuberculosis infection develops to active TB, it mostly concerns cases of 
pulmonary TB. Symptoms of active TB include chest pain, coughing up blood, and a 
productive, prolonged cough for more than three weeks. Systemic symptoms include 
fever, chills, night sweats, appetite loss, weight loss, pallor and often a tendency to 
fatigue very easily [4].
People who are (latently) infected with the tuberculosis bacteria show a positive 
response to the tuberculin skin test. Whenever clinical symptoms are present as well, 
radiographic or pathological tests and microscopic examination of acid-fast bacilli 
sputum smears (or other material) and, preferably, cultures [7, 8] will be performed in 
order to exclude or diagnose tuberculosis. 
Epidemiology
One third of the world population is latently infected with M.	tuberculosis. Throughout 
the world, an estimated 8,8 million new cases of TB are identified and approximately 
1,6 million people die from TB each year [2]. The synergy between TB and HIV worsens 
the situation dramatically, especially in Sub Saharan Africa. Available data indicate 
that this deadly combination is increasing in South-East Asia as well [5]. India, China, 
and Indonesia accommodate the highest numbers of TB cases worldwide [2]. 
Antituberculosis treatment
Until the forties of the last century, there was no medication effective against 
tuberculosis in humans. Patients were prescribed rest and fresh air [9]. The first 
antituberculosis drugs, streptomycin (SM) and para-aminosalicylic acid (PAS) were 
discovered in 1944 [8]. These drugs were first given separately. Later, it was observed 
that resistance was clearly reduced when these drugs were combined instead of given 
as monotherapy [6]. In the fifties, triple therapy with isoniazid (INH), PAS and SM was 
used in the so-called initial phase (see below) for 3-6 months and INH and PAS had 
to be continued for 24 months in the continuation phase,  resulting in satisfying and 
predictable cures [8, 10]. 
Finally, after substituting ethambutol for PAS and adding rifampicin and pyrazinamide, 
the treatment duration was shortened to six months in the eighties [8, 10]. Since 
1993, standard antituberculosis treatment consists of an intensive phase with daily 
introduction
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rifampicin, isoniazid, pyrazinamide and ethambutol of two months, followed by a 
four-month continuation phase consisting of rifampicin and isoniazid, either daily or 
intermittent (Table 1) [7, 11], although some guidelines may be slightly different.  
In the initial intensive phase, all actively dividing bacteria should be killed as soon 
as possible. Isoniazid causes the highest early reduction in causative organisms. 
The continuation phase is designed to eradicate the ‘persisters’, presumably slower 
replicating bacteria. Rifampicin has the unique properties of both early bactericidal 
effect against M.	tuberculosis and ‘sterilizing’ effect: the ability to kill M.	tuberculosis 
intracellularly and in the persistor phase. Therefore, it is used in both phases and 
considered as the cornerstone of TB treatment. Ethambutol may be discontinued when 
results of drug susceptibility testing indicate no drug resistance. In general, more than 
90% of treatment for drug-susceptible TB will respond completely to treatment [12]. 
In order to prevent non-adherence and treatment drop-outs, the World Health 
Organization introduced their Direct Observed Therapy (DOT) strategy in the early 
nineties [13]. One of the crucial components of this strategy is the direct observation 
by trained personnel of patients taking their medications to ensure adherence. 
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Table 1  Standard anti tuberculosis therapy [7, 11].
Intensive phase 1a  Continuation phase 2b
Drug Dose Drug Dosing interval
Rifampicin BW c < 50 kg:  Rifampicin Daily or
 450 mg daily  intermittent
 BW > 50 kg: 
 600 mg daily    
Isoniazid  300 mg daily Isoniazid Daily or 
   intermittent
Pyrazinamide 20-25 mg/kg daily 
Ethambutol 15-20 mg/kg daily 
a The duration of the intensive phase is two months
b The duration of the continuation phase is four months
c BW: Body weight
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Problems in tuberculosis treatment 
Currently, five main problems concerning the treatment of active tuberculosis can be 
defined: 
The long duration of current antituberculosis treatment1. 
Suboptimal effectiveness of current antituberculosis treatment 2. 
The emergence of multidrug resistant tuberculosis  3. 
A high incidence of adverse events to antituberculosis treatment;4. 
Combined treatment of TB and HIV infection.5. 
These problems are not independent, but are interrelated. 
The urgency for improved treatment of TB is driven by the fact that globally TB is not 
being controlled effectively with presently available treatment, particularly in parts of 
the world with limited health infrastructure, high HIV incidence, or both [14]. 
Within the scope of this dissertation, three problems with respect to treatment of active 
TB are addressed: the long duration of current TB treatment; suboptimal effectiveness 
of current antituberculosis treatment; and combined treatment of TB and HIV. 	
Long treatment duration
The treatment of tuberculosis is long and since multiple drugs are needed, treatment 
is complex. Therefore, TB treatment invites problems of non-adherence. The World 
Health Organization (WHO) has introduced the concept of directly observed therapy 
(DOT), but the results of randomized controlled trials provide no assurance that DOT 
compared with self administration of treatment has any quantitatively important 
effect on cure or treatment completion in people receiving treatment for tuberculosis 
[15]. In addition, few studies have assessed the ability of the larger DOTS approach to 
result in lasting cure for patients treated under routine programmatic conditions [16]. 
Hence, research efforts are now focusing on shortening the duration of TB treatment. 
This would have an extraordinary impact on TB patients and public health systems, 
rendering treatment adherence and DOTS much easier, possibly improving the 
efficacy of treatment in clinical practice, and reducing the selection of drug-resistant 
strains of M.	tuberculosis. 
A possible way to achieve the goal of shortened treatment, would be to improve 
the dosing of existing drugs, such as rifampicin. Rifampicin is the cornerstone of TB 
introduction
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treatment, it is available all over the world, there is a lot of experience with the drug 
and it is relatively cheap. Increasing the dosage of rifampicin seems promising. Early 
bactericidal activity studies in TB patients [17] and studies in the mouse model [18] 
suggest that the regular dose (10 mg/ kg body weight) of rifampicin is rather low. A 
modest increase in the dose of rifampicin from 10 to 15 mg/kg, could possibly reduce 
the duration of treatment by one-third [18]. 
An alternative approach to shortening treatment would be by utilizing new drugs. 
New anti TB agents capable of shortening TB treatment have raised much attention 
for that reason. Moxifloxacin is a promising agent since it has shown to be able to 
shorten TB treatment with two months when substituted for isoniazid in the murine 
model [19, 20]. The Global Alliance for TB Drug Development has stressed that new 
drugs for TB should be compatible with existing TB drugs, notably rifampicin. 
Suboptimal efficacy of tuberculosis treatment
With regard to the second problem, suboptimal efficacy of current antituberculosis 
treatment, it should be mentioned that certain subgroups of patients are more at risk 
to ineffective treatment than others. This may lead to delayed sputum conversion, 
treatment failures and relapses and continued spread of the disease. For example, 
type 2 diabetes is a strong risk factor for tuberculosis and is associated with a slower 
response to TB treatment and a higher mortality [21-24]. Furthermore, patients who are 
admitted to the hospital for reasons of severe or complex disease status, simultaneous 
treatment of co-morbidities and/or drug resistance may experience suboptimal 
efficacy as well. Inadequate exposure to TB drugs might be particularly relevant to 
these patients.  
Combined treatment of TB-HIV co-infection
The third problem concerns the treatment of TB-HIV treatment, which is complicated 
by the deadly synergy between the two diseases, immune reconstitution inflammatory 
syndrome (IRIS),  paradoxical reactions and overlapping toxicity profiles of antiretroviral 
(ARV) treatment and TB drugs. Tuberculosis treatment in HIV-positive patients is 
further complicated by drug-drug interactions between key TB drugs, especially 
rifampicin, and some of the antiretroviral agents [25]. Rifampicin is a strong inducer 
of cytochrome P450 enzymes and transporter proteins and therefore significant drug 
interactions between rifampicin and non nucleoside reverse transcriptase inhibitors 
(NNRTIs) and protease inhibitors are to be expected in TB-HIV treatment [26-32]. 
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Efavirenz-based antiretroviral therapy is recommended in TB-HIV treatment [33]. 
However, in cases of NNRTI-resistant HIV or impossibility to use this class of drugs, a 
second line ARV treatment is warranted and protease inhibitors are most appropriate 
for this purpose.
  
In summary, there are five main problems concerning the treatment of TB which 
should be addressed as soon as possible. These problems do not only have scientific, 
but also very strong social implications all over the world. This dissertation focuses 
on and contributes to at least three out of five of the main problems of current TB 
treatment. 
Objective of this dissertation 
The overall objective of the studies in this dissertation is to contribute to the 
optimization of TB drug treatment, more specifically to optimize the dose of TB drugs. 
The central principle underlying the studies in this dissertation is that adequate 
plasma drug concentrations are pivotal for a good treatment response and play a 
central role in optimizing TB treatment. 
Outline of the dissertation
Shortening TB treatment may be accomplished by increasing the dose of one of 
the cornerstones of TB treatment, rifampicin. Chapters 1 and 2 investigate the 
pharmacokinetics and pharmacodynamics (including adverse events) of a higher dose 
(13 mg/kg body weight) of rifampicin in Indonesian pulmonary TB patients. A shorter 
TB treatment may also be achieved by using the new promising drug moxifloxacin and 
combining it with rifampicin. Chapter 3  investigates the pharmacokinetic interaction 
between moxifloxacin and rifampicin in Indonesian TB patients. 
Certain patient groups show suboptimal efficacy to tuberculosis treatment. Some of 
them are admitted to a tertiary tuberculosis referral centre. Chapter 4 describes the 
pharmacokinetics of TB patients admitted to the two tertiary referral centers in The 
Netherlands. This group of patients consists of vulnerable patients who are prone to a 
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problematic course of TB treatment. In this population, optimal exposure to TB drugs 
might even be more critical. Chapter 5 focuses on another patient subgroup, TB patients 
who also have type 2 diabetes. In this chapter we compared the pharmacokinetics of 
the pivotal TB drug rifampicin in Indonesian TB patients with and without diabetes 
type 2. Diabetes seems to be associated with a less favorable response to TB treatment. 
Altered pharmacokinetics of antituberculosis drugs might explain the adverse effect 
of diabetes on the response to tuberculosis treatment. 
Chapter 6 and 7 focus on drug-drug interactions in TB-HIV co-infected patients. We 
aimed to evaluate the pharmacokinetics of two adjusted dose regimens of the newly 
introduced lopinavir/ritonavir tablets in healthy volunteers (Chapter 6). In Chapter 
7 we evaluated the clinical experience with the combined use of lopinavir/ritonavir 
and rifampicin in the Netherlands, with regard to lopinavir/ritonavir dose, lopinavir 
plasma trough concentrations, viral load and tolerability.
Finally, the results of these studies will be put into perspective in the General 
discussion.
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Part I
Pharmacokinetic contributions 
to shortening tuberculosis treatment
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Chapter 1
Evaluation of high versus standard 
dose rifampicin in Indonesian patients 
with pulmonary tuberculosis
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We previously found peak plasma concentrations of rifampicin below 4 mg/L in 
70% of Indonesian tuberculosis (TB) patients treated with 10 mg/kg rifampicin 
daily [1], much below the reference concentration of ≥ 8 mg/L [2]. In addition, 
both murine models [3] and studies in TB patients [4] suggest that the typical 
10 mg/kg dose of rifampicin may be too low and that a higher dose may reduce 
treatment duration [5]. Indeed a regimen incorporating a higher dose of 1200 
mg rifampicin daily yielded much more rapid conversion of sputum culture [6]. 
Based on these findings, we decided to investigate the effect of increasing the 
dose of rifampicin in terms of pharmacokinetics and tolerability. 
In an open-label randomized clinical trial in an urban clinic in Indonesia, 
consecutive patients with microbiologically proven pulmonary TB were 
randomized to a standard (450 mg, 10 mg/kg) or high (600 mg) dose of 
rifampicin. High and standard doses of rifampicin were administered every 
day in the intensive phase and three times weekly in the continuation phase of 
treatment. All other TB drugs were dosed according to the Indonesian National 
TB Program. All patients provided written informed consent and the study 
was approved by the local institutional review board. After 4 and 8 weeks of 
treatment, blood samples were collected two hours after witnessed intake of 
TB drugs on an empty stomach. Plasma was separated immediately and stored 
at -80°C until measurement of rifampicin concentrations with a validated high 
performance liquid chromatographic (HPLC) assay. Patients were questioned 
actively for possible adverse events and liver transaminases were monitored. 
The simultaneous effects of the dose of rifampicin and the week of treatment on 
the rifampicin peak plasma concentrations were evaluated with an analysis of 
variance (ANOVA).
Fifty patients were included and 46 completed the study (54% male; 
median age 25; range 18 - 50). Patients from both groups had a similar 
body weight, and the median dose of rifampicin corresponded to 13.3 mg/
kg in the 600 mg group and 10.3 mg/kg in the 450 mg group. The mean peak 
plasma concentration of rifampicin was higher in the 600 mg group (11.1 
vs 8.0 mg/L, F = 8.77, p = 0.005). The percentage of patients with rifampicin 
peak plasma concentrations ≥ 8 mg/L was 78% vs. 48% (Figure; χ 2, p=0.03). 
Mean plasma concentrations were similar in weeks 4 and 8 (9.3 mg/L and 9.9 
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mg/L, F = 0.64, p = 0.43). One patient receiving 600 mg developed reversible 
elevation of liver transaminases > 5 times normal, while four patients (two in 
each study arm) showed mild elevation transaminases. No differences were 
noted in terms of tolerability. 
In conclusion, this trial in Indonesia shows that a higher dose of rifampicin 
significantly increases the proportion of patients with rifampicin peak plasma 
concentrations above the reference value of 8 mg/L. Blinded studies with more 
extensive pharmacokinetic assessments will provide more insight in the merits 
of high-dose rifampicin and may pave the road for studies evaluating high dose 
rifampicin in shorther treatment regimens. 
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Figure
Two-hour plasma rifampicin concentrations after 4 weeks of TB treatment in  Indonesian
patients randomized to standard-dose (450 mg) or high-dose (600 mg) rifampicin daily, 
combined with standard dose INH, pyrazinamid and ethambutol. Depicted are data for 
individual patients (bullets) and means for both groups (horizontal bars).
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Abstract
Introduction: Rifampicin is a key drug for tuberculosis treatment. Available data 
suggest that the currently applied 10 mg/kg dose of rifampicin may be too low, and 
that increasing the dose may shorten the treatment duration. 
Methods: A double-blind randomized phase II clinical trial was performed to 
investigate the effect of a higher dose of rifampicin in terms of pharmacokinetics and 
tolerability. Fifty newly diagnosed adult Indonesian TB patients were randomized 
to receive a standard (450 mg; i.e. 10 mg/kg in Indonesian patients) or higher (600 
mg) dose of rifampicin besides other TB drugs. A full pharmacokinetic curve for 
rifampicin, pyrazinamide and ethambutol was recorded after 6 weeks of daily TB 
treatment. Tolerability was assessed during the 6-month treatment period. 
Results: Geometric means of exposure to rifampicin (AUC0-24) were increased by 
65% (p<0.001) in the higher-dose group (79.7 mg.h/L) compared to the standard-dose 
group (48.5 mg.h/L). Maximum rifampicin concentrations (Cmax) were 15.6 mg/L vs. 
10.5 mg/L (49% increase, p<0.001). The percentage of patients with rifampicin Cmax 
≥ 8 mg/L was 96% vs. 79%, p=0.094. The pharmacokinetics of pyrazinamide and 
ethambutol were similar in both groups. Mild (grade I or II) hepatotoxicity was more 
common in the higher-dose group (46 vs. 20%, p=0.054), but no patient developed 
severe hepatotoxicity. 
Conclusion: Increasing the rifampicin dose is associated with a more than dose-
proportional increase in the mean AUC0-24 and Cmax of rifampicin without affecting 
the incidence of serious adverse effects. Follow-up studies are warranted to assess 
whether high dose rifampicin may enable shortening of TB treatment. 
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Introduction
Each year eight million persons develop active tuberculosis (TB) and 2 to 3 million 
people die from this infectious disease. The treatment of TB is complicated by the 
length and complexicity of currently available drug regimens, which invites problems 
of nonadherence, inadequate response and resistance development. Therefore, 
a long-term goal for TB control has been to shorten the duration of treatment. This 
may possibly be achieved by increasing the dose of the pivotal TB drug rifampicin, 
considering that early bactericidal activity studies in TB patients [1] and recent work 
in the mouse model [2] suggest that the typical 10 mg/kg dose of rifampicin is rather 
low. A 50% increase in the rifampicin dose may reduce the duration of treatment by 
one-third [2]. Apart from these studies, we and others have found low two-hour (peak) 
plasma concentrations of rifampicin in TB patients treated with 10 mg/kg rifampicin 
daily [3-5] which also suggests that a higher dose of rifampicin merits further study. 
So far, only few clinical data have been available with regard to the pharmacokinetics, 
tolerability and effectiveness of drug regimens based on a higher dose of rifampicin 
[6, 7]. Hence we performed a pilot study in Indonesian patients, in which we compared 
a higher (600 mg) and the standard dose (450 mg or 10 mg/kg, considering the body 
weight of Indonesian people) of rifampicin. It appeared that 78% of patients in the 
higher-dose arm versus 48% of those in the standard-dose arm achieved a rifampicin 
peak (two-hour) plasma concentration above a reference value of 8 mg/L [8]. As the 
pilot study evaluated only a single time point in the rifampicin pharmacokinetic 
curve and was non-blinded, we decided to conduct a double-blind randomized 
clinical trial with intensive pharmacokinetic sampling to compare the steady-state 
pharmacokinetics and tolerability of a higher and the standard dose of rifampicin. 
Materials and methods
Subjects
The study was conducted in an urban outpatient tuberculosis clinic in Bandung, 
Indonesia. Study subjects were patients with newly diagnosed, untreated 
pulmonary tuberculosis. The diagnosis of pulmonary tuberculosis was based 
on clinical symptoms and chest X-ray examination, confirmed by microscopic 
detection of acid-fast bacilli.	Patients were excluded if they were below 18 years of 
pharmacokinetics and tolerability of a higher rifampin dose
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age, had a body weight less than 33 kg, were pregnant or lactating, had a history of 
liver or kidney disease or any other disease that might affect the pharmacokinetics 
of TB drugs, or if they had been treated for tuberculosis previously. HIV status was 
assessed anonymously at the end of the study. Informed consent was obtained from 
all subjects and the study was approved by the Independent Ethics Committee, 
Faculty of Medicine, University of Padjadjaran, Bandung, Indonesia and by the 
Ethical Review Board Region Arnhem/Nijmegen, The Netherlands.
Study design
This was a double-blind, randomized, two-arm, phase II clinical trial. Eligible 
patients were randomized to a standard dose (450 mg, corresponding to 10 mg/kg in 
Indonesian people) or a higher dose (600 mg) of rifampicin besides other TB drugs. 
In accordance with the Indonesian National TB Program, TB treatment consisted of 
daily isoniazide 300 mg, rifampicin (higher or standard dose), pyrazinamide 1500 
mg, and ethambutol 750 mg for two months, followed by isoniazid 600 mg and 
rifampicin (higher- or standard-dose) three times weekly for four months [9]. All 
patients received TB drugs from the same manufacturer, formulated in separate 
tablets. Bioequivalence of the rifampicin tablets and an international reference 
standard has been established before [10].
Double blinding for the dose of rifampicin was accomplished by inserting rifampicin 
tablets of 450 mg and 600 mg into blank capsule shells with the same colour and size. 
Five capsules were sealed into an aluminium blister. The encapsulation and sealing 
of tablets was performed by the manufacturer of the drugs. Information about the 
randomization of the participants was not available to anyone involved in the study 
until it was completed.  
A full pharmacokinetic curve was recorded at steady state after six weeks of 
treatment. Patients were followed every other week during the intensive phase 
and once-monthly thereafter for evaluation of possible adverse events as well as 
microbiological tests (sputum microscopy and culture).
Based on available data from the previous pilot study [8], it was estimated that at 
least 24 participants were required in each arm to be able to demonstrate a change 
(two-sided test) of at least 40% in the peak plasma concentration of rifampicin at a 
5% significance level and with 80% statistical power. The study was not powered to 
detect differences in bacteriological outcome. 
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Pharmacokinetic assessment
Patients refrained from the intake of any food or any drugs (other than the study 
medication) from 11 p.m. on the day preceding the pharmacokinetic assessment 
until four hours after the intake of study medication. They took all antituberculosis 
drugs with 230 ml of still water. Serial venous blood samples were collected just 
prior to, and 1, 1.5, 2, 2.5, 3, 4, 6 and 12 hours after witnessed drug intake. Plasma was 
immediately separated and frozen at -20°C, transferred to -80°C within 72 h and 
transported on dry ice to the Netherlands for bioanalysis. 
Bioanalysis
The plasma concentrations of rifampicin, desacetylrifampicin, pyrazinamide and 
ethambutol were assessed with validated high performance liquid chromatographic 
(HPLC) methods. Concentrations of isoniazid were not assessed, as undue degradation 
of this unstable drug was anticipated during storage and transport. 
Rifampicin and desacetylrifampicin were measured with protein precipitation 
followed by HPLC with ultraviolet (UV) detection.  Hundred microliters of acetonitrile 
and 10 µL ascorbic acid solution (20 mg/ml) were added to 200 µL of plasma sample. 
The mixture was vortexed for 20 sec and centrifuged for five minutes. Then 200 µL of 10 
mM potassium dihydrogen phosphate buffer was added and the mixture was vortexed 
and centrifuged again. One hundred microliters of the clear supernatant was injected 
in the HPLC system, which consisted of an Omnispher 5 C18 column (250 by 4.6 mm, 
Varian, Middelburg, The Netherlands) protected with a Chromguard RP guard column 
(10 by 3 mm, Varian, Middelburg, the Netherlands). The mobile phase consisted of 10 
mM potassium dihydrogen phosphate (pH 4.5) and acetonitrile (62:38 % v/v). The flow 
rate was set at 1 ml/min and the wavelength for UV detection was 334 nm. Accuracy for 
standard concentrations was between 99.8% and 100.4% for rifampicin and between 
102.4 and 103.9% for desacetylrifampicin, dependent on the concentration level. 
The intra- and inter-assay coefficients of variation were less than 4% over the ranges 
of 0.28-30 mg/L and 0.15-3 mg/L for rifampicin and desacetylrifampicin, respectively. 
Lower limits of quantitation were 0.28 and 0.15 mg/L respectively. Rifampicin containing 
plasma samples were stable (< 5% loss) for at least 16 months at -20°C and -80°C.   
Total plasma concentrations of pyrazinamide were measured by solid phase 
extraction followed by HPLC-UV. Briefly, Waters Oasis HLB 1 cc 30 mg extraction 
pharmacokinetics and tolerability of a higher rifampin dose
2
Nijland.1046-Proefschrift.indd   35 07-04-2009   15:39:49
36
cartridges were washed sequentially with methanol and HPLC-grade water. A half 
ml of plasma sample and 0.5 ml of water were drawn slowly onto the column and 
allowed to stand. The column was washed with water and elution was performed 
with methanol. The eluate was dried and after addition of 10 mM phosphate buffer 
pH 6.0/methanol (95/5% v/v), vortexing and centrifugation, the clear supernatant 
was injected into the HPLC apparatus. Chromatographic analysis was performed on 
an Atlantis dC18 column (150 by 4.6 mm, Waters). The mobile phase consisted of 10 
mM phosphate buffer pH 6.0 / acetonitrile (99/1% v/v) (fluid A) and acetonitril (fluid 
B), in which the percentage of acetonitril (fluid B) was changed linearly as follows: 
0 min, 0%; 11.5 min, 0 %; 12 min, 45 %;  17 min, 45%; 17.5 min, 0% and 25 min, 0%. 
The flow rate was set at 1.3 ml/min and the wavelength for UV detection was 266 
nm. The accuracy for standard concentrations was between 96.0% and 109.2%, 
intra- and inter-assay coefficients of variation were less than 10% over the range of 
0.1 to 66.8 mg/L and the lower limit of quantitation was 0.1 mg/L. Plasma samples 
with pyrazinamide were stable (< 5% loss) for at least 3 months at -20°C and -80°C.   
Ethambutol was quantitated with liquid-liquid extraction, followed by derivatization 
and HPLC-UV. Plasma samples (100 µL) were spiked with internal standard 
(N,N-diisopropylethylendiamine 99%), alkalized and extracted with chloroform. 
The chloroform layer was poured into other tubes containing derivatization reagens 
(0.01% phenylethylthyocyanate), and evaporated to dryness. Samples were resolved in 
acetonitrile/0.05 M phosphate buffer (40:60 v/v). After vortexing and centrifugation 
the supernatant was injected in the HPLC apparatus. Chromatographic analysis was 
performed on an Omnispher 5 C18 column (100 by 4.6 mm, Varian, Middelburg, the 
Netherlands). The mobile phase was 0.05 M phosphate buffer (pH 5.6) – acetonitril 
gradient in which the percentage of phosphate buffer was changed linearly as follows: 
0 min, 65%; 21 min, 46 %; 22 min, 65 %;  25 min, 65%. Flow rate was set at 1.5 ml/min and 
the wavelength for UV detection was 215 nm. Accuracy was between 101% and 105%, 
intra- and inter-assay coefficients of variation were less than 4% over the range of 0.05 
to 10 mg/L, and the lower limit of quantitation was 0.05 mg/L. Plasma samples with 
ethambutol were stable (< 5% loss) for at least 8 months at -20°C and -80°C.
Pharmacokinetic analysis
A noncompartmental analysis with WinNonLin version 4.1 (Pharsight Corp., 
Mountain View, California) was performed to compute the pharmacokinetic 
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parameters of rifampicin, desacetylrifampicin, pyrazinamide and ethambutol.
The maximum concentration of drug in plasma was defined as Cmax and the time 
to this maximum concentration as tmax. Cmax and tmax were determined directly 
from the plasma concentration-time data. The value of the slope (-β/2.303, where β 
is the first-order elimination rate constant) was calculated by least-squares linear 
regression analysis. If the concentration at 12 h post dose (C12) was quantifiable, the 
concentration at 24 h (C24) was estimated using the equation C24 = C12 * e-β(t24-t12). The 
area under the concentration-time curve from 0 to 24 h post dose (AUC0-24) was 
assessed using the linear-log trapezoidal rule from 0 up to the last concentration. 
Half life (t1/2) was calculated from the expression 0.693/β. Apparent clearance (CL/F, 
where F is bioavailability) was calculated by dividing dose by AUC0-24, and apparent 
volume of distribution (V/F) was obtained by dividing CL/F by β.
The relative exposure of metabolite desacetylrifampicin to rifampicin was expressed 
as the ratio of the metabolite and the parent drug.
Tolerability
Safety and tolerability were assessed by questioning patients actively (before the 
study and in weeks 2, 4, 6 and 8 in the intensive phase and weeks 12, 16, 20 and 26 
in the continuation phase, in total 8 times after inclusion), guided by a list of nine 
possible adverse events that could occur during treatment with TB drugs. Patients 
were questioned by a field investigator, who was a medical doctor at every time. Serum 
glutamine pyruvate transferase (SGPT) was measured to evaluate for hepatotoxicity in 
weeks 2, 4, 6 and 8 during the intensive phase, i.e. 4 times during the study. All possible 
adverse events were categorized according to an adverse event grading system (http://
ctep.cancer.gov). For elevations of SGPT, grade 1 was 1.25 - 2.5 times upper limit of normal 
(ULN); grade 2 was 2.6 - 5 times ULN; grade 3 was 5 - 20 times ULN and grade 4 was ≥ 20 
times ULN. Patients were withdrawn if they experienced grade 3 or 4 hepatotoxicity. 
After the reversal of hepatotoxicity, treatment was gradually resumed.  
Bacteriological examinations and treatment outcome
Microscopic examination of Ziehl-Neelsen stained sputum slides was done for 
acid-fast bacilli (AFB) and M.	 tuberculosis culture was performed on Ogawa 3%. 
Drug susceptibility testing for rifampicin, isoniazid, ethambutol and streptomycin 
was performed on cultured isolates, using an absolute concentration method with 
supranational control.
pharmacokinetics and tolerability of a higher rifampin dose
2
Nijland.1046-Proefschrift.indd   37 07-04-2009   15:39:50
38
After 6 months of TB treatment a patient was cured (referring to an initially smear-
positive patient who was smear-negative in the last month of treatment and on 
at least one previous occasion), failed treatment (i.e. a smear-positive patient who 
remained smear-positive at month 5 or later during treatment), completed treatment 
(a patient who completed treatment but did not meet the criteria for cure or failure 
because no sputum examination was possible during the last month of treatment, 
as the patient did not produce sputum), defaulted (treatment was interrupted for ≥ 2 
consecutive months) or died (death from any cause during treatment) [11].
Statistical analysis
Pharmacokinetic parameters were log-transformed before statistical analysis. 
Differences in AUC0-24, Cmax, t1/2, CL/F and V/F in the higher- versus standard-dose 
group were tested with the independent-samples t-test and a geometric mean ratio plus 
95% confidence interval was calculated for every comparison. Values for tmax were not 
transformed and were compared using Wilcoxon rank sum test. Pearson Chi-square 
test was used to compare the proportions of patients who reached a reference peak 
plasma concentration of 8 mg/L for rifampicin [12], as well as the incidence of adverse 
events, as reported at least once in eight consecutive reporting times during the study.
Univariate analyses were performed in the higher-dose and standard-dose arms 
separately to assess the effects of gender, age, body weight and the occurrence of nausea 
or vomiting on the AUC0-24 and Cmax of rifampicin, pyrazinamide and ethambutol. 
A multivariate linear regression analysis was performed to assess the variation in 
AUC0-24 and Cmax attributable to the presence of those variables that emerged from 
the univariate analyses. 
All statistical evaluations were performed with SPSS for Windows, version 12.0.1 
(SPSS Inc., Chicago, IL, USA). P values less than 0.05 were considered statistically 
significant in all analyses.
Results
Patients
Fifty patients were included in the study. They presented with a history of cough 
(100%), shortness of breath (70%), fever (76%), night sweats (62%) and weight loss 
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(84%). All patients showed chest X-ray abnormalities and M.	tuberculosis culture was 
positive in 92% of them. Fifty-two percent of the patients was male, median age was 
28 years (range: 18 – 55 years), and mean body weight was 46.1 kg (range 35.6 – 71.2 
kg). One patient was HIV-positive and type-2 diabetes was found in four patients 
(8%). One patient used glibenclamide as co-medication, a drug which is not known 
to affect the pharmacokinetics of TB drugs. Twenty-five patients were allocated to 
each of the two study arms. Both at baseline (data not shown) and at the time of 
the pharmacokinetic assessment (table 1), patient characteristics were similar in the 
two arms, except for rifampicin dose per kg.
Pharmacokinetic data were available from 47 patients (of whom 23 in the higher- 
dose arm), tolerability data were available from 49 patients (24 in the higher-dose 
arm) and 47 patients were available for an evaluation of treatment response (23 in 
the higher-dose arm). 
pharmacokinetics and tolerability of a higher rifampin dose
2
Table 1  Patient characteristics at the time of the pharmacokinetic 
assessment.
Rifampicin dose 600 mg 450 mg
N 23 24
Gender (%)
Male  12/23 (52%) 13/24 (54%)
Age (year)
Median (range) 27 (18 – 55) 34 (19 – 55)
Weight (kg)
Mean (s.d.) 47.3 (6.9) 48.4 (8.1)
Body Mass Index (kg/m2)  
Mean (s.d.) 18.4 (2.6) 18.8 (2.7)
Diabetes mellitus (%)
Yes 1/23 (4%) 2/24 (8%)
HIV status (%)
(+) 0 1 (4%)
Rifampicin dose (mg/kg)
Mean (s.d.) 12.9 (1.7) 9.5 (1.4)
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Pharmacokinetics of TB drugs 
All pharmacokinetic assessments occurred as planned without any events 
(e.g. vomiting) that may affect the pharmacokinetic profiles that were recorded. 
Marked inter-individual variability in AUC0-24 and Cmax values for rifampicin was 
observed both in the higher-dose and standard-dose arm (table 2). 
chapter 2
Table 2  Steady-state pharmacokinetics of rifampicin and desacetyl-
rifampicin after daily administration of a high (600 mg,  
13 mg/kg) or standard (450 mg, 10 mg/kg) dose of rifampicin 
(geometric mean plus range, unless stated otherwise)
Parametera Rifampicin  Rifampicin Ratio p-value
 600 mg 450 mg 600mg/450 mg
 (n=23) (n=24) (geometr. mean 
    + 95 CI)
Rifampicin
AUC0-24 (mg⋅h/L) 79.7 (38.7-138.1) 48.5 (26.7-72.8)  1.65 [1.38 – 1.96] <0.001b
Cmax (mg/L) 15.6 (5.1-26.6) 10.5 (6.2-16.6) 1.49 [1.22 – 1.81] <0.001b
Cmax  > 8 mg/L (%) 22/23 (96%) 19/24 (79%)  0.090c
tmax (h; median, range) 1 (1 – 6) 2 (1 – 4)  0.428d
T1/2 (h) 2.2 (1.3-6.3) 1.9 (1.5-5.2) 1.13 [0.95 – 1.35] 0.176b
CL/F (L/h) 7.5 (4.3-15.5) 9.2 (6.1-16.8) 0.82 [0.69 – 0.97] 0.021b
V/F (L) 23.3 (12.3-96.1) 25.3 (12.9-55.7) 0.92 [0.72 – 1.18] 0.502b
Desacetylrifampicin
AUC0-24 (mg⋅h/L) 13.2 (7.2-25.6) 6.4 (2.3-13.3) 2.07 [1.61 – 2.65] <0.001b
Cmax (mg/L) 2.2 (0.6-3.9) 1.2 (0.5-2.6) 1.83 [1.40 – 2.41] <0.001b
tmax (h; median, range) 4 (1.5 – 6) 4 (1.5 – 4)  0.586d
T1/2 (h) 2.5 (1.7-9.9) 3.2 (2.0-18.9) 0.80 [0.63 – 1.03] 0.085b
Ratio desacetyrifampicin/rifampicin
AUC0-24 0.17 (0.10-0.25) 0.13 (0.08-0.20)  1.26 [1.09 – 1.45] 0.002b
Cmax 0.14 (0.07-0.22) 0.11 (0.05-0.19) 1.23 [1.03 – 1.48] 0.024b
a AUC0-24: area under the concentration-time curve from 0 to 24 h post-dose, Cmax: maximum 
concentration, tmax: time to maximum concentration, CL/F : total clearance, V/F: apparent 
volume of distribution, F: bio-availability, CI: confidence interval.  b Independent t-test on log 
transformed data.  c Pearson Chi-square test.  d Wilcoxon rank sum test.
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Exposure to rifampicin (AUC0-24) was 65% (or 1.65 fold) higher in the higher-dose 
group, which reflects a more than dose-proportional increase of the exposure upon 
increasing the dose (table 2 and figure 1). Likewise, rifampicin Cmax was significantly 
higher in the higher-dose group (table 2). The percent of patients who reached a 
reference value of at least 8 mg/L [12] was 96% in the higher-dose group and 79% 
in the standard-dose group (p=0.094). At two hours post dose, 87% of patients in 
the higher-dose group and 58% in the standard-dose group had a concentration of at 
least 8 mg/L (p= 0.01).
With regard to metabolite desacetylrifampicin, it appeared that absolute values 
for AUC0-24 and Cmax were approximately two fold higher in the higher-dose group 
compared to the standard-dose group (table 2). In addition, desacetylrifampicin / 
rifampicin ratios for AUC0-24 and Cmax were significantly higher in the higher-dose 
group.   
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Figure 1
Mean steady-state plasma concentration - time profiles of rifampicin in tuberculosis 
 patients who received high dose (600 mg, 13 mg/kg, n=23) or standard dose (450 mg,  
10 mg/kg, n=24) of rifampicin, with standard deviations.
standard dose group (rifampicin 10 mg/kg)
high dose group (rifampicin 13 mg/kg)
time after dose (h)
ri
fa
m
pi
ci
n
 p
la
sm
a 
co
n
ce
n
tr
at
io
n
 (m
g/
L)
Nijland.1046-Proefschrift.indd   41 07-04-2009   15:39:50
42
The pharmacokinetics of pyrazinamide and ethambutol did not differ between the 
two study groups (table 3). Of note, there were strong correlations between AUC0-24 
values of rifampicin, pyrazinamide and ethambutol, and the same applied to Cmax 
values (data not shown). 
Tolerability and bacteriological examinations  
No significant differences were found between the higher and standard dose group 
in the incidence of nausea (33% resp. 24%, p=0.47), vomiting (21% resp. 12%, p=0.40), 
abdominal pain (4% resp. 8%, p=0.58), itching (50% resp. 64%, p=0.32), arthralgia 
(21% resp. 28%, p=0.57), hyperuricemia (21% resp. 20%, p=0.94), dizziness (13% resp. 
8%, p=0.60), fever (13% resp. 4%, p=0.28), paresthesia (8% resp. 8%, p=0.97), and 
hepatotoxicity grade 3 (4% resp. 12%, p=0.32).    
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Table 3  Steady-state pharmacokinetics of pyrazinamide and  
ethambutol after daily administration of 1500 mg  
(30 mg/kg) and 750 mg (15 mg/kg) (geometric mean plus 
range, unless stated otherwise).
Parametera Rifampicin  Rifampicin Ratio p-value
 600 mg 450 mg 600mg/450 mg
 (n=23) (n=24) (geometr. mean 
    + 95 CI)
Pyrazinamide 
AUC0-24 (mg⋅h/L) 514.5 (266.4-775.3) 472.8 (258.9-705.1)  1.04 [0.93 – 1.27] 0.269b
Cmax (mg/L) 46.0 (23.3-71.8) 43.8 (19.2-62.1) 1.05 [0.91 – 1.21] 0.493b
tmax (h; median, range) 2.5 (2-6) 2.75 (1-6)  0.897c
t1/2 (h) 6.9 (4.1-11.7)  6.6 (3.9-12.7) 1.04 [0.89 – 1.22] 0.593b
Ethambutol 
AUC0-24 (mg⋅h/L) 14.7 (10.0-23.4) 14.4 (9.6-22.5) 1.02 [0.88 – 1.17] 0.830b
Cmax (mg/L) 2.3 (1.2-5.6) 2.4 (1.1-4.9) 0.98 [0.77 –1.24] 0.863b
tmax (h; median, range) 2.5 (1.5-4) 2.5 (1.5-6)  0.397c
t1/2 (h) 4.6 (1.8-6.8) 4.2 (2.6-5.5) 1.09 [0.95 – 1.24] 0.217b
a AUC0-24: area under the concentration-time curve from 0 to 24 h post-dose, Cmax: maximum 
concentration, tmax: time to maximum concentration, CI: confidence interval.  b Independent 
t-test on log transformed data. c Wilcoxon rank sum test
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Hepatotoxicity grade 1 or 2 was more common in the higher dose group (46% vs. 20%; 
p=0.054), but none of the patients developed serious hepatotoxicity and no action had 
to be taken. The grade 3 hepatotoxicity which developed in four of 49 patients (8%, 
three from the standard-dose arm and one from the higher-dose arm) was reversible 
in all patients. The majority of adverse events (99%) occurred in the first weeks of 
the intensive phase. No ‘flu-like syndrome’ was reported during intermittent dosing 
of rifampicin in the continuation phase. 
Among 47 patients available for an evaluation of treatment response, nobody died, 
38 patients were cured (81%), four completed the treatment (9%), three (6%) showed 
bacteriological failure (one received rifampicin 600 mg) and two patients defaulted 
(4%, one from the higher-dose group). Drug susceptibility tests revealed isoniazid 
monoresistance in two patients (one from the higher-dose group), rifampicin 
monoresistance in one (from the standard-dose group), and multidrug-resistant TB 
in one patient (from the standard-dose group). There was no significant difference 
in the cumulative culture conversion rate between the higher- and standard-dose 
group, but it should be noted that the study was not powered to detect a difference 
in this respect. 
The low number of undesirable events precludes firm conclusions about relationships 
between pharmacokinetic data on the one hand and the occurrence of adverse effects 
or inadequate response on the other. Patients with rifampicin Cmax values above an 
upper reference value of 24 mg/L [12] did not report any serious adverse event and 
patients with grade 3 and 4 hepatotoxicity did not show unduly high exposure to 
rifampicin or pyrazinamide. Likewise, the few patients with bacteriological failure 
had rifampicin Cmax values within the reference range. 
Determinants of the pharmacokinetics of rifampicin, pyrazinamide 
and ethambutol
In univariate analyses, both in the higher- and in the standard-dose group, gender 
and age did not show a significant relationship with the AUC0-24 and Cmax of 
rifampicin, pyrazinamide and ethambutol. However, body weight correlated with the 
AUC0-24 of all three drugs in both study groups; for rifampicin, the Pearson correlation 
coefficient was -0.371 (p=0.081) in the higher-dose group and -0.445 (p=0.029) in the 
standard-dose group. Patients in the separate study arms who had reported nausea or 
pharmacokinetics and tolerability of a higher rifampin dose
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vomiting at least once did not have lower exposures to rifampicin, pyrazinamide or 
ethambutol compared to those patients who never reported nausea or vomiting. For 
example, in the higher dose arm, the mean value for the AUC0-24 of rifampicin was 
80.6 h*mg/L (geometric mean: 76.1 h*mg/L) among patients who once experienced 
nausea or vomiting compared to 85.1 h*mg/L (geometric mean 81.7 h* mg/L) who did 
not (p=0.62, independent-samples t-test on log-transformed data). Similarly, the 
occurrence of just vomiting was not associated with large or significant decreases in 
exposure to the TB drugs in each of the study arms. Rifampicin, pyrazinamide and 
ethambutol Cmax values for three patients with diabetes mellitus (one in the higher-
dose group and two in the standard-dose group) and one HIV-infected patient were 
within reference ranges.   
Multivariate analysis in all study patients revealed that both the dose of rifampicin 
and body weight were independent predictors of the AUC0-24 of rifampicin, according 
to the formula ln AUC0-24 (in h.mg/L) = 3.288 + [0.003 × rifampicin dose (mg)] – [0.017 
× body weight (kg)].  
Discussion
This phase II clinical study shows that an increase in the rifampicin dose from 10 to 
13 mg/kg daily results in a more than dose-proportional increase in the mean AUC0-
24 (65% increase) and mean Cmax (49 % increase) of rifampicin without a significant 
increase in the incidence of serious adverse events. An increase in the AUC0-24 or Cmax 
of rifampicin predicts an increase in effectivity, as rifampicin exhibits exposure- [2] 
or concentration-dependent [13] activity against M.	tuberculosis. Therefore increasing 
the dose of rifampicin appears to be effective (from a pharmacokinetic point of view) 
and feasible. This calls for follow-up phase II studies that evaluate an even higher (15 
or 20 mg/kg) dose of rifampicin. In-vitro and murine data [2] and data from humans 
[14] indicate that TB treatment duration could possibly be shortened to 4 months by 
using higher doses of rifampicin. This should eventually be tested in larger numbers 
of patients, within the context of a phase III trial.    
The main problem of currently available TB treatment is its length and complexity. 
Strategies to shorten treatment include further optimization of the dosing of 
chapter 2
Nijland.1046-Proefschrift.indd   44 07-04-2009   15:39:51
45
available TB drugs and the evaluation of new antituberculosis drugs (of which the 
quinolone moxifloxacin seems most promising [15]), or a combination of these [16]. 
Based on available data [1, 2], increasing the dose of rifampicin seemed a promising 
means to optimize the response to this drug. This intervention is particularly 
attractive when it is acknowledged that rifampicin is widely available at low costs, 
and that the properties of this drug are well-known to physicians all over the world. 
If increasing the dose of rifampicin proves worthwhile, this intervention could be 
implemented broadly and quickly to the benefit of many patients.      
Only few clinical studies have addressed the concept of high-dose rifampicin in 
TB treatment so far [7]. In one study a short regimen that incorporated a high dose 
of rifampicin (1200 mg daily or every other day) yielded very high sputum culture 
negativity by two months [14]. On the other hand, another study demonstrated 
no difference in effectivity between patients who used 600 (10 mg/kg) or 750 mg 
rifampicin daily. In the latter study, 750 mg of rifampicin was well-tolerated [6]. 
Past attempts to use large intermittent doses of rifampicin were met with a high 
incidence of a ‘flu-like syndrome’, but this was ascribed to the intermittency of 
dosing rather than the height of the dose [7, 17]. 
In the current study, a moderate (one-third) increase in the dose of rifampicin was 
evaluated. We chose to be cautious, considering the paucity of clinical data regarding 
higher-dose rifampicin in general, and taking into account that there are only scarce 
pharmacokinetic and tolerability data for even a standard dose of rifampicin in 
Asian populations. A high dose of rifampicin (20 mg/kg) is used in the treatment 
of brucellosis [7], but it should be considered that tolerability data for high dose 
rifampicin in brucellosis can not be directly extrapolated to TB. In the treatment of 
brucellosis, high dose rifampicin is combined with just one other drug (doxycyclin) 
instead of several toxic TB drugs, and treatment of this infection takes only 45 days. 
The moderate increase in rifampicin dose, as applied in this study, resulted in a relatively 
strong, more than dose-proportional increase in rifampicin plasma concentrations, 
which is consistent with the non-linear pharmacokinetics of rifampicin [17-19]. 
Increasing the dose of rifampicin also caused a more than proportional (around 
2-fold) increase in the AUC0-24 of active metabolite desacetylrifampicin and an 
increase in the desacetylrifampicin/rifampicin ratio, which is in agreement with 
previous data [18]. Considering the relatively small contribution of the active 
pharmacokinetics and tolerability of a higher rifampin dose
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metabolite to the exposure and effectivity of rifampicin, these findings do not seem 
to be clinically relevant. Importantly, the increase in rifampicin dose did not affect 
the mean AUC0-24 and Cmax of pyrazinamide and ethambutol, despite the observed 
correlations between the pharmacokinetics of rifampicin on the one hand and those 
of pyrazinamide and ethambutol on the other.  
The toxicity of rifampicin is known to be related to dose and administration 
interval[17]. In this study, the incidence of adverse events was relatively high, both in 
the higher- and standard-dose group. This high incidence may be attributable in part 
to the active and frequent questioning of patients that we applied to guarantee their 
safety. The large majority of adverse events were mild in severity. The incidence of 
grade 1-2 hepatotoxicity was higher in the higher-dose group, but this was transient 
and did not cause treatment interruption or alteration. More importantly, this study 
did not show evidence for an increase in the incidence of serious hepatotoxicity 
related to a higher dose of rifampicin, which is in agreement with previous data [6]. 
Nausea and vomiting occurred some 10% more often in the higher dose arm, which 
reflects a (non-significant) difference of only 2-3 patients in this small phase II study. 
These adverse events should be monitored carefully in follow-up studies, as they 
may possibly affect adherence and the absorption of rifampicin, which may offset 
the advantages of high dose rifampicin. In the current study, nausea or vomiting 
were not associated with exposure to the TB drugs. This may not be surprising, 
considering that no vomiting occurred during the pharmacokinetic assessments.  
A limitation of this study, inherent to phase II studies in general, is the relatively 
small number of participants. This means that only large differences in the incidence 
of adverse events became statistically significant. Furthermore, the number of 
participants, in combination with a relatively short (6-month) follow-up, did not 
allow for a valid comparison of bacteriological response between the two treatment 
arms. As another limitation, it should be considered that all participants were 
Indonesian. Although rifampicin doses were based on body weight, it can not be 
excluded that the pharmacokinetics and/or tolerability of high-dose rifampicin may 
be different in people with another race or genetic background. As a third limitation, 
the effect of high-dose rifampicin on the pharmacokinetics of isoniazid was not 
assessed in this study.
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In conclusion, this study shows that an increase in the rifampicin dose from 10 to 13 
mg/kg daily causes a more than dose-proportional increase in the mean AUC0-24 and 
Cmax of rifampicin without causing an increase in severe adverse events to the TB 
treatment. Therefore increasing the dose of rifampicin is feasible and effective from 
a pharmacokinetic point of view. Follow-up phase II studies should be performed 
to evaluate an even higher dose of rifampicin. These studies should be carefully 
monitored, considering the non-linear pharmacokinetics of rifampicin. Eventually, 
high dose rifampicin is to be tested in larger phase IIII trials. For certain risk groups, 
e.g. patients with drug resistance or patients with HIV infection [4] or diabetes 
mellitus [20], a higher dose of rifampicin may be useful as part of the current 
6-month TB treatment regimen. In the absence of such risk factors, a higher dose of 
rifampicin (possibly in conjunction with new TB drugs) may enable shortening of 
TB treatment. 
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Abstract 
Introduction:	The long duration of the current tuberculosis treatment is demanding 
and warrants new drugs. Moxifloxacin shows promising results and may be 
combined with rifampicin for shortening of TB treatment. Rifampicin induces 
the phase II metabolic enzymes that are involved in the biotransformation of 
moxifloxacin. Therefore, the interaction between rifampicin and moxifloxacin 
should be investigated. 
Methods:	Nineteen Indonesian pulmonary tuberculosis patients in the last month 
of their tuberculosis treatment completed this one-arm, two-period, fixed-order 
pharmacokinetic study. They received 400 mg of moxifloxacin q.d. for five days 
in addition to rifampicin 450 mg and isoniazid 600 mg thrice weekly (phase 1). 
After a one-month washout period, patients received moxifloxacin for another 
five days (without rifampicin and isoniazid; phase 2). A 24h-pharmacokinetic 
curve for moxifloxacin was recorded on the last day of both study periods and its 
pharmacokinetic parameters were evaluated for an interaction with rifampicin, 
using a bioequivalence approach. 
Results:	Co-administration of moxifloxacin with rifampicin and isoniazid resulted 
in an almost uniform decrease (18 out of 19) in moxifloxacin exposure. The geometric 
means [90% CI] for the ratio AUCphase1/AUCphase2 and Cmax,phase1/Cmax,phase2 were 
0.69 [0.65-0.74] and 0.68 [0.64-0.73]. Moxifloxacin tmax was prolonged from 1h to 2.5 
h (median values) when combined with rifampicin and isoniazid (p=0.003).  
Conclusion:	Co-administration of moxifloxacin with intermittently administered 
rifampicin and isoniazid results in reduced moxifloxacin plasma concentrations, 
which is most likely due to induced glucuronidation or sulphation by rifampicin. 
Further studies are warranted to evaluate the impact of the interaction on the 
outcome of tuberculosis treatment. 
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Introduction
Worldwide, tuberculosis (TB) claims approximately two million victims each year 
[1, 2]. The main problem of TB treatment is its duration (6 months), which is very 
demanding in terms of adherence and tolerability.  New TB drugs may help to shorten 
the treatment duration. The quinolone antibiotics have raised great interest for 
their possible ability to shorten TB treatment, following a study with the quinolone 
ofloxacin [3].
Newer generation quinolones possess even greater in-vitro activity against M.	
tuberculosis	than ofloxacin. The quinolone moxifloxacin, currently recommended in 
multidrug resistant TB [4], shows the highest in	vitro activity against M.	tuberculosis 
[5]. Moxifloxacin has shown the potential to shorten TB treatment with two months 
when used as a substitute for isoniazid in a murine model [6, 7]. Studies in humans 
show that the early bactericidal activity (EBA) of moxifloxacin is comparable to that 
of isoniazid [8, 9]. Furthermore, it has been shown that moxifloxacin is safe in long-
term use in TB patients [10]. A recent study evaluated the effect of moxifloxacin 
versus ethambutol, both in combination with other TB drugs, on sputum conversion 
at 2 months [11], and similar studies are underway.
Rifampicin is the strongest known inducer of cytochrome P450 isoenzymes. 
No pharmacokinetic interaction between moxifloxacin and rifampicin is anticipated 
at the level of phase I metabolism, since moxifloxacin is entirely metabolized 
by the phase II metabolizing processes of glucuronidation and sulphation. 
However, rifampicin also induces the phase II enzymes uridine diphoshate 
glucuronosyltransferase (UGT) and sulphotransferase, which may possibly affect the 
area under the curve (AUC) and peak plasma concentrations (Cmax) of moxifloxacin. 
This interaction could also be of relevance in western countries when moxifloxacin 
and rifampicin are combined in TB treatment, for example in case of intolerability 
of first-line TB drugs or in patients with isoniazid monoresistance and extensive 
disease [12]. 
The objective of this pharmacokinetic study was to assess the interaction between 
rifampicin and moxifloxacin. 
rifampicin reduces plasma concentrations of moxifloxacin
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Methods
Subjects
Study subjects were Indonesian pulmonary TB patients in the last month of the 
continuation phase of TB treatment. They had a body weight above 35 kg, were 
between 18 and 55 years of age and had a normal ECG. All patients had a satisfactory 
response to treatment, and none had been sputum smear-positive after two months 
of treatment. Subjects were excluded in case of pregnancy or lactation; a relevant 
history or condition that might interfere with drug absorption, distribution, 
metabolism or excretion; heart rhythm disturbances; a history of seizures or 
epilepsy; G-6PD deficiency; hypersensitivity to quinolones; experience of tendon 
disorders related to fluoroquinolone treatment; hypokalaemia or use of any drug 
that might interact with moxifloxacin.
Study design
This study was an open-label, multiple dose, one-arm, two-period, fixed-order 
pharmacokinetic interaction study and was performed in an outpatient clinic 
in Bandung, Indonesia. According to the National Tuberculosis Program (NTP) of 
Indonesia, the continuation phase of TB treatment consists of 600 mg of isoniazid 
and 450 mg of rifampicin, both dosed three times weekly. The dose of rifampicin 
is lower than the usual 600 mg dose, considering the low mean body weight of 
Indonesian people. Since all patients were in the last month of TB treatment, steady 
state for rifampicin and isoniazid was already achieved at the start of the study. 
Next to regular TB treatment, subjects were given 400 mg of moxifloxacin QD 
during five days to attain steady-state of this drug ([13], figure 1). After finishing TB 
treatment and a washout period of one month, patients received moxifloxacin 400 
mg QD for another five days. A full pharmacokinetic curve was recorded at day 5 
in both phases. Intake of study medication was observed on days 1, 3, and 5 in each 
phase. Furthermore, adherence with study medication was evaluated by counting 
capsules and by the use of Medication Event Monitoring System (MEMS) vials. These 
vials contain microprocessors that register the date and time of each opening of the 
vial. All patients gave written informed consent and both the Ethical Review Board 
of Hasan Sadikin Hospital / Padjadjaran University in Bandung, Indonesia and the 
Advisory Board of Radboud University Nijmegen Medical Centre, The Netherlands 
approved the study. 
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Experimental procedures
Steady state pharmacokinetic parameters were assessed on the last day in both 
phases.  Patients were asked to refrain from any food intake from 11 p.m. the 
preceding night until standardized lunch was provided, four hours after intake of 
study medication. Study drugs (moxifloxacin in phase 1 and 2 plus rifampicin and 
isoniazid in phase 1 only) were taken together on an empty stomach. In order to 
assess plasma concentrations of moxifloxacin and rifampicin, serial blood sampling 
was performed before intake and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 hours after 
intake of the drugs. All blood samples were centrifuged immediately and placed 
in –20ºC within 20 minutes. Afterwards, all samples were transferred to –80ºC. 
Samples were shipped on dry ice to the Netherlands for bio-analysis. 
Plasma concentrations
Moxifloxacin plasma concentrations were measured by means of a validated high 
performance liquid chromatography (HPLC) method with fluorescence detection. 
Accuracy was > 95% for the moxifloxacin standard concentrations of 0.074 mg/L, 
0.15 mg/L, 0.74 mg/L and 7.4 mg/L, respectively. Intraday precision and between-
day precision (in %, coefficient of variation) ranged from 1.4% to 5.4% and from 
0.2% to 3.9%, dependent on the concentration. Ninety-eight drugs were tested for 
rifampicin reduces plasma concentrations of moxifloxacin
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Figure 1  Study design
S: Screening; MXF: moxifloxacin 400 mg once daily; INH: isoniazid 600 mg thrice weekly; 
RIF: rifampicin 450 mg thrice weekly. The washout phase had a duration of one month. 
PK: Pharmacokinetic assessment. Phase 1 took place in the last month of TB treatment; 
therefore steady state was already achieved for rifampicin and isoniazid at the start of the 
study. Phase 2 took place after TB treatment had finished for one month.
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interference. The lower and upper limits of quantitation were 0.03 mg/L and 10.0 
mg/L. Moxifloxacin in plasma is stable at –20°C and –80°C for at least 12 months. 
The plasma concentrations of rifampicin and desacetylrifampicin were analyzed 
by a previously described validated HPLC-UV method [14]. Accuracy was 99.8%, 
100.4%, and 100.4% for the rifampicin standard concentrations of 2.9 mg/L, 9.5 
mg/L and 23.7 mg/L respectively. The accuracy of the desacetylrifampicin standard 
concentrations of 0.09 mg/L, 2.25 mg/L and 27.0 mg/L was 103.9%, 102.4% and 102.6% 
respectively. Intraday precision and between-day precision ranged from 0.7% to 1.1% 
and from 0.1% to 0.6% for rifampicin, and from 0.9% to 2.9% and from 0.5 to 3.6% 
for desacetylrifampicin, respectively. Rifampicin in plasma is stable for at least 16 
months in –20°C and –80°C. 
Concentrations of isoniazid were not assessed, as measurement of this drug was not 
relevant to the study. 
Tolerability and safety
Tolerability and safety were assessed on days 1, 3, and 5 in both study phases. 
Patients were actively questioned about the occurrence of the known adverse effects 
of moxifloxacin. Clinical chemistry and hematological tests and evaluations of vital 
signs (heart rate, blood pressure) and ECGs were performed on the same days. All 
possible adverse events were graded according to the Common Toxicity Criteria 
(CTC), version 2.0 [15]. 
Pharmacokinetic and statistical analysis
All pharmacokinetic evaluations for rifampicin and moxifloxacin were performed 
using non-compartmental methods using WinNonLin version 4.1 (Pharsight Corp., 
Mountain View, California). The highest observed plasma concentration was defined 
as Cmax, with the corresponding time as tmax. Cmin was the plasma concentration at 
24 hours after intake of study medication. The area under the curve (AUC0-24h) was 
calculated using the log-linear trapezoidal rule from zero up to the last concentration. 
The terminal log-linear period (log C versus t) was based on the last data points 
(n ≥ 3). The absolute value of the slope was calculated by least squares linear 
regression analysis. β is the first order elimination rate constant. Terminal half-life 
was obtained by the equation: 0.693/β. The apparent clearance of the drug (Cl/F) was 
calculated by (dose/ AUC0-24h). The volume of distribution (Vd/F) was calculated by 
the equation (Cl/F /  [β]).
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The sample size of the study was derived from the main pharmacokinetic parameter, 
the AUC0-24h of moxifloxacin, and determined for a data-analysis that is similar 
to a within-subject two-period bioequivalence study [16], as recommended for 
interaction studies. The desired power of the study was 90% and the within-subject 
coefficient of variation for the logarithmically transformed AUC0-24h of moxifloxacin 
was conservatively estimated at 15%.  Based on these data, at least 12 subjects were 
required. Since this was an estimation and dropouts were expected, 22 patients were 
enrolled in the study.  
The MIC of moxifloxacin on M.	tuberculosis	(0.5 mg/L, [17]) was used to calculate the 
pharmacodynamic (PD) parameters AUC0-24h/MIC and Cmax/MIC. The number of 
patients that reached the targets of AUC24h/MIC and Cmax/MIC ratios of 100 and 10 
[18-23], respectively, was compared using the Chi square test. The mutant prevention 
concentration (MPC) for moxifloxacin in TB treatment was set at 2.5 mg/L [24], 
uncorrected for protein binding. Time > MPC was the time when moxifloxacin 
concentration was above the MPC. 
All statistical evaluations were performed with SPSS for Windows, version 12.0.1. 
Pharmacokinetic parameters were log-transformed before statistical analysis. 
The values for tmax were not transformed and were compared using Wilcoxon signed 
rank test. Using a bio-equivalence approach for the evaluation of the interaction, the 
90% confidence interval of the geometric mean ratios AUCphase 1/ AUCphase 2 and 
Cmax,phase 1/Cmax,phase 2 should lie between 80 and 125% to conclude the absence of 
an interaction. P-values < 0.05 were considered statistically significant in all other 
analyses. 
Results
Patients
Twenty-two subjects were included in the study. Two of them dropped out during the 
second phase of the study: the first for medical reasons unrelated to the study and the 
second for personal reasons. A third subject was excluded from all analyses after the 
study, since this subject missed one dose on the day preceding the pharmacokinetic 
assessment in phase 2. 
rifampicin reduces plasma concentrations of moxifloxacin
3
Nijland.1046-Proefschrift.indd   57 07-04-2009   15:40:02
58
The diagnosis of TB in the study subjects was based on the following clinical 
symptoms; history of cough (100%), shortness of breath (50%), fever (60%), night 
sweats (65%) and weight loss (65%). All patients showed X-ray abnormalities and 
had cultures positive for M.	tuberculosis	at initiation of TB treatment. The mean age 
of the nineteen study subjects who completed the study (of whom 6 females) was 
30 years (range: 20-55) and their mean weight was 55 kg (range: 38-80 kg) at the first 
day of pharmacokinetic assessment. Type 2 diabetes was present in one patient, but 
the patient did not take antidiabetic medication. Adherence was excellent in all 
subjects: all 19 patients were 100% adherent.  
Pharmacokinetics of moxifloxacin and rifampicin and safety
The geometric mean for the ratio AUCphase1/AUCphase2 of moxifloxacin was 0.69, 
and the lower and upper 90% confidence intervals of the ratio were 0.65 and 0.74 
respectively. Similar figures were shown for moxifloxacin Cmax (table 1). Moxifloxacin 
Cmin showed a stronger decrease (ratio 0.38) when co-administered with rifampicin 
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Table 1  Steady-state pharmacokinetic results for moxifloxacin (n=19).
PK parameter a Geometric mean (range) Geometric
 
Phase 1b Phase 2c
 mean ratio
   (period 1/ period 2)
    and 90% CId
AUC0-24h (h mg/L) 33.3 (25.1-55.5) 48.2 (37.2-60.5)  0.69 (0.65-0.74)
Cmax (mg/L) 3.2 (2.5-4.5) 4.7 (3.4-6.0) 0.68 (0.64-0.73)
Cmin (mg/L) 0.38 (0.18-0.78) 0.78 (0.51-1.1) 0.38 (0.31- 0.48)
tmax (h) 2.5 (0.5-6.0)e 1.00 (0.5-3.0)f 0.003f
CL/F (L/h) 12.0 (7.2-16.0) 8.3(6.6-10.8) 1.45 (1.35-1.54)
Vd/F (L) 123 (83-187) 119 (8.4-179) 1.04 (0.98-1.09)
t1/2 (h) 7.1 (5.0-9.6) 9.9 (7.4-14.0) 0.72 (0.68-0.75)
a PK: pharmacokinetic, AUC0-24h: area under the concentration-time curve, Cmax: highest 
 observed plasma concentration, Cmin: trough concentration at 24h after intake of study 
 medication, tmax: time at which Cmax occurs, CL/F: total clearance, Vd/F: volume of distribution, 
t1/2: elimination half-life, F: bioavailability. b Combination of 400 mg moxifloxacin once daily, 
600 mg isoniazid and 450 mg rifampicin three times weekly. c Moxifloxacin 400 mg once daily.  
d CI: confidence interval. e Median and range. f Wilcoxon signed rank test.
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and isoniazid. As a result, bioequivalence for the combination of rifampicin, isoniazid 
and moxifloxacin when compared to moxifloxacin alone cannot be concluded. 
Moxifloxacin tmax was prolonged when combined with rifampicin and isoniazid 
(p=0.003; figure 2). Moxifloxacin exposure decreased in all but one subject (figure 3). 
A relatively small interindividual variability in pharmacokinetic parameters for 
moxifloxacin was observed, which has been described elsewhere [25].
The AUC24h for moxifloxacin without rifampicin (in phase 2) did not correlate with 
the relative difference between the two phases (ratio of AUC phase2/ AUC phase1) 
(Pearson correlation coefficient 0.195, p=0.423).
The geometric mean values (range) for AUC/MIC and Cmax/MIC for moxifloxacin in 
phase 2 approached the desired values for fast growing bacilli (96.4 (74.4-121) and 
9.5 (6.8-12.1), respectively), in contrast to the values in phase 1 (66.7 (50.3-111) and 6.5 
rifampicin reduces plasma concentrations of moxifloxacin
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Figure 2
Mean (+ SD) moxifloxacin steady state plasma concentrations versus time (n=19). 
Open squares, 400 mg moxifloxacin once daily. Closed squares, combination of 400 mg 
moxifloxacin once daily and 450 mg rifampicin and 600 mg isoniazid thrice weekly.  
time after intake (h)
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(4.9-9.1), p<0.01). When moxifloxacin was given alone (phase 2), nine out of nineteen 
participants (47%) reached an AUC24h/MIC greater than 100 versus only one patient 
(5%) when moxifloxacin was combined with rifampicin and isoniazid in phase 1. 
These results were similar concerning the Cmax/MIC ratio. The median (range) time 
of moxifloxacin above the mutant prevention concentration (MPC) was 5.5 h. (2.5-7.5) 
when given alone in phase 2, versus 2 h. (0-7.5) when combined with rifampicin and 
isoniazid (p<0.01).
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Table 2  Pharmacokinetic results for rifampicin 450 mg thrice weekly 
and its main metabolite desacetylrifampicin (n=19).
PK parameter a Geometric mean (range) 
AUC0-24h (h mg/L) 35.7 (10.4-55.4)
Cmax (mg/L) 6.9 (2.4-11.5)
Cmin (mg/L) 0.34 (0.23-0.87) 
tmax  (h) 2.5 (1.5-6.0)b
CL/F (L/h) 12.7 (8.1-45.6)
Vd/F (L) 36.2 (23.9-91.8)
t1/2 (h) 2.0 (1.4-3.1)
Desacetylrifampicin c
AUC0-24h (h mg/L) 4.5 (0.0-7.1)b 
Cmax  (mg/L) 0.92 (0.0-1.5)b
Cmin (mg/L) 0.23 (0.0-0.39)b
tmax  (h) 4.0 (0.0-6.0)b
t1/2 (h) 1.94 (0.0-3.1)b 
Ratio desacetylrifampicin/ rifampicin
AUC0-24h (h mg/L) 0.13 (0.0-0.26)b
Cmax  (mg/L) 0.12 (0.0-0.21)b
Data are for study phase 1, in which patients received a combination of 400 mg moxifloxacin 
administered once daily and 600 mg of isoniazid and 450 mg of rifampicin administered three 
times weekly. a PK: pharmacokinetics, AUC0-24h: area under the concentration-time curve, Cmax: 
highest observed plasma concentration, Cmin: trough concentration at 24h after intake of study 
 medication, tmax: time at which Cmax occurs, CL/F: total clearance, Vd/F: volume of distribution, 
t1/2: elimination half-life,  F: bioavailability. b Median and range. c Desacetylrifampicin was not 
found in four subjects.
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The pharmacokinetic parameters of rifampicin and its main metabolite 
desacetylrifampicin are shown in table 2. No significant correlation was found 
between exposure to rifampicin (AUC) and the ratio of AUC phase2/ AUC phase1 for 
moxifloxacin (Pearson correlation coefficient 0.168, p=0.493). The one diabetic patient 
showed average exposure to rifampicin, although plasma rifampicin concentrations 
have been found to be reduced in type 2 diabetes [26]. Only grade I adverse events 
and no laboratory abnormalities were noticed. 
Discussion 
To our knowledge, these are the first pharmacokinetic data of moxifloxacin 
in tuberculosis patients. The study demonstrates that steady state plasma 
concentrations of moxifloxacin are significantly reduced when combined with 
rifampicin and isoniazid. 
The interaction is expected to result from an increase in phase II metabolism caused 
by rifampicin, as moxifloxacin does not undergo phase I oxidative metabolism 
[13]. No interference of isoniazid in the metabolism of moxifloxacin is anticipated, 
since isoniazid is only known to affect cytochrome P450 mediated metabolism 
[27]. Rifampicin is known as a very strong inducer of CYP-P450 iso-enzymes. It is 
probably less well-known that this drug also induces phase II metabolism. More 
specifically, rifampicin induces uridine diphoshate glucuronosyltransferase (UGT) 
and sulphotransferase, thereby reducing plasma concentrations of rofecoxib, 
mycophenolate mofetil, lamotrigine, zidovudine and propafenone [13, 28-34]. 
A similar mechanism may be involved in the interaction with moxifloxacin, as 
this drug undergoes phase II biotransformation and will be excreted as a sulpho-
compound or a as glucuronide via the kidneys (2.5% and 14%, respectively) and the 
faeces (34% and 14%, respectively) [35]. Recently, it was found in healthy volunteers 
that rifampicin mainly induces the sulphation pathway of moxifloxacin [36]. Of note, 
the difference in tmax between phases could be suggestive for a role of P-glycoprotein. 
The expression of P-glycoprotein in intestinal cells is induced by rifampicin and 
moxifloxacin could be a substrate of this protein [37]. However, induced sulphation 
or glucuronidation could also cause this difference. 
rifampicin reduces plasma concentrations of moxifloxacin
3
Nijland.1046-Proefschrift.indd   61 07-04-2009   15:40:03
62
The AUC0-24h and Cmax of moxifloxacin showed a mean decrease of 31 and 32% 
respectively. This reduction in plasma concentrations can be characterized as 
modest and similar reductions in AUC (27%) and tmax were found in a similar 
study in healthy subjects [36]. Strikingly, Cmax was found to be unaffected by 
rifampicin in this study. In the current study, the reduction of moxifloxacin plasma 
concentrations occurred near-uniformly; in all but one of the study subjects. Daily 
instead of intermittent dosed rifampicin could possibly amplify the extent of this 
interaction. For gram-negative, fast-growing bacteria, the greatest bactericidal 
effect and a decreased probability of resistance development to fluoroquinolones 
occurs at AUC24h/MIC and Cmax/MIC ratios above 100-125 or more and above 10 or 
more, respectively [17, 18, 23], in which AUC and Cmax values refer to total (protein 
bound plus unbound) concentrations [18-22]. For M.	tuberculosis, a slowly duplicating 
organism with the capacity for dormancy, the pharmacodynamic parameters for 
optimal fluoroquinolone activity against are less well defined [21]. Recently, the 
activity of moxifloxacin against M.	tuberculosis	has been found to be best described 
by the ratio between AUC and MIC indeed [17, 20]. Nuermberger showed that even 
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Figure 3
Steady state area under the curve (AUC0-24h) of moxifloxacin alone once daily (phase 2) 
and when combined with rifampicine and isoniazid, thrice daily (phase 1, n=19)
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the potent quinolone moxifloxacin, when used in TB treatment, does not reach the 
ideal pharmacodynamic values for activity against gram-negative bacilli [21].  Apart 
from this, a mutant prevention concentration (MPC) has been defined [24], above 
which plasma concentrations should be maintained to prevent the emergence of 
resistance. It has been demonstrated that only a few quinolones (among which 
moxifloxacin) achieve brief periods of concentrations above the mutant prevention 
concentration (MPC) [24]. In line with this, previous research using an aerosol model 
concluded that a moxifloxacin dose of 800 mg/day instead of 400 mg/day is likely 
to achieve excellent M.	tuberculosis	microbial kill and suppress drug resistance [38]. 
It should be acknowledged that the clinical relevance of all these pharmacodynamic 
parameters in the setting of multidrug TB treatment is yet unclear. Presumably, the 
same interaction between rifampicin and moxifloxacin is occurring in the murine 
model of tuberculosis treatment, and even so, the substitution of moxifloxacin 
for isoniazid markedly improves the activity of treatment. Therefore, it should be 
concluded that the clinical relevance of the interaction between rifampicin and 
moxifloxacin is unknown at this time, and this applies to the administration of 
this drug combination to shorten TB treatment duration as well as for other clinical 
situations in which this combination is used.   
On the basis of the current study, we would propose that follow-up pharmacokinetic 
studies are performed to assess whether a dose increase to 600 mg or 800 mg 
moxifloxacin compensates for the decrease in plasma levels caused by (daily) co-
administration of rifampicin. In addition, a pharmacokinetic interaction study 
between moxifloxacin and rifapentine, another rifamycin, is warranted, considering 
that clinical trials with this combination are underway. Finally, additional research 
should be performed to explore the activity and tolerability of higher doses of 
moxifloxacin, even in the absence of rifampicin co administration. 
This study is limited by the design of the study, which did not allow discrimination 
between an effect on the moxifloxacin metabolism of rifampicin or isoniazid. 
Besides, the MIC and MPC values of M.	 tuberculosis for moxifloxacin were not 
determined, but based on previous publications. Therefore, pharmacodynamic 
ratios were partly derived. Furthermore, this study was not designed to assess the 
impact of moxifloxacin on the pharmacokinetics of rifampicin. Such an effect is not 
expected, since moxifloxacin does not induce any metabolism. 
rifampicin reduces plasma concentrations of moxifloxacin
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In conclusion, we showed a 31% decrease in exposure to moxifloxacin when 
combined with intermittently administered rifampicin and isoniazid in Indonesian 
TB patients. This finding is in agreement with data from healthy volunteers [36], 
but the clinical relevance of this interaction has yet to be elucidated. A higher 
dose of moxifloxacin may possibly overcome the effect of rifampicin on the 
pharmacokinetics of moxifloxacin. Additional studies are warranted to assess the 
pharmacokinetics, dynamics and tolerability of a higher dose of moxifloxacin when 
combined with rifampicin or other rifamycin derivatives. 
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Abstract 
To improve tuberculosis (TB) treatment, a better knowledge of  the pharmacokinetics 
of TB drugs in patients is needed. We conducted a descriptive pharmacokinetic study 
of antituberculosis drugs involving a cohort of hospitalized patients from two TB 
referral centers in the Netherlands. Forty-one culture-confirmed TB cases treated 
with rifampicin, pyrazinamide, ethambutol, moxifloxacin or a combination of these 
drugs were asked to participate and a 24h- pharmacokinetic curve was obtained at 
steady-state. Patients fasted on the day of the pharmacokinetic assessment until four 
hours after intake of study medication. Observed maximum serum concentrations 
were compared with published reference ranges. A large inter-individual variation in 
pharmacokinetics of rifampicin was shown. Thirty percent of the study population 
did not reach the reference peak plasma concentrations for rifampicin. Co-
administration of pyrazinamide was associated with reduced exposure to rifampicin. 
Use of ethambutol was associated with an increased exposure to pyrazinamide and 
smoking with reduced exposure to ethambutol.  The reducing effect of rifampicin on 
the exposure to moxifloxacin was confirmed. The C2h concentration of rifampicin, 
pyrazinamide and moxifloxacin, but not ethambutol, correlated with Cmax and 
AUC. Additional pharmacokinetic and pharmacodynamic studies in larger patient 
populations are warranted. 
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Introduction
Tuberculosis (TB) has been a leading cause of death throughout the world, and still is 
in low-income and middle-income countries [1]. It kills one person every 20 seconds 
[2]. Multidrug treatment within the context of directly observed therapy short course 
(DOTS) is the therapy of choice all over the world. This treatment strategy needs 
optimization in order to improve outcome of tuberculosis treatment. Suboptimal 
response, emergence of drug resistance and adverse events are the main problems 
causing treatment failure and relapse. 
From a classical clinical pharmacological perspective, pharmacokinetics and 
pharmaco dynamics determine the eventual effect of TB drugs. The relation between 
the actual drug intake and the (time course of) plasma drug concentrations achieved 
is described by the pharmacokinetics of the drugs. The plasma drug concentrations are 
related to treatment outcome (including problems of suboptimal response, emergence 
of resistance and adverse events) as determined by pharmacodynamics. Therefore, 
plasma drug concentrations are an important intermediary link between the dose 
and desirable and undesirable effects. Only limited data are available regarding both 
the pharmacokinetics and pharmacodynamics of TB drugs.  
To optimize TB treatment, a better understanding of the pharmacokinetics of TB 
drugs is required. First, more descriptive pharmacokinetic data from TB patients 
should be obtained; second, determinants associated with the pharmacokinetics 
of antituberculosis drugs should be identified; and third, interventions to improve 
plasma drug concentrations should be carried out. From the clinical pharmacological 
perspective as described above, it could be derived that when the plasma 
concentrations are optimized, the response will improve as well. Until now, some 
studies have demonstrated a plasma concentration-effect relation for TB drugs [3-7], but 
others [8-10]  have not. 
In the Netherlands, there are two tertiary referral centers for TB patients. Patients are 
referred to these hospitals for reasons of suspected non-adherence, severe or complex 
disease status, simultaneous treatment of co-morbidities such as HIV/AIDS, and/or 
drug resistance. In these vulnerable patients who are prone to a problematic course of 
TB treatment, optimal exposure to tuberculosis drugs may even be more critical and 
therefore needs careful study. 
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The objective of this study was to describe the pharmacokinetics of rifampicin, 
pyrazinamide, ethambutol, and moxifloxacin in a cohort of tuberculosis patients who 
were admitted to the Dutch tuberculosis referral centers and to evaluate possible 
determinants of pharmacokinetic parameters in these patients.  
Methods
Subjects 
The study subjects were pulmonary and extrapulmonary TB patients who were admitted 
to two TB referral centers, the Center for Tuberculosis, Beatrixoord, Haren, and University 
Lung Centre Dekkerswald, Nijmegen, both in The Netherlands. Tuberculosis was 
diagnosed according to the guidelines of the American Thoracic Society (ATS) [11]. Patients 
were included if they were above 18 years of age and had been using antituberculosis 
drugs for at least two weeks, given the expected steady state at this point. Patients 
were excluded if the medical condition of the patient did not allow participation in the 
study as judged by the physician in attendance. All patients provided written informed 
consent and the study was approved by the Ethical Review Board of Radboud University 
Nijmegen Medical Centre, Nijmegen, The Netherlands. A local feasibility declaration was 
obtained from University Medical Centre Groningen as required by Dutch law.  
Design and procedures 
A prospective descriptive pharmacokinetic study was performed. Antituberculosis 
drugs were administered once daily and dosed as described by the ATS guidelines 
[11]. TB drugs were ingested together and under direct observed therapy by the 
nurses. All tuberculosis drugs were approved and separately formulated. Non-
tuberculosis medication was taken at least four hours after intake of TB drugs. A full 
pharmacokinetic curve was recorded during the intensive phase of TB treatment. 
Patients refrained from the intake of any food from 11.00 p.m. on the day preceding the 
pharmacokinetic assessment until four hours after intake of study medication. Serial 
venous blood samples were collected just prior to, and at 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 
8.0, 12.0 and 24.0 h. after witnessed intake of study medication. Plasma was separated 
immediately, frozen to –20°C and transported on dry ice for bioanalysis.  
Pharmacokinetic  analysis
All pharmacokinetic evaluations were performed using non-compartmental methods 
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using WinNonLin version 4.1 (Pharsight Corp., Mountain View, California). The highest 
observed plasma concentration was defined as Cmax, with the corresponding time as 
tmax. Clast was the plasma concentration at 24 hours after intake of study medication. 
The area under the curve (AUC0-24h) was calculated using the log-linear trapezoidal rule 
from zero up to the last concentration. The terminal log-linear period (log C versus t) 
was based on the last data points (n ≥ 3). The absolute value of the slope was calculated 
by least squares linear regression analysis. β is the first order elimination rate constant. 
Terminal half-life was obtained by the equation: 0.693/β. The apparent clearance of 
the drug (Cl/F) was calculated by (dose / AUC0-24h). The volume of distribution (Vd/F) 
was calculated by the equation (Cl/F /  [β]).
Bioanalysis
The plasma concentrations of rifampicin, its metabolite desacetylrifampicin, 
pyrazinamide, ethambutol and moxifloxacin were assessed by validated high-
performance liquid chromatographic (HPLC) methods as described before [12, 13].
Statistics
Pharmacokinetic parameters were log transformed before statistical analysis. 
Descriptive statistics were calculated for AUC0-24h, Cmax, Clast , t1/2, CL/F and V/F. Values 
for tmax were not transformed and a median was calculated. Proportions of patients 
who reached a peak plasma concentration within a reference range of 8-24 mg/L for 
rifampicin, 20-50 mg/L for pyrazinamide,  and 2-6 mg/L for ethambutol [14] were 
calculated. For moxifloxacin, a minimum inhibitory concentration (MIC) of 0.5 mg/L 
was used to calculate the pharmacodynamic parameters of AUC0-24h / MIC and Cmax 
/ MIC. The AUC0-24h / MIC and Cmax / MIC of moxifloxacin should reach the desired 
values of 100 and 10, respectively. These values are established for fast growing Gram 
negative bacilli [15], and may possibly apply to M.	 tuberculosis	as well [16-20]. The 
mutant prevention concentration (MPC) of moxifloxacin was set at 2.5 mg/L [21]. The 
pharmacodynamic parameter time > mutant prevention concentration was calculated. 
Univariate analyses were performed to assess the effects of gender, age, body weight 
and BMI, pharmacokinetic parameters of other drugs or the use of co-medication 
on the AUC0-24h, Cmax and tmax of all evaluated drugs. Values for pharmacokinetic 
parameters between subgroups were compared using either an independent-samples 
t-test or a Wilcoxon rank-sum test. A multivariable analysis was performed to assess 
the variation in AUC0-24h and Cmax to be attributed to the presence of the variables 
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which emerged from the univariate analysis. All statistical evaluations were performed 
with SPSS for Windows version 12.0.1 (SPSS Inc., Chicago, IL). P values of less than 0.05 
were considered significant in all analyses. 
Results
Patients
Forty-one tuberculosis patients were included in the study. Patient and treatment 
characteristics are summarized in Table 1 and 2. Concomitant medication as used by 
the study population is shown in Table 2. These drugs are not expected to influence 
the pharmacokinetics of the measured antituberculosis drugs, except for the 
decreasing effect of prednisolone on the exposure to isoniazid. None of the patients 
had compromised kidney or liver function. 
Pharmacokinetics of antituberculosis drugs
The pharmacokinetic parameters of the anti tuberculosis drugs are summarized 
in Table 3. Pharmacokinetic curves of rifampicin, pyrazinamide, ethambutol and 
moxifloxacin are depicted in Graph 1. At the time of writing of this manuscript, 
the pharmacokinetic parameters of isoniazid had not been evaluated and they are 
therefore not presented.  
Rifampicin and desacetylrifampicin
A remarkable interpatient variability was observed in the exposure to rifampicin (range 
11.7-118.6 h *mg /L). Ten of the 33 (30%) patients receiving rifampicin did not reach the 
reference  peak plasma concentration of 8 mg/L. Two of the patients had a maximum 
concentration above the upper limit of the reference range. No differences were found 
in exposure between male and female patients. Surprisingly, no significant correlation 
was found between body weight or BMI and the AUC of rifampicin (Pearson correlation 
coefficient -0.278, p = 0.117 and -0.207, p = 0.265, respectively). Rifampicin AUC0-24h 
was correlated to Cmax, C2h and Clast (Pearson correlation coefficient 0.887, 0.823 and 
0.734, all p < 0.01, respectively). The pharmacokinetic parameters of rifampicin and 
desacetylrifampicin correlated significantly with each other. The mean (range) ratio of 
the AUC values of the active metabolite desacetylrifampicin and rifampicin was 0.14 
(0.06-0.27) and the mean (range) ratio for Cmax was 0.13 (0.05-0.25). Co-administration 
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of pyrazinamide was associated with a reduction in the AUC0-24h and Cmax of rifampicin 
(58.1 vs. 39.8 mg h/L, p = 0.051 and 13.7 vs. 8.8 mg h/L, p < 0.01). Co-administration of 
proton pump inhibitors did not influence the exposure to rifampicin (p > 0.05).
Pyrazinamide
The plasma pyrazinamide concentrations showed relatively small inter-patient 
variability (range in AUC0-24h: 266.7-678.3 mg h/L). None of the patients had a Cmax 
below the lower limit of the reference range of 20-50 mg/L, four patients had a Cmax 
pharmacokinetics of tb drugs in patients from tb referral centers
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Table 1  Patient and disease characteristics for study participants.
Characteristic 
Male, n (%) 32 (78%)
Age, mean (s.d.) 44.1 (17.1)
Body weight (kg), mean (s.d.) 64.5 (14.6)
Body Mass Index (kg/m2), mean (s.d.) 21.5 (4.6)
Ethnicity, n (%) 
 Caucasian 11 (27%)
 Asian 6 (15%)
 Sub Saharan African 13 (32%)
 Middle East 7 (17%)
 Mixed origin 4 (10%)
Type of TB, n (%) 
 Pulmonary 33 (81%)
 Miliary  2 (5%)
 Extrapulmonary 6 (15%)
Comorbidity, n (%) 
 HIV infection 3 (7 %) 
 Type 2 diabetes 2 (5%)
 Cardiovascular disease 3 (7%)
 Respiratory disease 2 (5%)
 Gastrointestinal disorders (diarrhoea, nausea)  2 (5%)
 Cancer 2 (5%) 
 Endocrine disorder  1 (2%)
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Table 2  Patient and disease characteristics for study participants.
Tuberculosis  No. of  Other tuberculosis drugs
medicationa patients
HRZE  13
HRZ 8 
HR  7 
HRZEM 4 Kanamycine (1)
RZM 1 
RM  2 
M  3 Clofazimine (2) rifabutin (1) protionamide (1) linezolid (1)
EM  2 Clofazimine (2) linezolid (1)
ZEM 1 Clofazimine (1) linezolid (1)
a H: isoniazid, R: rifampicin, Z: pyrazinamid, E: ethambutol, M: moxifloxacin.
Other drugs    No. of 
   patients
Vitamins:   22
 Multivitamins (4) pyridoxine (15) hydroxocobalamine (1)  
 folic acid(2) 
Mineral regulating agents
 Alendronate sodium (1) ferrofumarate (2)    3
Benzodiazepins:   25
 Oxazepam (3) temazepam (16) diazepam (2) lorazepam (2)  
 zolpidem (1) zopiclone (1)   
Gastrointestinal tract:  19
 Omeprazole (7) pantoprazole (8) domperidone (1) ranitidine (1) 
 metoclopramide (1) sucralfate (1) 
Analgesic:   19
 Acetaminophen (14) codeine (2) tramadole (1) methadone (1)  
 diclofenac (1) 
Cardiovascular:  13
 Amiloride/HCl thiazide  (1) atenolo l(1) captopril (1) 
 carbasalate calcium (1) digoxin (1) fosinopril (1) furosemide (2)  
 nadroparin (3) nifedipine (1) triamterene/HCl thiazide (1) 
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above the reference range. No correlations were found between gender, body weight 
or BMI with the AUC0-24h, Cmax or tmax of pyrazinamide. The AUC0-24h of pyrazinamide 
was significantly correlated to Cmax, C2h and Clast (Pearson correlation coefficient 0.873, 
0.711 and 0.474, p < 0.01, p < 0.01 and p = 0.04, respectively).
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Anti(retro)virals:  7
 Efavirenz (2) tenofovir (2) emtricitabine (2) valaciclovir (1)  
Urinary tract:  2
 Alfuzosin (1) tamsulosin (1)    
Antihistaminics:  4
 Promethazine (2) cetirizine (2) 
(Gluco)corticoids:  4
 Prednisolone (1) hydrocortisone (1) dexamethasone (1)             
 Budesonide (1) 
Laxatives:  4
 Bisacodyl (1) psyllium fibers (1) lactulose (2)  
Airways:  4
 Salbutamol/ipratropium (2) ipratropium (1) tiotropium (1) 
Antidepressants:  2
 Mirtazapine (1) paroxetine (1) 
Antimicrobials:  2
 Ciprofloxacin (2)  
Antibacterials:  2
 Cotrimoxazole (2)  
Hormonal:  2
 Octreotide (1) levothyroxine (1) 
Glucose:  4
 Insulin (2)  
 Metformin (1) tolbutamide (1) 
Antimycotics:  1
 Nystatin (1) 
Antiprotozoics:  1
 Pentamidine (1)  
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Graph 1  Pharmacokinetics of antituberculosis drugs (mean and 
standard deviation).
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AUC0-24h and Cmax of pyrazinamide seemed to be increased when combined with 
ethambutol. The mean AUC0-24h and Cmax of pyrazinamide were 327.4 mg h/L and 
39.4 mg/L when given alone (n = 6), and 429 mg h/L and 47.7 mg/L, respectively when 
combined with ethambutol (n = 13), both p < 0.05. 
Ethambutol
Large variability in exposure to ethambutol was observed (11.5 to 87.9 mg h/L). One 
patient (5%) had a Cmax below and one above the reference range of 2-6 mg/L. Female 
patients seemed to have a higher AUC0-24h  and Cmax for ethambutol (44.5 vs. 20.8 mg 
h/L and 4.1 vs. 3.1, both p < 0.05 respectively), but it should be noted that from the twenty 
pharmacokinetic curves, only four were from female patients. Both AUC0-24h and Cmax 
of ethambutol tended to increase with a higher BMI (Pearson correlation coefficient, 
0.471, p = 0.042 and 0.436, p = 0.062), but not with body weight (Pearson correlation 
coefficient, 0.158, p = 0.505 and 0.297, p = 0.204). Smoking appeared to be significantly 
associated with a reduction in the AUC0-24h of ethambutol (30.7 vs. 19.3 mg h/L, p = 
0.042). The AUC0-24h of ethambutol was correlated to Cmax and Clast significantly 
(Pearson correlation coefficient 0.774 and 0.902, both p < 0.01, respectively), but not to 
C2h (Pearson correlation coefficient 0.338, p = 0.237). 
Moxifloxacin 
Large variability in exposure to moxifloxacin was observed (range 15.3-84.2 mg h/L). 
The AUC0-24h of moxifloxacin was significantly correlated to the Cmax and Clast (Pearson 
correlation coefficient 0.909 and 0.939, p < 0.01). Previous studies [13, 22] reported 
an interaction between rifampicin and moxifloxacin. This current study showed that 
the mean AUC0-24h of moxifloxacin was 34% lower when combined with rifampicin 
compared to moxifloxacin without rifampicin (28.6 vs. 43.3 mg h/L, p = 0.195, n = 5 versus 
n = 7). 
Three out of 12 had an AUC0-24h/MIC above 100 (25%) and one of them had a Cmax/
MIC above 10 (8%), none of these patients were using rifampicin. The geometric mean 
values (range) for AUC0-24h/MIC and Cmax/MIC were 56.2 (44.7-76.5) and 5.6 (4.8-7.9) 
respectively, when moxifloxacin was given with rifampicin, and 76.3 (30.6-168.5) 
and 7.34 (5.15-11.64) respectively, when it was given alone (p = 0.195 and p = 0.126, 
respectively). The median time > MPC was 1.0 h. when moxifloxacin was given with 
rifampicin and 5.5 h. when it was given without rifampicin (p = 0.038). 
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Multivariate analysis
Multivariate analysis of possible determinants did not result in a valid linear regression 
equation for AUC or Cmax for  any of the antituberculosis drugs.
Discussion 
In this study, we have described the steady-state pharmacokinetic parameters of 
rifampicin, pyrazinamide, ethambutol and moxifloxacin and their determinants in a 
cohort of hospitalized tuberculosis patients admitted to Dutch referral centers. 
Rifampicin showed the highest interindividual variation in pharmacokinetics and 
approximately 30% of the patients using rifampicin (10 mg/kg) did not achieve the 
minimum reference concentration. In comparison, McIlleron showed that 67% of 
patients did not reach the minimum reference concentration in South Africa [23]. 
In this study, HIV infection was associated with lower plasma drug concentration. 
In our study, only three patients were HIV infected, and no statistical analysis was 
performed to confirm this observation because of the small number of HIV-infected 
cases in our cohort. Type 2 diabetes is another risk factor for low exposure to TB 
drugs [24]. Only two patients had diabetes in our study and therefore, no statistical 
analysis was performed. An earlier study performed by us in Indonesia, showed that 
42% of Indonesian TB patients had a rifampicin plasma concentration below the 
reference range after a standard dose at two hours post-dose  [12]. Considering these 
differences in percentages, it seems that dissimilarities in patient population may 
affect the pharmacokinetics of rifampicin. Tappero found a difference in absorption 
between HIV infected North American and HIV infected South African patients [25]. 
Of note, these reference ranges are based on expected plasma drug concentrations as 
established in healthy volunteers [14] and have not been derived from pharmacokinetic-
pharmacodynamic correlations in TB patients. 
Antimicrobial activity of rifamycins in general is considered to be concentration-
dependent [15, 26, 27]. Previous studies have also found a relation between low rifampicin 
concentrations and suboptimal response [3, 5]. Higher doses of rifampicin are associated 
with improved early bactericidal activity [28], improved killing in the mouse model [29] 
and may possibly result in better treatment results [30] or even reduced treatment 
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duration [31]. However, other studies [8, 10] did not find an association between the 
maximum rifampicin concentrations and the rate of culture conversion. 
Our results suggest that pyrazinamide is able to reduce the plasma concentrations 
of rifampicin. This has been shown before, although to a much smaller extent [32]. 
The mechanism for this possible interaction and for the effect of ethambutol on 
pyrazinamide as observed in this study are not clear. 
To our knowledge, the negative impact of smoking on the exposure to ethambutol 
was never reported before, except for the ethambutol concentration in alveolar cells 
in smoking women being higher than in non-smoking subjects [33]. It is known that 
smoking induces cytochrome P450 (CYP) 1A2, and that 8-15% of the ethambutol appears 
in the form of metabolites. If ethambutol is a substrate for CYP 1A2 enzymes remains 
to be investigated. 
The activity of moxifloxacin against M.	tuberculosis has been found to be best described 
by the AUC0-24h/MIC ratio [18, 34]. The greatest bactericidal effect and a decreased 
probability of resistance development occurs at an AUC0-24h/MIC ratio above 100-125 
or Cmax/MIC above 10 or more, at least for fast-growing Gram negative bacilli [16, 20, 
34]. Seventy-five percent of the patients did not reach these desired reference ranges 
and this is roughly comparable with our study in Indonesian TB patients [13], in which 
95% did not reach these values. Previous findings were confirmed: moxifloxacin plasma 
concentrations were only one hour above MPC when combined with rifampicin 
versus 5.5 hour when given without rifampicin [13]. The clinical relevance of these 
pharmacodynamic parameters in the setting of multidrug TB treatment is yet unclear. 
As regards to pharmacokinetic determinants, female gender was associated with 
decreased exposure to ethambutol and moxifloxacin (data not shown), although the 
first finding was in contrast to previous findings [23]. The reducing effect of rifampicin 
on the plasma concentrations of moxifloxacin as found by us and others [13, 22], was 
confirmed. We believe that additional research on the optimal dose of moxifloxacin 
with or without concomitant rifampicin for the treatment of tuberculosis is essential. 
The differences in exposure to TB drugs between patients could have been detected by 
physicians if they applied Therapeutic Drug Monitoring (TDM). When patients fail to 
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respond appropriately to directly observed therapy, have renal or hepatic dysfunction, 
drug-drug interactions are suspected or an absorption problem is suspected, plasma 
concentration monitoring and repeat susceptibility testing should be considered [27]. 
TDM  allows one to determine the extent to which the failure to achieve the desired 
clinical and bacteriological outcomes can be attributed to inadequate dosing. It seems 
reasonable to check the plasma concentrations and adjust the doses of these drugs 
before embarking on many months of potentially toxic treatment [27]. TDM can be 
performed by sampling TB drugs two hours after intake, since the effect of TB drugs 
is concentration-dependent and this study showed that the plasma concentration 
at two hours post-dose (C2h) of rifampicin, pyrazinamide and moxifloxacin, but not 
ethambutol, can serve as a good surrogate marker for exposure to antituberculosis 
drugs (AUC).
The strength of this study is that the pharmacokinetic data were obtained with 
intensive pharmacokinetic monitoring resulting in good estimates of pharmacokinetic 
parameters. Our study population is a good reflection of the target population. 
However, the study was limited by the small sample size, which hampers statistical 
power to detect correlations and interactions. Subgroup analysis was often not possible 
due to the small sample size. In addition, no pharmacodynamic data were assessed 
in this study. The number of participants in this intensive pharmacokinetic study 
would not have been sufficient to assess firm pharmacokinetic-pharmacodynamic 
relationships. 
In summary, in order to improve tuberculosis treatment, a better knowledge of  the 
pharmacokinetics in patients is needed. This study showed a large interindividual 
variation in pharmacokinetics of rifampicin. Thirty percent of the study 
population did not reach the reference plasma drug concentrations for rifampicin. 
Furthermore, co-administration of pyrazinamide was associated with reduced 
exposure to rifampicin. Ethambutol was associated with an increased exposure to 
pyrazinamide and smoking was associated with reduced  exposure to ethambutol. 
Finally, the reducing effect of rifampicin on the exposure to moxifloxacin was 
confirmed. The C2h concentration of rifampicin, pyrazinamide and moxifloxacin, but 
not ethambutol, correlates with Cmax and AUC. The significance of these findings 
should be studied in additional pharmacokinetic and pharmacodynamic studies in 
larger patient populations. 
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Abstract
Background: Type 2 diabetes (DM) is a strong risk factor for tuberculosis (TB), and 
is associated with a slower response to TB treatment and a higher mortality. As 
lower concentrations of antituberculosis drugs might be a contributing factor, we 
compared the pharmacokinetics of rifampicin in tuberculosis patients with and 
without diabetes.
Methods: Seventeen adult Indonesian TB patients with type 2 diabetes (TB-DM) and 
17 age and gender matched TB patients without diabetes were included during the 
continuation phase of TB treatment, using rifampicin 450 mg (10 mg/kg) and 600 
mg isoniazid three times weekly. Steady-state plasma concentrations of rifampicin 
and its metabolite desacetylrifampicin were assessed at 0, 2, 4 and 6h after drug 
intake. 
Results: Geometric means (95% CI) of rifampicin exposure (AUC0-6h) were 12.3 mg·h/L 
(8.0-24.2) in TB-DM patients, and 25.9 mg·h/L (21.4- 40.17) in TB patients (p=0.003). 
Similar differences were found for the Cmax of rifampicin. No significant differences 
in tmax values of rifampicin were observed. The AUC0-6h of desacetylrifampicin 
was also much lower in TB-DM versus TB patients (geometric means 0.60 versus 
3.2 mg·h/L, p =0.001). Linear regression analysis revealed that higher body weight 
(p<0.001), the presence of DM (p=0.06) and the plasma glucose concentration 
(p=0.016) were  correlated with exposure to rifampicin. 
Conclusion:	 Exposure (AUC0-6h) to rifampicin was 53% lower in Indonesian 
tuberculosis patients with diabetes compared to patients with TB only. Tuberculosis 
patients with diabetes and a higher body weight may need a higher dose of 
rifampicin. 
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Introduction
Worldwide the prevalence of type 2 diabetes (DM) is increasing, especially in 
developing countries, where tuberculosis (TB) is highly endemic. More specifically, 
it is estimated that, in 20 years, 75% of the patients with DM will live in countries 
which harbor the majority of tuberculosis cases [1]. As a result, a growing number of 
tuberculosis patients will have diabetes. Recent studies from Saudi Arabia [2], Russia 
[3], and from our own group in Indonesia [4] show that between 10 and 30% of patients 
with TB may have diabetes at this time. This is important, because DM seems to be 
associated with a less favourable response to tuberculosis treatment [5, 6]. Indeed, in 
a large Indonesian cohort of TB patients, the presence of diabetes was associated with 
significantly lower sputum conversion rates after eight weeks of treatment [7].
Altered pharmacokinetics of antituberculosis drugs might explain the adverse 
effect of diabetes on the response to tuberculosis treatment. It has been shown 
that diabetes patients have lower plasma concentrations of certain drugs [8, 9]. If 
this also applies to antituberculosis drugs, this might explain the slower response 
to tuberculosis treatment in diabetes patients. Lower plasma concentrations of 
antituberculosis drugs have been associated with clinical failure and acquired drug 
resistance [10-12]. For rifampicin, a key drug in tuberculosis treatment, available 
evidence suggests that its efficacy is dependent on exposure to the drug or to the 
maximum drug concentrations achieved [13].
 
Recent studies including ours, have reported low plasma concentrations of TB 
drugs in patients [14-17] but thus	far no studies have systematically examined the 
pharmacokinetics of tuberculosis drugs in patients with diabetes. Therefore in the 
present study, we compared plasma concentrations of rifampicin in tuberculosis 
patients with and without type 2 diabetes.
Methods
Study design and recruitment of subjects
We conducted a prospective pharmacokinetic study in the urban outpatient 
tuberculosis clinic Perkumpulan Pemberantasan Tuberculosis Indonesia (PPTI) in 
exposure to rifampicin reduced in type 2 diabetes
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Jakarta, Indonesia. Within the context of a larger study evaluating the effect of 
diabetes on the immune response in tuberculosis, tuberculosis patients with type 2 
diabetes (TB-DM) were included, and age and gender matched TB patients without 
diabetes (TB) were selected as controls. 
Tuberculosis diagnosis was based on clinical symptoms and chest radiography 
examination and was confirmed by microscopic detection of acid-fast bacilli and 
culture of Mycobacterium	tuberculosis.	 Treatment consisted of a standard regimen 
of daily rifampicin, isoniazid, pyrazinamid, and ethambutol for two months, as 
well as rifampicin and isoniazid thrice weekly for another four months  (2HRZE/ 
4H3R3), according to the Indonesian National Tuberculosis Program (NTP). 
All patients were administered identical TB drugs from a national manufacturer. 
Isoniazid and rifampicin were formulated in separate tablets. Bioequivalence of the 
rifampicin tablets to an international reference standard was established previously 
[18]. All patients were included after at least two weeks of tuberculosis treatment 
in the continuation phase. The Indonesian NTP prescribes 450 mg rifampicin (10 
mg/kg, considering the lower average body weight of Indonesian people) and 600 
mg isoniazid three times a week during the continuation phase. Capillary and 
venous blood glucose were measured in all patients before start of tuberculosis 
treatment. Newly established diabetes was diagnosed according to WHO criteria 
[19], that is a fasting blood glucose value ≥ 7.0 mmol/L, a capillary blood glucose 
value of ≥ 6.1 mmol/L or a random plasma glucose value of ≥ 11.1 mmol/L, measured 
at two different time points. A diagnosis of diabetes was also accepted if patients 
had established diabetes and were using antidiabetic agents. At the time of 
blood sampling for measurement of rifampicin pharmacokinetics, diabetes was 
confirmed, as hyperglycemia may disappear during tuberculosis treatment [20]. 
This confirmation showed that capillary fasting blood glucose concentrations 
were ≥ 6.1 mmol/L in all patients and fasting blood glucose from plasma was ≥ 7.0 
mmol/L in all but one subject whose diabetes was very strictly controlled (Table 1). 
In accordance with national guidelines, tuberculosis patients with type 2 diabetes 
were treated with oral antidiabetic drugs after 2-4 weeks of tuberculosis treatment. 
Study subjects had to be at least 18 years of age, and were not allowed to use any 
drug that is known to affect the pharmacokinetics of rifampicin. Patients were 
excluded if they were pregnant or lactating, had gastro-intestinal problems, e.g. 
diarrhea or vomiting on the days preceding the pharmacokinetic assessment, were 
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HIV positive,	or if they had elevated creatinine (>1.25 times above the upper limit 
of normal) or alanine transaminase levels (>2 times the upper limit of normal). 
The study protocol of the main diabetes-immune response study was approved by the 
local institutional review board. Written informed consent for the pharmacokinetic 
substudy was obtained from all subjects. 
Pharmacokinetic assessment
From 11 p.m. on the day preceding the study day until four hours after drug intake 
on the study day, patients refrained from the intake of any food or any drugs, other 
than the study medication. Considering that the patients did not take food, they also 
did not take their antidiabetic drugs in this period. 
On the day of pharmacokinetic assessment the patients took 450 mg of rifampicin 
and 600 mg of isoniazid with 230 ml of still water. Serial venous blood samples 
were collected just prior to, and 2, 4 and 6 hours after witnessed drug intake in a 
fasted state. Plasma was immediately separated and frozen at –20°C, transferred 
to –80°C within 60h, until transport on dry ice to the Netherlands for bio-analysis. 
The stability of rifampicin and its metabolite desacetylrifampicin under all these 
conditions has been validated before. 
exposure to rifampicin reduced in type 2 diabetes
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Table 1  Patient characteristics.
  TB-DM TB p-value
Male sex (%) 9 / 17 (53%) 11 / 17 (65%) 0.49θ
Age (yr) 50 (28-60) 48 (27-59) 0.85δ
Weight (kg) 55.6 (36.6-75.2) 46.2 (33.6-70.8) 0.01
     Male 55.6 (45-75.2) 50.0 (33.6-55.2) 0.03δ
     Female 55.4 (36.6-65.2) 40.4 (36.2-70.8) 0.15δ
Body mass index (kg/m2) 23.9 (16.5-27.7) 18.9 (13.8-33.0) 0.007δ
     Male 20.9 (16.5-26.6) 19.1 (13.8-21.0) 0.015δ
     Female 24.8 (18.8-27.7) 18.7 (15.6-33.0) 0.19δ
Fasting blood glucose (mmol/L) 9.3 (6.3-12.3) 5.2 (4.4-5.6) <0.001δ
HbA1c (%) 9.85 (0-13) 5.6 (0-7) 0.014δ
Rifampicin dose (mg/kg body weight) 8.1 (6.0-12.3) 9.7 (6.4-13.4) 0.008δ
Data are presented as median (range). θ Pearson Chi-square test. δ Independent t-test.
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Bioanalysis
Total rifampicin concentrations and the concentrations of its main metabolite 
desacetylrifampicin were analyzed by a validated high performance liquid 
chromatography (HPLC) method with UV detection. Two hundred microliters of 
acetonitrile and 10 µL ascorbic acid solution were added to 200 µL of plasma sample. 
The mixture was vortexed for 20 s and centrifuged for 5 min. Then 400 µl of 10 mM 
potassium dihydrogen phosphate was added and the mixture was vortexed and 
centrifuged again. Two hundred microliters of the clear supernatant were injected 
in the HPLC apparatus. Chromatographic analysis was performed on an Omnispher 
5 C18 column  (250 by 4.6 mm, Varian, Middelburg, the Netherlands) protected with 
a Chromguard RP guard column (10 by 3 mm, Varian, Middelburg, the Netherlands). 
The mobile phase consisted of 10 mM potassium dihydrogen phosphate (pH 4.5) and 
acetonitrile (62:38 % v/v). The flow rate was set at 1 ml/min and the wavelength 
for UV detection was 334 nm. Rifampicin and desacetylrifampicin retention times 
were 7.8 and 3.6 min., respectively. The lower limits of quantitation for rifampicin 
and desacetylrifampicin were 0.28 and 0.15 mg/L respectively. Accuracy was 99.8%, 
100.4%, and 100.4% for the rifampicin standard concentrations of 2.9 mg/L, 9.5 
mg/L and 23.7 mg/L respectively. The accuracy of the desacetylrifampicin standard 
concentrations of 0.09 mg/L, 2.25 mg/L and 27.0 mg/L was 103.9%, 102.4% and 102.6% 
respectively. Intraday precision and between-day precision (in %, coefficient of 
variation) ranged from 0.7% to 1.1% and from 0.1% to 0.6% for rifampicin, and from 
0.9% to 2.9% and from 0.5 to 3.6% for desacetylrifampicin, respectively. 
Pharmacokinetic analysis
Pharmacokinetic parameters of rifampicin and desacetylrifampicin were calculated 
using noncompartmental methods. The area under the plasma concentration time 
curve from 0h until 6 hours after the dose (AUC0-6h) was assessed using the linear 
trapezoidal rule. The highest observed plasma concentration was defined as Cmax 
and the corresponding sampling time as tmax. Cmax and tmax were determined 
directly from the plasma concentration-time data. Pharmacokinetic parameters 
were calculated by using the WinNonlin software package (version 4.1; Pharsight 
Corporation, Mountain View, California). The relative exposure of metabolite 
desacetylrifampicin compared to rifampicin was expressed as the ratio of the 
metabolite and the parent drug.
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Data and statistical analysis 
Differences in AUC0-6h and Cmax values in TB patients versus TB-DM patients were 
tested with an independent-samples t-test on the natural logarithm-transformed 
pharmacokinetic data. Pearson Chi-square test was used to determine the difference 
in proportions of patients reaching a reference peak plasma concentration of 8 mg/L 
for rifampicin [21, 22]. Values for tmax were not transformed and were compared 
using Wilcoxon rank sum test. Univariate analyses were performed in the separate 
groups (TB and TB-DM) to assess the effect of gender, age, body weight and fasting 
plasma glucose.  A multivariate linear regression analysis with forced entry was 
performed to assess the variation in rifampicin pharmacokinetics (AUC0-6h and 
Cmax) attributable to the presence of diabetes and other variables that emerged 
from the univariate analyses. All statistical evaluations were performed with SPSS 
for Windows, version 12.0.1 (SPSS Inc., Chicago, IL, USA). P values less than 0.05 were 
considered statistically significant in all analyses.
Results
Patients
Thirty-six patients with pulmonary tuberculosis were recruited for the study, of 
whom two patients were excluded from further analysis. Rifampicin concentrations 
in one patient could not be analyzed due to interference from endogenous substances. 
A analysis of the second excluded patient revealed a trough plasma rifampicin 
concentration of 2.8 mg/L before witnessed drug intake, which suggests that the 
patient had already taken the drug before arrival at the clinic. The remaining 34 
patients presented with a 2 – 6 month history of cough (100%), shortness of breath 
(85%), fever (91%), night sweats (68%), and weight loss (85%). All patients showed 
chest radiograph abnormalities, and sputum microscopy and M.	 tuberculosis	
culture were positive for all patients. Characteristics of the patients are presented 
in table 1. Twelve of 17 (71%) tuberculosis patients with type 2 diabetes (TB-DM) 
used oral antidiabetic treatment at the time of plasma rifampicin measurement. 
Glibenclamide was mostly used, only one patient used glipizid. No patient was 
treated with metformin or insulin. 
Two patients used captopril for the treatment of hypertension. These co-medications 
are not known to affect the pharmacokinetics of anti-TB drugs. As expected, body 
exposure to rifampicin reduced in type 2 diabetes
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weight and body mass index (BMI) were significantly higher in the TB-DM group 
(Table 1). As a result, the rifampicin dosage per kg of body weight was lower for the 
patients in the TB-DM group. 
Pharmacokinetics of rifampicin and desacetylrifampicin
Marked interindividual variability was observed in the exposure to rifampicin 
(range AUC0-6h; 5.5-71.6 mg·h/L). Tuberculosis patients with DM had significantly 
lower rifampicin plasma concentrations than TB patients without DM (Table 2). The 
mean exposure to rifampicin (AUC0-6h) in TB-DM patients was 53% lower than the 
exposure in TB patients (Figure 1). Similar differences were found for Cmax, and a strong 
correlation was observed between AUC0-6h and Cmax in both TB and TB-DM patients 
(Pearson correlation coefficient 0.983, and 0.987; p<0.01). The percentage of patients 
who reached a reference value of at least 8 mg/L for rifampicin was significantly 
lower in TB-DM patients compared to TB patients. Although the median rifampicin 
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Table 2  Pharmacokinetic parameters of rifampicin and desacetylrifampicin 
in tuberculosis patients with type 2 diabetes (n=17) and patients 
without type 2 diabetes (n=17). 
.
Parameter# TB-DM TB Ratio TB-DM/TB p-value
Rifampicin*     
 AUC0-6h (mg⋅h/L) 12.3 (8.0-24.2) 25.9 (21.4– 40.2) 0.47 (0.31-0.77) 0.003ς
 Cmax (mg/L) 3.49 (2.4- 6.3) 6.74 (5.6-10.1) 0.52 (0.34-0.80) 0.004ς
 > 8mg/L (%) 1 / 17 (5.9%) 8 / 17 (47.0%)  0.007θ
 tmax (h; median, 
 range)    4 (2-6) 2 (2-4)  0.52ψ
Desacetylrifampicin    
 AUC0-6h (mg⋅h/L) 0.60 (0.76-2.06) 3.2 (2.7-6.0) 0.27 (0.17-0.62) 0.001ς
 Cmax (mg/L) 0.24 (0.26 –0.65) 0.87 (0.72-1.60) 0.40 (0.09-0.82) 0.023ς
 tmax (h; median, 
 range) 4 (4-6) 4 (4-6)  0.524ψ
Data are represented as geometric mean (95% CI), unless stated otherwise. # AUC0-6: the area 
under the plasma concentration-time curve from time 0 until 6 hours post-dose,  
Cmax: the maximum observed plasma concentration, tmax: the time to Cmax
* 450 mg (10 mg/kg), in the continuation phase of tuberculosis treatment. ς Independent t-test  
on ln transformed data. θ Pearson Chi-square test. ψ Wilcoxon rank sum test.
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tmax values differed between TB-DM and TB patients, this difference did not reach 
statistical significance at all. With regard to desacetylrifampicin, the AUC0-6h and 
Cmax of desacetylrifampicin were significantly lower in the TB-DM group, while 
tmax was not different. The geometric mean (95% CI) of the desacetylrifampicin/ 
rifampicin AUC0-6h ratio was 0.13 (0.11-0.15) in the TB-group, and 0.09 (0.06-0.11) in 
the TB-DM group (p=0.009.  
Univariate analyses
In the TB-DM group, no statistically significant difference was found in exposure 
between male and female patients (AUC0-6h 18.8 vs. 13.0 mg·h/L respectively; 
NS). In the TB-group, male patients had lower rifampicin exposure than females 
(mean AUC0-6h 24.4 vs. 42.5 mg·h/L; p=0.048). Age did not show a significant 
correlation with rifampicin pharmacokinetics. Body weight inversely correlated 
exposure to rifampicin reduced in type 2 diabetes
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Figure 1  Mean plasma concentration time profiles of rifampicin in  
17 tuberculosis (TB) and 17 tuberculosis patients with diabetes 
(TB-DM), with standard deviations.
The open circles represent the tuberculosis patients without diabetes and the closed  
squares represent the tuberculosis patients with diabetes. * P value of comparison  
between groups < 0.05
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with rifampicin exposure, both in the TB-DM group (Pearson correlation coefficient 
-0.462, p=0.062), and in the TB group (-0.468, p=0.058; Figure 2). The parallel lines 
in figure 2 demonstrate an equal effect of body weight on exposure in both groups. 
In addition, the difference between the dashed (TB) and solid (TB-DM) lines illustrates 
a clear effect of the presence of diabetes on the exposure to rifampicin. Fasting 
plasma glucose showed an inverse correlation with AUC0-6h (Pearson correlation 
coefficient –0.476, p=0.004) in the group as a whole. 
Multivariate analysis
The assumptions for multivariate linear regression were met, including the absence 
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Figure 2  Natural logarithm (ln) of the Area under the Curve (AUC0-6h) of 
rifampicin versus body weight.
The dashed regression line represents the tuberculosis patients without diabetes and the 
solid regression line represents the tuberculosis patients with diabetes. 
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of multicollinearity, independence of the outcome value and linearity of the model. 
The effect of the independent variables body weight and diabetes on the dependent 
variable ln AUC0-6h were assessed in Model 1 (Table 3). The absolute difference in 
ln AUC0-6h between TB and TB-DM patients was 0.745. Every additional kg of body 
weight decreased ln AUC0-6h by 0.035. The weight difference between TB and TB-
DM patients was approximately 9.5 kg. The weight corrected portion in the absolute 
difference for the presence of type 2 diabetes was 0.425, corresponding with 57% of 
the difference in exposure to rifampicin between groups. 
A second regression analysis was performed in which fasting blood glucose was 
assessed as independent variable for ln AUC0-6h. The presence of diabetes and 
fasting blood glucose cannot be assessed in one model simultaneously, as these 
variables are highly correlated. Multivariate regression analysis revealed that 
fasting blood glucose was significantly associated with rifampicin AUC0-6h (Table 3) 
and Cmax (data not shown). Every extra mmol of fasting blood glucose/L resulted in 
a decrease of ln AUC0-6h of 0.114. The mean difference of approximately 4 mmol/L in 
fasting plasma glucose between TB and TB-DM patients corresponds with 61% of the 
difference in exposure to rifampicin. Fasting blood glucose and diabetes status show 
equal effects on the dependent variable ln AUC0-6h. 
exposure to rifampicin reduced in type 2 diabetes
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Table 3  Regression analysis of independent associations of various  
variables with exposure to rifampicin (AUC0-6h).
Model Regression parameter B* (SE) p-value
1A Intercept  4.889 (0.544) <0.001
 Body weight - 0.035 (0.011) 0.004
 Type 2 diabetes - 0.425 (0.219) 0.062
2B Intercept  5.423 (0.517) <0.001
 Body weight - 0.034 (0.011) 0.004
 Fasting plasma glucose at PK assessmentζ - 0.114 (0.045) 0.016
A Adjusted R2 = 0.424   
B Adjusted R2 = 0.466 
* B: the regression coefficient for determining the regression equation, SE: standard error.  
Adjusted R2: reflects the effect size, i.e. 42.2% of the variation in ln AUC0-6h  is explained by  
the model. ζ PK assessment: pharmacokinetic assessment
Nijland.1046-Proefschrift.indd   101 07-04-2009   15:40:40
102
Thus, body weight and diabetes and hyperglycemia are strongly and inversely 
associated with rifampicin AUC0-6h and Cmax. 
Discussion
 
In this study, we showed that exposure (AUC0-6h) to rifampicin was 53% lower in 
Indonesian tuberculosis patients with diabetes, compared to tuberculosis patients 
without diabetes. Similarly, Cmax of rifampicin was above the target concentration 
of 8 mg/L in only one out of seventeen (6%) tuberculosis patients with diabetes, 
compared to eight of seventeen (47%) patients without diabetes. A higher body 
weight and the presence of diabetes contributed to lower rifampicin exposure. 
In addition, more profound hyperglycemia was associated with lower plasma 
rifampicin concentrations. 
The magnitude of the difference in AUC0-6h and Cmax of rifampicin between TB-
DM patients and TB patients was much larger than anticipated and is likely to 
be clinically relevant. A 50% lower exposure to a key tuberculosis drug such as 
rifampicin may cause clinical failures and favor the emergence of resistance. In 
fact, the findings of this study suggest that the unfavorable response of patients 
with type 2 diabetes to tuberculosis drugs [5, 6] may at least partially be explained 
by differences in pharmacokinetics. If these findings are confirmed, higher fixed 
dosages of rifampicin may be warranted for patients with diabetes and a higher 
body weight. If available, physicians may consider to assess plasma concentrations 
of rifampicin in diabetes patients in order to individualize dosing. In this case we 
would advise to use multiple time point sampling.   
Several mechanisms have been postulated to explain the altered pharmacokinetics 
in diabetes patients. The absorption, distribution, metabolism and excretion of drugs 
could all be changed in diabetes [9]. 
With regard to absorption, gastro-intestinal tract problems are common in 
diabetes patients. In this study, diarrhea and vomiting were excluded beforehand. 
Gastroparesis (delayed gastric emptying) could decrease the rate of absorption, as 
reflected in an increase in tmax and a decrease in rifampicin Cmax. However, this 
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study did not reveal any marked difference in tmax between the two study groups, 
suggesting that delayed absorption was not responsible for a lower Cmax in TB-
DM patients. It should be acknowledged that the number of sampling points may 
have been too small to detect a change in tmax. Furthermore, it is unlikely that 
gastroparesis is associated with reduced absorption of rifampicin, because this drug 
is not subject to saturable first-pass metabolism after multiple doses and does not 
have an absorption window in the gastro-intestinal tract [23, 24]. 
The low exposure to rifampicin in TB-DM patients may possibly be explained by 
the highly pH-dependent solubility and absorption of rifampicin [24, 25]. Diabetes-
associated hyperglycemia, strongly related to rifampicin exposure in this study, can 
reduce secretion of gastric hydrochloric acid resulting in a higher gastric pH [8, 26], 
which in turn has been associated with a decrease in rifampicin absorption [24]. This 
hypothesis needs confirmation as no gastric pH was measured in our study and others 
have not found an effect of antacids on the pharmacokinetics of rifampicin [27]. 
With regard to metabolism and excretion, our results suggest that metabolism of 
rifampicin to the desacetyl-metabolite was reduced or excretion of this metabolite 
was increased in TB-DM patients, at least in the first 6 hours after administration. 
However, these findings do not explain the low exposure to rifampicin in TB-DM 
patients. On the contrary, decreased metabolism in the hepatocytes of diabetes 
patients might be explained by the expression of advanced glycosylation end 
products (AGE) in the liver [28], which impairs the normal function of the basement 
membranes of cells, for example [29]. 
Linear regression analysis revealed an unexpectedly strong effect of body weight 
on the exposure to rifampicin. These results emphasize that rifampicin should be 
carefully dosed on the basis of body weight as recommended by the World Health 
Organization and others [21]. Apparently, uniform dosing of rifampicin for all 
Indonesian patients (‘one dose fits all’) is inadequate. As was clearly shown, the fact 
that tuberculosis patients with diabetes had a higher body weight, can only partially 
explain the differences in rifampicin pharmacokinetics.
This study was limited by the small sample size, and by the limited number of 
time points for pharmacokinetic assessment. In addition, this study only assessed 
exposure to rifampicin reduced in type 2 diabetes
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the pharmacokinetics of rifampicin in the continuation phase of treatment. 
Furthermore, this study focused on pharmacokinetics and did not assess the outcome 
of tuberculosis treatment. 
In summary, we showed that exposure to rifampicin was strongly reduced in 
tuberculosis patients with type 2 diabetes. Tuberculosis patients with concomitant 
diabetes and a higher body weight may possibly need a higher dose of rifampicin. 
Screening for diabetes at tuberculosis diagnosis could be worthwhile, and physicians 
may consider pharmacokinetic assessment of rifampicin in this patient group (if 
available). Additional studies are warranted to assess the influence of diabetes, as 
well as the possible benefit of active treatment of diabetes on the pharmacokinetics 
of TB drugs and the outcome of tuberculosis treatment.
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Abstract
Objective:	Previous research in healthy volunteers has demonstrated that rifampicin 
and adjusted doses of lopinavir/ritonavir soft-gel capsules resulted in adequate 
exposure to lopinavir. Our objective was to study the combined use of rifampicin and 
the newly introduced lopinavir/ritonavir tablets. 
Methods:	A total of 40 healthy subjects was planned to start with 600 mg rifampicin 
once daily from day 1–5. From days 6-15, subjects were randomized to receive lopinavir/
ritonavir tablets dosed as either 600/150 mg or 800/200 mg twice daily, both in 
addition to 600 mg rifampicin once daily. A 12h pharmacokinetic curve was planned 
on day 15. Safety assessments were conducted regularly throughout the study period. 
Results: Eleven subjects started as the first group in this study. No major complaints 
occurred during day 1–5 (rifampicin only). After addition of lopinavir/ritonavir, eight 
subjects suffered from both nausea and vomiting, one from nausea only, and one from 
vomiting only. On day 7 increases in AST/ALT levels were reported in all subjects and 
on day 8 the study was prematurely terminated. The AST/ALT levels continued to rise 
and peaked (grade 2: n=2, grade 3: n=1, grade 4: n=8) on days 9-10. All values returned 
to normal within six weeks. 
Conclusions:	This study showed a high incidence of adverse events when a higher than 
standard dose of the new lopinavir/ritonavir tablets was combined with rifampicin. 
In the future, this drug combination should not be given to healthy volunteers. Liver 
function should be carefully monitored when rifampicin and lopinavir/ritonavir are 
combined in patients.
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Introduction
Approximately one-third of the 40 million people living with HIV/AIDS worldwide 
are co-infected with tuberculosis (TB) [1]. Rifampicin is the most powerful component 
of current TB treatment, but is also a strong inducer of cytochrome P450 enzymes, 
resulting in drug-drug interactions with antiretroviral therapy [2, 3], in particular non-
nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs). 
The World Health Organization (WHO) recommends to combine rifampicin-based TB 
treatment with efavirenz-based antiretroviral therapy in TB-HIV co-infected patients 
[3]. The modest decrease in concentrations of the NNRTI efavirenz is not expected 
to be clinically relevant [4, 5]. Although rifampicin reduces concentrations of the 
NNRTI nevirapine by 20-55% [6], collected experience is sufficient to make nevirapine 
an alternative to efavirenz among non-Caucasian patients receiving rifampicin [7, 
8]. A disadvantage of NNRTI drugs is the low genetic barrier for the development 
of resistance; only one point mutation is required to confer high-level cross-class 
resistance [9].
One alternative for patients with NNRTI-resistant HIV or those unable to take NNRTIs 
would be triple nucleoside regimens without interaction to rifampicin. However, 
these regimens are associated with less antiretroviral activity [10] and therefore not 
advisable. An equally active alternative to NNRTI-based therapy among patients being 
treated with rifampicin may be PI-based antiretroviral therapy. However, standard PI 
doses, whether boosted with ritonavir or not, cannot be given with rifampicin because 
of large decreases in PI concentrations [11-14]. 
In HIV infected adults without active tuberculosis, WHO recommends lopinavir/
ritonavir at 400/100 mg twice daily (BID) in combination with two nucleosides as 
PI-based therapy [15]. We have previously evaluated the pharmacokinetics of two 
adjusted dose regimens of lopinavir/ritonavir (800/200 mg BID and 400/400 mg BID) 
soft gel capsules when combined with rifampicin in healthy volunteers [11]. Because 
of more variable pharmacokinetics of lopinavir in the better tolerable arm of 800/200 
mg lopinavir/ritonavir, therapeutic drug monitoring (TDM) appeared to be indicated. 
In the absence of TDM, 400/400 mg lopinavir/ritonavir could be combined with 
rifampicin, while closely monitoring for liver enzyme elevations. 
combined use of rifampicin and lopinavir/ritonavir tablets
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Recently, a new tablet formulation of lopinavir/ritonavir has become available. 
Compared to the soft gel capsule, the novel tablet formulation shows reduced 
pharmacokinetic variability and exhibits slightly higher (18%) bioavailability, 
irrespective of concomitant food intake [16].
The aim of this study was to evaluate the pharmacokinetics of two adjusted dose 
regimens of lopinavir/ritonavir tablets in combination with rifampicin in healthy 
volunteers. Due to an unexpectedly high incidence of adverse events, this study was 
terminated prematurely. 
 
Methods
Study design
The study was designed as an open-label, sequential, 2-period, phase IV multiple dose 
trial in healthy volunteers. From day 1 until day 5, subjects received 600 mg rifampicin 
once daily (QD). From day 6 until day 15, subjects were randomized to receive either 
three (600/150 mg) or four (800/200 mg) of the new lopinavir/ritonavir (Kaletra) 
tablets BID, combined with 600 mg rifampicin QD. On days 1, 3, 5, 6, 7, 9, 11, 13 and 15 
study medication was planned to be taken under observation and immediately after 
a standardized breakfast (± 350 kcal, ± 13 g. of fat). The other drug doses were taken 
at home. All subjects gave written informed consent and the Ethical Review Board of 
Radboud University Nijmegen Medical Centre, The Netherlands, approved the study.  
Subjects
Healthy subjects, aged 18-55 years were eligible for enrolment after pre-entry and 
laboratory evaluation. The main exclusion criteria were: positive HIV test result; 
positive hepatitis B or C test result; positive Mantoux test result; abnormal clinical 
laboratory test results and abnormal ECG. 
Pharmacokinetic assessment
Blood samples of 5 ml were planned to be collected at the following time points; on 
day 5 just before and two hours post-dose (C2h) for the determination of rifampicin 
(and desacetylrifampicin) plasma concentrations; on day 7, 9, 11 and 13 pre-dose for 
the determination of plasma concentrations of lopinavir and ritonavir; and on day 15 
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pre-dose until 12 hours post-dose for the analysis of all three drugs. Blood samples 
were stored in the refrigerator immediately and centrifuged at 2,500 g for 10 minutes. 
Plasma was separated and stored below -40 °C (for the determination of lopinavir 
and ritonavir) or –80 °C (for the determination of rifampicin and desacetylrifampicin) 
within 4 hours after collection. All procedures concerning collection and storage of 
drug samples have been validated. 
Bioanalysis
Plasma lopinavir, ritonavir, rifampicin and desacetylrifampicin concentrations were 
determined by validated high-performance liquid chromatography (HPLC) methods 
[17, 18]. 
Safety and tolerability 
We planned to perform clinical chemistry and hematology tests and to ask subjects 
about the occurrence of adverse events at each study visit on day 1, 3, 5, 6, 7, 9, 11, 13 
and 15. Adverse events, clinical chemistry and hematology test results were graded 
according to the grading system of the Division of AIDS [19]. After termination of 
the study, hepatitis B and C tests were repeated. In addition, Epstein-Barr virus and 
cytomegalovirus antibody tests were performed to exclude acute viral infection.
Results
Subjects 
Forty healthy volunteers were enrolled in the study. The first group consisted of eleven 
subjects of whom eight were Caucasians, two were Caucasian-black and one was 
black. The median (range) age, body weight and body mass index were 24 (19-51) years, 
63 (53-92) kg and 22 (19-30) kg/m2, respectively. Five subjects (three females) received 
600/150 mg lopinavir/ritonavir BID and six (four females) received 800/200 mg 
lopinavir/ritonavir BID in addition to rifampicin 600 mg. The remaining 29 subjects 
were withdrawn from the study after receiving only one dose of rifampicin (n=10) or 
no study medication at all (n=19). 
Pharmacokinetics 
The geometric mean (range) of rifampicin and desacetylrifampicin C2h on day 5 
(rifampicin only) was 11.3 (6.8-17.4) and 1.12 (0.74-2.37) mg/L, respectively (n=11). In five 
combined use of rifampicin and lopinavir/ritonavir tablets
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Table 1  Distribution of adverse events (n, %) in eleven healthy volunteers. 
Medication was stopped on day 7 or 8. 
Adverse event Day 1-11 Day 1-5  Day 6- 11
  (overall) (rifampicin) (day 6-7/8: rifampicin
    and lopinavir/ritonavir)
Flatulence 1 (9%) 0 1 (9%)
Headache 1 (9%) 1 (9%) 0
Rash    
 Grade 1 1 (9%) 1 (9%) 0
Fever   
 Grade 1 1 (9%) 0 1 (9%)
Myalgia    
 Grade 2 1 (9%) 0 1 (9%)
Joint pain   
 Grade 1 2 (18%) 2 (18%) 0
Fatigue   
 Grade 1 1 (9%)  1 (9%)
 Grade 2 1 (9%) 0 1 (9%) 
Trismus* 1 (9%) 0 1 (9%)
Diarrhoea    
 Grade 1 2 (18%) 1 (9%) 2 (18%)
 Grade 2 1 (9%) 0 1 (9%)
Nausea   
 Grade 1 3 (18%) 1 (9%) 2 (18%)
 Grade 2 8 (73%) 2 (18%) 7 (64%)
Vomiting    
 Grade 2 3 (27%) 0  3 (27%)
 Grade 3 6 (55%) 0 6 (55%)
Pruritis    
 Grade 1 3 (27%) 3 (27%) 3 (27%)
 Grade 2 1 (9%) 1 (9%) 0
Headache 1 (9%) 1 (9%) 0
ALT   
 Grade 2 2 (18%) 0 2 (18%) 
 Grade 3 1 (9%)  0 1 (9%)
 Grade 4 8 (73%) 0 8 (73%)
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subjects, plasma concentrations of lopinavir and ritonavir were undetectable in the 
morning of day 7 due to vomiting after the evening dose on day 6. In the remaining 
six subjects, the geometric mean (range) of the lopinavir and ritonavir trough 
concentrations on day 7 were 7.9 (6.6-10.3) mg/L and 0.71 (0.35-1.61) mg/L in the 600/150 
mg group (n=3) and 10.9 (8.3-13.8) mg/L and 1.20 (0.64-1.85) mg/L in the 800/200 mg 
group (n=3). The median (range) of the rifampicin and desacetylrifampicin trough 
concentrations in the morning of day 7 were 0.41 (0.0-1.13) mg/L and 0.40 (0.0-0.83) 
mg/L in the 600/150 mg group (n=5) and 0.47 (0.0-1.17) mg/L and  0.21 (0.0-1.12) mg/L 
in the 800/200 mg group (n=6). 
Tolerability 
No major complaints or abnormal AST/ALT levels occurred during day 1–5, when 
rifampicin was given only (Table 1). After addition of lopinavir/ritonavir, eight subjects 
suffered from both nausea and vomiting, one had nausea only, and one vomited only. 
Eight subjects were given the antiemetic drug metoclopramide. All six subjects in 
the 800/200 mg lopinavir/ritonavir group vomited, compared to three out of five in 
the 600/150 mg group. On day 7, increases in AST and ALT levels were reported in all 
subjects and increases in GGT in all but one subject. Study medication was stopped 
on day 7 for 8 subjects and on day 8 for the remaining three subjects. The AST/ALT 
combined use of rifampicin and lopinavir/ritonavir tablets
6
AST   
 Grade 2 2 (18%) 0 2 (18%)
 Grade 3 1 (9%) 0 1 (9%)
 Grade 4 8 (73%) 0 8 (73%)
GGT   
 Grade 1 4 (36%) 0 4 (36%)
 Grade 2 2 (18%) 0 2 (18%)
 Grade 3 1 (9%) 0 1 (9%)
Bilirubin   
 Grade 2 3 (27%) 0 3 (27%)
 Grade 3 5 (45%) 0 5 (45%)
ALT (aminotransferase), AST (aspartate aminotransferase), GGT (gamma glutamyl transferase. 
*Probably related to excessive metoclopramide usage. 
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levels continued to rise and peaked (range 125-1400 and 201-1657 U/L, respectively) on 
days 9-10 (Table 1). The GGT levels increased more gradually and peaked (range 21-
177 U/L) on days 10-12 (Table 1). Four out of six subjects in the 800/200 mg lopinavir/
ritonavir group experienced grade 4 AST or ALT toxicity versus four out of five in the 
600/150 mg group. All clinical parameters returned to normal within six weeks after 
study termination (Fig. 1). Test results for hepatitis B and C, Epstein-Barr virus and 
cytomegalovirus were all negative after study termination.
Discussion
This study showed an unexpected high incidence of nausea, vomiting and liver enzyme 
elevations when a higher than standard dose of the recently introduced lopinavir/
ritonavir tablets was combined with rifampicin in healthy volunteers. Therefore, the 
study was terminated prematurely.  
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Figure 1  Mean clinical parameters versus time in eleven healthy 
 volunteers until study day 47 (day 1-5: rifampicin only; day 6-7/8: 
rifampicin and lopinavir/ritonavir; day 7/8-47: no medication).
GGT (gamma glutamyl transferase), AST (aspartate aminotransferase), ALT (alanine 
aminotransferase).
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In our previous study in which rifampicin and adjusted doses of lopinavir/ritonavir 
capsules were combined [11], toxicity of this magnitude was not observed. However, 
the current study differed from our previous study [11] in several aspects, and this may 
explain the higher incidence of adverse events. Firstly, rifampicin was introduced prior 
to lopinavir/ritonavir; secondly, the adjusted dose of lopinavir/ritonavir tablets was 
not escalated; and thirdly, the new lopinavir/ritonavir tablet formulation was used 
instead of the capsule formulation. 
Firstly, the sequence of introduction of rifampicin and lopinavir/ritonavir may 
have played a role. Termination of a study because of unexpected hepatotoxicity in 
healthy volunteers using the combination of rifampicin and saquinavir/ritonavir, was 
reported before [20]. The majority of the adverse events was observed in the study 
arm in which rifampicin usage was followed by the combination of rifampicin and 
the PI [20], analogous to the current study. However, this sequence is a reflection of 
the clinical situation of TB-HIV co-infected patients as TB is preferably treated first. 
Besides, TB-HIV co-infected patients seem to tolerate the combination of rifampicin 
and saquinavir/ritonavir well in both sequences [14, 21], suggesting a yet unidentified 
difference between patients and healthy volunteers. It has not been investigated so 
far, whether TB-HIV co-infected patients tolerate the combination of rifampicin and 
lopinavir/ritonavir better than healthy volunteers.
With respect to the second difference, the absence of a dose escalation scheme for 
the adjusted dose of lopinavir/ritonavir may have contributed to the high incidence 
of adverse events in the current study. We decided to omit dose escalation because 
the liver enzymes  had been induced by rifampicin already. The efflux transporter 
P-glycoprotein (P-gp) can mediate the transport of lopinavir and ritonavir [22, 23] 
as well as rifampicin [24]. A time-dependent effect by lopinavir/ritonavir on P-gp 
was previously suggested; inhibition after single-dose and induction after repeated 
administration [25]. The immediate administration of the high dose of lopinavir/
ritonavir in the current study may have resulted in inhibition of the efflux transporter 
P-gp and therefore to the relatively high trough concentrations of the study medication 
observed. This may explain part of the adverse events. 
Finally, unidentified toxic excipients of the new tablet formulation and its slightly 
higher bioavailability may have played a role. Studies show that this slight increase in 
combined use of rifampicin and lopinavir/ritonavir tablets
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bioavailability of lopinavir/ritonavir tablets may compensate for the inductive effect 
of efavirenz [26]. This same compensation may occur when combined with rifampicin, 
as in the current study in which we found relatively high non steady-state lopinavir 
trough levels compared to the steady-state levels in the previous study [11]. In short, 
data from interaction studies with one formulation cannot be extrapolated to another 
formulation.
In conclusion, this study demonstrates the challenging character of the compatibility 
of rifampicin and PIs in TB-HIV therapy. We advise that further studies investigating 
the interaction between rifampicin and lopinavir/ritonavir tablets be performed in 
the actual target population of TB-HIV co-infected patients rather than in healthy 
volunteers. Awaiting these results, simultaneous treatment with rifampicin and 
lopinavir/ritonavir should not be applied. In case no alternatives are available, extreme 
caution and close monitoring of liver enzymes and plasma drug concentrations is 
warranted.  
Acknowledgements
We would like to thank the healthy volunteers for their participation in this study. 
The staff at the Clinical Research Centre Nijmegen (CRCN) is acknowledged for their 
cooperation and effort. The technicians of the Department of Clinical Pharmacy, 
Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands are 
acknowledged for the analysis of the plasma samples. This study was funded by 
Radboud University Nijmegen Medical Centre. 
chapter 6
Nijland.1046-Proefschrift.indd   120 07-04-2009   15:41:03
121
References 
 (1)  WHO. Frequently asked questions about HIV and TB, available at: http://www.who.int/
tb/hiv/faq/en/index.html. 2006.
 (2)  Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for 
Disease Control and Prevention/Infectious Diseases Society of America: treatment of 
tuberculosis. Am J Respir Crit Care Med 2003 Feb 15; 167(4):603-62.
 (3)  WHO. TB/HIV A clinical manual, available at: http://whqlibdoc.who.int/
publications/2004/9241546344.pdf. Website 2004.
 (4)  Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, et al. Pharmacokinetic interactions between 
efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 
2002; 41(9):681-90.
 (5)  Manosuthi W, Kiertiburanakul S, Sungkanuparph S, et al. Efavirenz 600 mg/day versus 
efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin:  
48 weeks results. AIDS 2006 Jan 2; 20(1):131-2.
 (6)  Ribera E, Pou L, Lopez RM, et al. Pharmacokinetic interaction between nevirapine and 
rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr 2001 
Dec 15; 28(5):450-3.
 (7)  Autar SR, Wit FW, Sankote J, et al. Nevirapine plasma concentrations and concomitant 
use of rifampin in patients coinfected with HIV-1 and tuberculosis. Antivir Ther 2005; 
10(8):937-43.
 (8)  van Cutsem G, Cohen K, Bedula M, et al. TB/HIV co-infected patients on rifampin 
containing treatment have equivalent ART treatment outcomes, and concurrent use of 
nevirapine is not associated with increased hepatotoxicity. 2005.
 (9)  Waters L, John L, Nelson M. Non-nucleoside reverse transcriptase inhibitors: a review. Int J 
Clin Pract 2007 Jan; 61(1):105-18.
 (10)  Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-
containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004 Apr 
29; 350(18):1850-61.
 (11)  La Porte CJ, Colbers EP, Bertz R, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir 
combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004 May; 
48(5):1553-60.
 (12)  Burger DM, Agarwala S, Child M, Been-Tiktak A, Wang Y, Bertz R. Effect of rifampin 
on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. 
Antimicrob Agents Chemother 2006 Oct; 50(10):3336-42.
 
combined use of rifampicin and lopinavir/ritonavir tablets
6
Nijland.1046-Proefschrift.indd   121 07-04-2009   15:41:03
122
 (13)  Justesen US, Andersen AB, Klitgaard NA, Brosen K, Gerstoft J, Pedersen C. Pharmacokinetic 
interaction between rifampin and the combination of indinavir and low-dose ritonavir in 
HIV-infected patients. Clin Infect Dis 2004 Feb 1; 38(3):426-9.
 (14)  Ribera E, Azuaje C, Lopez RM, et al. Pharmacokinetic interaction between rifampicin and 
the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients 
with tuberculosis. J Antimicrob Chemother 2007 Apr; 59(4):690-7.
 (15)  WHO. Antiretroviral therapy for HIV infection in adults and adolescents: 
recommendations for a public health approach. 2006, available at: http://www.who.int/
hiv/pub/guidelines/adult/ en.index.html.
 (16)  Klein CE, Chiu YL, Awni W, et al. The tablet formulation of lopinavir/ritonavir provides 
similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic 
variability and diminished food effect. J Acquir Immune Defic Syndr 2007 Apr 1; 44(4):401-
10.
 (17)  Droste JAH, Verweij-van Wissen CPWGM, Burger D.M. Simultaneous Determination of 
the HIV Drugs Indinavir, Amprenavir, Saquinavir, Ritonavir, Lopinavir, Nelfinavir, the 
Nelfinavir hydroxymetabolite M8 and Nevirapine in Human Plasma by Reversed Phase 
High Performance Liquid Chromatography. Therapeutic Drug Monitoring 2003; 25:393-9.
 (18)  Ruslami R, Nijland HM, Alisjahbana B, Parwati I, van CR, Aarnoutse RE. Pharmacokinetics 
and tolerability of a higher rifampicin dose versus the standard dose in pulmonary 
tuberculois patients. Antimicrob Agents Chemother 2007 Apr 23.
 (19)  Division of aids. Division of AIDS table for grading the severity of adult and pediatric 
adverse events, available at: http://rcc.tech-res.com/DAIDS%20RCC%20Forms/TB_
ToxicityTables_DAIDS_AE_GradingTable_FinalDec2004.pdf. Website 2004;(1.0).
 (20)  Grange S, Schutz M, Schmitt C, Riek M, Gaudel-Ehrhart E. Unexpected hepatotoxicity 
observed in a healthy volunteer study on the effects of multiple dose rifampicin on 
the steady-state pharmacokinetics of ritonavir-boosted saquinavir and vice versa. 6th 
International Workshop on Clinical Pharmacology of HIV Therapy, Quebec, Canada, April 
28-30, 2005 (abstract 35) 2005.
 (21)  Losso MH, Lourtau LD, Toibaro JJ, Saenz C, Gonzalez C. The use of saquinavir/ritonavir 
1000/100 mg twice daily in patients with tuberculosis receiving rifampin. Antivir Ther 
2004 Dec; 9(6):1031-3.
 (22)  Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology 
and clinical use of HIV protease inhibitors. AIDS 2000; 14(3):237-42.
 (23)  Agarwal S, Pal D, Mitra AK. Both P-gp and MRP2 mediate transport of Lopinavir, a protease 
inhibitor. Int J Pharm 2007 Jul 18; 339(1-2):139-47.
 
chapter 6
Nijland.1046-Proefschrift.indd   122 07-04-2009   15:41:03
123
 (24)  Schuetz EG, Schinkel AH, Relling MV, Schuetz JD. P-glycoprotein: a major determinant of 
rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl 
Acad Sci U S A 1996 Apr 30; 93(9):4001-5.
 (25)  van Heeswijk RP, Bourbeau M, Campbell P, et al. Time-dependent interaction between 
lopinavir/ritonavir and fexofenadine. J Clin Pharmacol 2006 Jul; 46(7):758-67.
 (26)  Klein C, Zhu T, Chiu Y-L., et al. Effect of efavirenz on lopinavir/ritonavir pharmacokinetics 
from a new tablet formulation. [Abstract] In: 10th European AIDS clinical society, Dublin, 
Ireland 2005 A4.3/2.
combined use of rifampicin and lopinavir/ritonavir tablets
6
Nijland.1046-Proefschrift.indd   123 07-04-2009   15:41:03
Rafaëlla FA L’homme1,2, Hanneke MJ Nijland1,2, Luuk Gras3, Rob E Aarnoutse1,2, 
Reinout van Crevel2,4, Martin Boeree2,5, Kees Brinkman6, Jan M Prins7, 
Job R Juttmann8, David M Burger1,2
1Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, 
The Netherlands 2Nijmegen University Centre for Infectious diseases (NUCI), Nijmegen, 
The Netherlands 3HIV Monitoring Foundation, Amsterdam, The Netherlands 4Department 
of General Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, 
The Netherlands 5Department of Pulmonary Diseases, Radboud University Nijmegen Medical 
Centre and University Lung Centre Dekkerswald, Nijmegen, The Netherlands 6Department of 
Internal Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands 7Department 
of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Centre, Amsterdam, 
The Netherlands 8Department of Internal Medicine, St Elisabeth Hospital, Tilburg, 
The Netherlands
AIDS 2009; 23: 863-5
Nijland.1046-Proefschrift.indd   124 20-04-2009   17:11:24
Chapter 7
Clinical experience with the combined use 
of lopinavir/ritonavir and rifampicin
Nijland.1046-Proefschrift.indd   125 07-04-2009   15:41:13
126
Abstract
Thirty-four patients treated concomitantly with lopinavir/ritonavir and rifampicin 
were evaluated.  
Overall, only 15% used the recommended increased dose of lopinavir/ritonavir. 
Of  patients on a non-adjusted dose of lopinavir/ritonavir, 67% had a subtherapeutic 
lopinavir  plasma concentration and 38% had a detectable viral load. Forty percent of 
patients on an increased dose of lopinavir/ritonavir prematurely stopped the drug 
combination because of adverse events. Combined use of lopinavir/ritonavir and 
rifampicin is challenging as it implies  balancing between suboptimal efficacy and 
toxicity. 
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Rifampicin is an important drug in the treatment of TB but has strong liver enzyme 
inducing capacity, resulting in drug-drug interactions with antiretroviral therapy 
[1]. We have previously performed two studies in healthy volunteers to evaluate 
whether dose adjustment of lopinavir/ritonavir could compensate for the drug 
interaction with rifampicin, one with the soft-gel capsules of Kaletra® [2], the other 
one with heat-stable tablets [3]. The latter study was terminated prematurely due to 
an unexpectedly high incidence of adverse events.
In the absence of similar interaction studies in patients, we performed a retrospective 
analysis of observational data to describe the clinical experience of combining 
lopinavir/ritonavir and rifampicin. 
 
Adult HIV-infected patients treated concomitantly with lopinavir/ritonavir and 
rifampicin were selected from the Dutch ATHENA cohort [4]. Lopinavir trough 
plasma concentrations were classified as subtherapeutic (<1.0 mg/L) or therapeutic 
(≥1.0 mg/L) [5]. For patients who used the drug combination of lopinavir/ritonavir 
and rifampicin for at least four months, plasma viral load data were collected until 
the end of concomitant treatment. Acute, premature termination of lopinavir/
ritonavir and rifampicin was defined as stopping concomitant treatment within four 
weeks from the start. 
Median (interquartile range) age, weight, CD4 cell count and plasma viral load at 
baseline of the 34 patients (8 women, 26 men) were 36 (32, 43) years, 62 (55, 70) kg, 105 
(27, 248) cells/µl and 75,750 (<50, 204, 085) copies HIV-RNA/ml. 
Overall, 23 of 34 (68%) patients were on a non-adjusted dose of lopinavir/ritonavir 
(400/100 mg BID or 800/200 mg QD), 6 (18%) on a slightly adjusted dose (500/125 or 
533/133 mg BID) and 5 (15%) on a recommended dose (400/400 or 800/200 mg BID).
Of the 8 patients who started concomitant treatment before the recommendation of 
lopinavir/ritonavir dose adjustment was first presented [6], 7 (88%) were on a non-
adjusted dose, 1 (13%) on a slightly adjusted dose, and none on a recommended dose. 
Of the 26 patients who started concomitant treatment after the recommendation 
of lopinavir/ritonavir dose adjustment was in the public domain, 16 (62%) were 
on a non-adjusted dose, 5 (19%) on a slightly adjusted dose and 5 (19%) on a 
recommended dose.
clinical experience with rifampicin-lopinavir combinations
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Lopinavir trough plasma concentrations during combined use were available for 6 
of 23 (26%) patients on a non-adjusted dose of lopinavir/ritonavir, none of 6 patients 
on a slightly adjusted dose and 2 of 5 (40%) patients on a recommended dose. Four of 
6 (67%) patients on a non-adjusted dose of lopinavir/ritonavir had a subtherapeutic 
lopinavir trough plasma concentration, whereas the 2 patients on a recommended 
dose had a therapeutic concentration.
A total duration of combined use of rifampicin and lopinavir was less than 4 
weeks in 12 patients, between 4 weeks and 4 months in 11 patients, and 4 months 
or longer in the remaining 11 patients. In Figure 1, the proportion of patients with 
an undetectable plasma viral load  is shown for patients with at least 4 months of 
combined treatment according to lopinavir/ritonavir dose group. 
Overall, 7 of 34 (21%) patients prematurely stopped the combination within 4 weeks 
because of acute adverse events; this was 4 of 23 (17%) on a non-adjusted dose, 1 
of 6 (17%) on a slightly adjusted dose and 2 of 5 (40%) on a recommended dose of 
lopinavir/ritonavir. 
This retrospective study demonstrates that the dose of lopinavir/ritonavir was 
usually not increased when combined with rifampicin in Dutch HIV-infected 
patients. This may have led to the relatively high proportion of subtherapeutic 
lopinavir trough plasma concentrations and detectable viral loads. 
Recommendations of lopinavir/ritonavir dose increment when combined with 
rifampicin [7] have been based on one of our previous pharmacokinetic interaction 
studies [8]. Although the uptake of this dose recommendation was noticed to some 
extent after the first presentation of the particular study [6], general adherence to 
the recommendation remained low. This is in line with a recent study looking at 
interactions between antiretroviral therapy and rifabutin [9].
Whereas the limited available data suggest that inappropriate virological response 
may be explained by low lopinavir exposure due to non-adjusted doses, alternative 
factors, such as non-adherence to antiretroviral therapy or resistance of the virus, 
may also have contributed. 
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The occurrence of nausea, vomiting and liver enzyme elevations when combining 
lopinavir/ritonavir and rifampicin in our cohort of HIV-infected patients was far less 
than previously reported in healthy volunteers on recommended increased doses of 
the SGC formulation [10] and in particular the tablet formulation [3] of lopinavir/
ritonavir. 
This can be explained by various factors. Firstly, the fact that the lopinavir/ritonavir 
dose was increased as recommended in only the minority of patients on rifampicin 
may have contributed to the lower incidence of adverse events in the current study. 
Secondly, the fact that the current study was performed in HIV-infected patients 
rather than healthy volunteers may have led to the better tolerability of the 
combination lopinavir/ritonavir and rifampicin. This explanation is supported by 
other studies demonstrating that HIV patients tolerate another PI-combination, 
saquinavir/ritonavir, and rifampicin better than healthy volunteers [11-13].
clinical experience with rifampicin-lopinavir combinations
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Figure 1  Proportion of patients with an undetectable viral load 
 according to lopinavir/ritonavir dose group at baseline and 
after at least 4 months of co-administration with rifampicin.
* 400/100 mg lopinavir/ritonavir twice daily
** 533/133 mg (n=2) or 800/200 mg (n=1) lopinavir/ritonavir twice daily
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Several limitations of our study need to be mentioned. This was a retrospective 
analysis of an observational cohort. Data were not collected on prespecified time 
points and were not always available. Also, the number of patients involved in this 
evaluation was limited.
In conclusion, a small minority of HIV-infected patients in the Netherlands has been 
treated with the recommended increased dose of lopinavir/ritonavir in combination 
with rifampicin. This was associated with inferior exposure to lopinavir and, 
possibly, virological failure. The overall tolerability of the drug combination was 
better than previously reported in healthy volunteers, whereas a higher proportion 
of those on a recommended increased dose prematurely stopped the combination 
because of adverse events. Concomitant use of lopinavir/ritonavir and rifampicin 
remains challenging. 
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Introduction
The overall objective of this thesis was to contribute to the optimization of 
tuberculosis (TB) drug treatment. Within the scope of this dissertation, the following 
problems affecting effective TB therapy were addressed: the long duration of 
current TB treatment; suboptimal efficacy of current antituberculosis treatment; 
and combined treatment of TB and HIV infection. All studies focused on the 
pharmacokinetics of TB drugs and other co-administered drugs.  
This discussion starts with an outline on the clinical pharmacology of tuberculosis 
drugs. Then, the topics of shortening TB treatment, suboptimal response to 
tuberculosis treatment and combined treatment of TB-HIV are addressed, followed 
by reflections on research in developing countries and a description of the study 
setting. Finally, this general discussion is concluded with future perspectives. 
Clinical pharmacology of tuberculosis drugs
From a classical clinical pharmacological perspective, pharmacokinetics and 
pharmacodynamics determine the eventual effect of TB drugs. The relation 
between the actual drug intake and the (time course of) plasma drug concentrations 
achieved is described by the pharmacokinetics of the drugs. The plasma drug 
concentrations are subsequently related to treatment outcome (including problems 
of suboptimal response, emergence of resistance and adverse events) as determined 
by pharmacodynamics. Therefore, plasma drug concentrations are supposed to be 
an important intermediary link between the dose of TB drugs and their desirable 
and undesirable effects (Figure 1). 
Tuberculosis therapy has been available for 60 years now [1] and since the current 
first-line regimen was developed in an era when regulatory requirements for drug 
development did not exist [2], only limited data on the pharmacokinetics and 
pharmacodynamics of TB drugs are available. To optimize TB treatment, a better 
understanding of both the pharmacokinetics and pharmacodynamics of TB drugs 
is clearly required. 
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As to pharmacokinetics, more descriptive pharmacokinetic data from TB patients 
should first be obtained; second, determinants associated with the pharmacokinetics 
of antituberculosis drugs should be identified; and third, interventions to improve 
plasma drug concentrations should be carried out. The studies in chapters 4 and 5 are 
examples of the first and second type of studies, whereas the studies in chapters 1 and 
2 are examples of the third type of study. Another type of pharmacokinetic study is 
the drug-drug interaction study. The studies in chapters 3 and 6 are such interaction 
studies. All these types of pharmacokinetic studies aim to gather data that can be used 
to optimize drug regimens and dosing, thereby improving the response to TB drugs. 
 
As regards to pharmacodynamics, for rapidly dividing gram-positive and gram-
negative infections, it has been observed that for intracellular-acting agents such as 
the quinolones and aminoglycosides maximizing the pharmacodynamic parameter 
‘peak plasma concentration (Cmax) / minimum inhibitory concentration (MIC)’ is 
desirable [3, 4]. High Cmax/MIC ratios tend to improve bacterial killing and may 
limit adaptive resistance and the selection of resistant subpopulations. For cell wall-
D
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Figure 1  The clinical pharmacological view of tuberculosis treatment. 
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active agents such as the penicillins and the cephalosporins, time > MIC should 
be maximized when treating gram-positive and gram-negative infections [5]. 
This means that certain minimum concentrations of drugs should be maintained 
throughout the dosing interval.  
For M.	tuberculosis,  less information is available and it is questionable whether the 
principles mentioned above can be applied [6]. Firstly, the mechanism of action of 
many TB drugs is poorly understood. Secondly, M.	tuberculosis	 is replicating quite 
slowly and can achieve a poorly understood “latent” state in vivo, which both are 
likely to affect the pharmacokinetic-pharmacodynamic (PK-PD) relationships 
that have been demonstrated for fast-growing bacteria. Moreover, the fact that 
TB drugs usually are given as combination therapy complicates the study of 
pharmacodynamics of individual TB drugs. 
Nevertheless, as to the rifamycins, available evidence points in the direction of 
concentration-dependent killing. The microbial killing by rifampicin was found to 
be linked to the area under the curve (AUC)/MIC and Cmax/MIC ratio in a recent in 
study in mice [7]. This lends experimental PK-PD support to the calls for the use of 
higher doses of rifamycins by Peloquin [8] and Weiner [9]. Therefore, higher doses of 
rifampicin are likely to improve both microbial killing and resistance suppression, 
as long as patients can tolerate them [10]. For isoniazid, a single clinical trial using 
divided dosing suggests that killing may be concentration-dependent as well. In that 
study a single daily dose of 400 mg was more effective than 200 mg twice daily [11]. 
In a study in the murine model, the bactericidal effect of isoniazid also correlated 
with AUC and Cmax [12]. Little is known about the pharmacodynamics of the first-
line drugs pyrazinamide and ethambutol. For all first line TB drugs, the possibility of 
intermittent (twice/thrice weekly) dosing strongly points to concentration–dependent 
inhibition.
As yet there are only limited data regarding the association between plasma drug 
concentrations and outcome of tuberculosis treatment. Lower plasma rifampicin 
concentrations have been associated with delayed sputum conversion, treatment 
failure, relapse and resistance [13]. Weiner et al showed an association between 
plasma concentrations of rifabutin and acquired rifamycin resistance [14], despite the 
small number of patients with acquired rifamycin resistance available for analysis. 
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Low plasma concentrations of rifampicin were also measured in slow responders 
to therapy [15], although a recent study was not able to demonstrate a relation 
between the height of peak plasma concentrations and slow culture conversion [16]. 
In another study, risk of tuberculosis recurrence was not associated with plasma 
drug concentrations [17]. Weiner showed an association between low isoniazid 
concentrations and failure and relapse after one-weekly treatment with isoniazid. 
N-acetyltransferase (NAT-2) genotype, a determinant of isoniazid pharmacokinetics, 
was also associated with worse treatment outcome [18]. In a recent study among Thai 
TB patients, no pharmacokinetic-pharmacodynamic relationship could be assessed 
between the AUC of rifampicin and putative biomarkers of sterilizing activity, whereas 
associations with the exposure to isoniazid were demonstrated [19, 20].
In general, target concentrations for TB drugs are only partially known. Until now, 
target drug concentrations are based on studies with healthy volunteers and 
relevance of these concentrations have not been defined in studies with TB patients 
[2]. For other TB drugs than rifamycins or isoniazid, either less data or conflicting data 
are available. In conclusion, the lack of pharmacodynamic data for TB drugs is an 
important shortcoming in the knowledge on tuberculosis drug treatment and should 
be addressed in the near future.
Shortening tuberculosis treatment
Focus on existing drugs
Long treatment durations are difficult to sustain because of both the commitment 
required by the patient to complete the treatment course and to attend follow-up 
outpatient appointments, and the investment required by health services to supervise 
treatment. Failure to complete, or intermittent completion, increases the risk of 
treatment failure, relapse and the emergence of drug resistant strains. 
Shortening of TB treatment duration will have enormous implications for public 
health. Shorter treatment implies a reduced number of outpatient appointments and 
less burden from treatment (daily intake of drugs) for the patient and will probably 
lead to higher completion ratios. Consequently, shortened treatment will have a 
positive impact on treatment outcome. 
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As mentioned in the introduction section, shortening treatment could be achieved by 
using two different approaches. First, the application or dosing of existing drugs could 
possibly be improved. Second, new drugs can be used in the fight against TB. 
With regard to the first approach, the potential of higher dosages of rifampicin as 
a means to shorten the treatment of tuberculosis seems to be most promising. A 
preclinical study in the mouse model showed that the current dose of rifampicin is at 
the lower end of the dose-response curve and predicted a one-third reduction of the 
duration associated with a rifampicin dose increase of 50% [7]. A phase 2 clinical study 
investigated a short regimen of high dose rifampicin (1200 mg or 20 mg/kg daily or 
every other day) together with isoniazid 900 mg and streptomycin 1000 mg daily and 
yielded almost 100% sputum conversion after three months of treatment. All patients 
remained culture negative up to one year. However, sixteen percent of patients 
relapsed after 12-24 months. Pyrazinamide was not included in the regimen and might 
have improved the response. No pharmacokinetic nor safety data are available from 
this study [21]. Another phase 2-phase 3 study demonstrated no difference between 
patients who used 600 mg or 750 mg rifampicin daily [22], but did show that 450 mg 
was significantly less effective compared to 600 mg. 
We ourselves have studied the pharmacokinetics and tolerability of a higher than 
standard dose of rifampicin (13 mg/kg instead of 10 mg/kg) in Indonesian patients 
with pulmonary tuberculosis in a phase 2 study [23, 24]. Increasing the rifampicin 
dose from 450 (10 mg/kg in Asian people) to 600 mg (13 mg/kg) caused a more than 
proportional 65% increase in the mean rifampicin AUC0-24h and a 49% increase in 
mean rifampicin peak plasma concentrations (Cmax) (Chapter 1 and 2). The increase 
in rifampicin dose did not affect the mean AUC0-24h and Cmax of pyrazinamide and 
ethambutol. Although not significant, nausea and vomiting occurred more often in 
the higher dose arm than the standard dose arm. Grade 1 and 2 hepatotoxicity was 
more common in the higher dose group (46% versus 20%; p=0.054). 
Follow-up studies in larger patient populations are needed to further evaluate the 
concept of high dose rifampicin. First, it seems necessary to assess the maximum 
tolerable dose of rifampicin in short term phase I/II maximum tolerability trials, both 
when the drug is administered alone and when combined with the currently available 
TB drugs. Adequate evaluation of the maximum dose of rifampicin as a single drug is 
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required as a basis for future studies in which rifampicin will be combined with new, less 
toxic TB drugs. Second, selected higher doses will have to be studied in phase 2 studies 
that evaluate the pharmacokinetics, tolerability and efficacy of such combinations. 
Finally, a pivotal phase 3 study will have to prove the possible benefits of using this 
approach of higher doses of rifampicin to really shorten the TB treatment duration. 
One of the required phase 2 studies has just started under the name APRIORI in Tanzania. 
This phase 2 study will investigate three dosages of rifampicin, i.e. 600, 900 and 1200 mg 
once daily. These dosages of rifampicin will be combined with the standard tuberculosis 
drugs during the first two months of treatment. Safety, tolerability, pharmacokinetics 
and effect on two months sputum culture conversion, time to sputum conversion and 
serial sputum colony forming units count (SSCC) will be evaluated.    
The low price of rifampicin favors using rifampicin for shortening TB treatment. Since 
TB especially affects poor patients in resource-limited and overpopulated countries, 
a renewed TB treatment should contain cheap drugs in order to be effective. Another 
advantage of rifampicin is that physicians all over the world have experience with this 
drug and its adverse effects. If increasing the dose of rifampicin proves to be safe and 
effective, this intervention could be implemented broadly and quickly, and it would 
benefit many patients worldwide.
Following the studies on high dose rifampicin, the long-acting rifamycin rifapentine 
is also considered as a candidate for the high dose concept. Many studies in mice 
are being performed now and show that high dose rifapentine with or without 
moxifloxacin enables treatment shortening in mice [25, 26].  
Focus on new drugs
First of all, the development of new tuberculosis drugs is an expensive and time-
consuming process. For a pharmaceutical industry to obtain return on investments, 
the market prices of new TB drugs should be relatively high, but there is no market for 
expensive drugs, also considering the low cost of the standard regimen (only €10-20 per 
patient). Therefore, the Global Alliance for TB Drug Development, a non-profit venture 
that supports the discovery and development of cost-effective new drugs, was formed 
[27]. In 2001, the Global Alliance for TB Drug Development published guidelines for 
drug discovery and highlighted a number of desirable properties for new drugs. These 
should have increased potency, so that the duration of treatment could be reduced to 
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four months at most; display activity to MDR-TB; kill the latent tubercle bacillus; be 
compatible with existing TB drugs, notably rifampicin; and act on new targets.   
Currently, seven drugs are under investigation for their abilities to improve TB 
treatment. The two furthest advanced of the drug candidates are fluoroquinolones. 
Fluoroquinolones attracted the attention after a promising study with ofloxacin [28] 
Unfortunately, this study did not have a standard therapy arm, therefore the ability to 
interpret the results was limited [29]. In this study the relapse rates after 3 and 4 months 
treatment with rifampicin, isoniazid and pyrazinamide and ofloxacin were 4 % and 2 % 
respectively. This study was especially encouraging because the newer fluoroquinolones, 
such as moxifloxacin and gatifloxacin are more potent antimycobacterial than is 
ofloxacin [30-32]. In the murine model, the combination of rifampicin, pyrazinamide 
and moxifloxacin showed sterilizing activity that substantially exceeded not only that 
of the standard regimen, but also that of the standard regimen with moxifloxacin [33]. 
Recently, the sterilizing activities of moxifloxacin and gatifloxacin were assessed in 
a Phase 2 study in pulmonary tuberculosis patients in South Africa (OFLOTUB) by 
means of serial sputum colony counts (SSCC). Moxifloxacin appeared superior during 
the early phase, and both moxifloxacin and gatifloxacin showed significant sterilizing 
activity and therefore seem to be capable of shortening treatment [34]. 
Unfortunately, a recent study showed no difference in the percent negative cultures 
after two months of treatment in patients who used moxifloxacin instead of 
ethambutol in combination with other first-line TB drugs [35]. 
Currently, a phase 3 trial evaluates the ability of moxifloxacin-based regimens to 
shorten treatment to four months, while safety and efficacy should not be inferior to 
the current standard six-month therapy for active, drug-sensitive, pulmonary TB. This 
trial (Remox TB) has recently started in African HIV-positive and HIV-negative adults. 
As mentioned before, the Global Alliance for TB Drug Development has noted that new 
drugs for TB should, amongst other requirements, be compatible with existing TB drugs, 
notably rifampicin. Rifampicin is the strongest known inducer of cytochrome P450, but 
it also induces phase 2 metabolism. Moxifloxacin is metabolized by phase 2 metabolizing 
enzymes. We investigated the possible interaction between rifampicin and moxifloxacin 
in Indonesian TB patients (Chapter 3). Rifampicin reduced the AUC of moxifloxacin with 
30%. According to simulations by Gumbo et al, a regular moxifloxacin dose of 400 mg 
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daily is not sufficient and only 800 mg/day is likely to achieve excellent M.	tuberculosis	
microbial kill and suppression of drug resistance [36]. This suggests that the 30% reduction 
in exposure to moxifloxacin by rifampicin may actually be relevant. Further studies are 
warranted to define the exact impact of this interaction on the outcome of tuberculosis 
treatment. In the ongoing Remox TB study, a pharmacokinetic substudy is needed to 
verify the interaction between rifampicin and moxifloxacin in African patients. 
Although it was always thought that moxifloxacin was safe in long-term use [37], a 
Dear Doctor letter on moxifloxacin, warning for rare but severe skin and liver adverse 
reactions has recently been sent. Treatment with moxifloxacin has been associated 
with the development of fulminant hepatitis or the development of Stevens Johnsons 
syndrome or toxic epidermal necrolysis. This shows that careful monitoring of patients 
on moxifloxacin remains mandatory.
After moxifloxacin and gatifloxacin, the diarylquinolone TMC207 is the third new and 
promising drug. TMC207 has very potent in vitro activity against both multi-drug 
resistant and drug-susceptible strains of M.	 tuberculosis. It acts through targeting 
the proton pump of ATP synthase [38, 39]. In mice, use of TMC207 enabled a strong 
reduction in TB treatment duration [38]. In treatment-naïve pulmonary TB patients, its 
early bacterial activity showed to be similar in magnitude to isoniazid and rifampicin 
and it was well-tolerated [40]. As rifampicin decreases the plasma concentrations of 
TMC207, the owners of the compound have decided that it will enter a randomized 
phase 2 trial in a population of patients with MDR-TB [41].
It is generally believed that the latent state of M.	tuberculosis	is induced by physiological 
conditions, such as hypoxia. Therefore, another class of compounds which is of interest 
because of their exclusive activity against microaerophilic or anaerobic bacteria, are 
the nitroimidazoles [42]. Currently, two nitroimidazoles are in clinical development; 
PA824, which is being developed by the TB Alliance, and OPC67683. PA-824 is active in 
vitro against a variety of both drug-susceptible strains and strains of M.	tuberculosis 
with known resistance to standard TB treatment [43]. The drug shows excellent tissue 
penetration in the rat, but the mechanism of action is not well understood yet, although 
it has shown to be a pro-drug requiring activation [41, 42]. Based on available evidence, 
its ability to shorten the treatment duration is limited. The more recently discovered 
nitroimidazole, OPC67683 has extremely potent in vitro and in vivo activity against M.	
tuberculosis [44].  In a mouse model of chronic infection, its efficacy was superior to 
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that of currently used TB drugs. Furthermore, no mutagenicity and no cross-resistance 
with any of the currently used antituberculosis drugs was found. 
The pyrrole LL3858 is being evaluated in a multidose phase 1 trial in healthy volunteers 
in India. In combination with currently used antituberculosis drugs, LL3858 is reported 
to sterilize the lungs and spleens of infected animals in a shorter time frame than 
conventional therapy [45]. The mechanism of action for this class of compounds has 
not yet been established, it is hypothesized that these compounds work trough a novel 
mechanism of action [46].    
The most recent compound to enter phase 1 clinical trials for TB is the diamine SQ109. 
Although it was initially developed to be an improvement of the weak first-line TB drug 
ethambutol, its structural difference from ethambutol and its potential intracellular 
targets, suggest that it may be a truly novel antimycobacterial agent. Of note, its 
oral bioavailability is only 4% [47]. SQ109 recently entered phase 1 studies involving 
human volunteers. 
A major obstacle in the quest for new effective TB drugs is the lack of appropriate in 
vitro models that predict in vivo sterilizing activity. This makes the development of new 
drugs that shorten TB less predictable. Moreover, it is extremely time-consuming and 
difficult to evaluate TB drug candidates because of the slow growth of tubercle bacilli, 
contamination problems, lengthy animal models and lengthy clinical trials, especially 
those that assess the sterilizing activity of a new compound, which takes 12-24 months 
following treatment [48]. An important obstacle is the absence of a valid surrogate 
parameter for response in TB treatment. The conversion rate at two months is validated 
to some extent as a measure of relapse rate. Other parameters are being evaluated, with 
much attention focused on serial sputum colony forming units count (SSCC) [49]. 
 
Combination of high dose rifamycin and moxifloxacin
Eventually, a combination of a higher dose of rifampicin or rifapentine plus 
moxifloxacin may be most promising. Considering that the induction of liver enzymes 
by rifampicin is maximal at a dose of 300 mg [50], there will probably be no stronger 
effect of a higher dose rifampicin on the exposure to moxifloxacin, but this needs to 
be confirmed. The inductive potential of rifapentine is less than that of rifampicin and 
the effect of rifapentine doses on enzyme induction warrants further study.
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Since rifampicin reduces plasma concentrations of moxifloxacin (Chapter 3), the dose 
of moxifloxacin will probably have to be increased when combined with rifampicin. 
A recent study showed that rifapentine also decreases the exposure to moxifloxacin 
[51], but this 17% decrease may not require a dose adjustment for moxifloxacin. Both 
the rifampicin –moxifloxacin and rifapentine-moxifloxacin combinations will have to 
be investigated in terms of tolerability and efficacy. 
Suboptimal efficacy of current antituberculosis drugs
Suboptimal response to TB treatment can be expressed by treatment failure, usually 
defined by persisting positive cultures of M.	tuberculosis	after 4 months of treatment, 
or relapse, defined by recurrent tuberculosis at any time after completion of treatment, 
and/or the development of drug-resistance. Special patient groups, such as severely 
ill hospitalized patients and tuberculosis patients with concomitant diseases, such as 
diabetes, may be especially prone to suboptimal treatment response (see below).
Hospitalized TB patients with suboptimal response to TB therapy 
In the Netherlands, most TB patients are treated by a  a public health physician [52]. 
Patients with a complicated form of TB or with complications in TB treatment, are 
often referred to a specialized TB centre. Serious hepatotoxicity and suboptimal 
response to therapy are the most common reasons for referral [52]. We evaluated 
the pharmacokinetics of TB drugs in a cohort of hospitalized TB patients from two 
TB referral centers in the Netherlands (Chapter 4) and established pharmacokinetic 
determinants in this specific study population. 
A relatively high proportion of the patients (30%) did not reach the reference ranges for 
rifampicin. This seems to be an argument in favour of measuring plasma rifampicin 
concentrations in certain cases, namely slow responders in whom inadequate dosing 
of rifampicin is suspected, and to increase the dose when necessary. This has been 
advised before [15]. We found that the plasma drug concentration two hours after 
intake can be used to monitor the total exposure (AUC) in patients who do not respond 
to therapy as expected despite the fact that patients’ adherence and drug-susceptibility 
of the tuberculosis strain is ascertained [13]. 
In this study, our finding regarding the interaction between rifampicin and 
D
iscu
ssion
Nijland.1046-Proefschrift.indd   145 07-04-2009   15:41:24
146
moxifloxacin in patients was also confirmed (Chapter 3) and more research regarding 
the clinical significance of this interaction is warranted. 
The advantage of studies in patients is that the situation mimics the real-life situation. 
However, since these patient may have co-morbidities, and use co-medication besides 
multiple TB drugs, it is difficult to grasp which effect on pharmacokinetics is caused by 
which of the present factors. Variability in pharmacokinetics of rifampicin in TB (–HIV) 
patients, as found in this study, is commonly observed [19], even after intravenous 
administration [53]. Therefore, more research is needed to comprehend interindividual 
as well as interoccasional variability in absorption [54]. 
Moreover, large studies assessing the outcome of TB treatment in terms of sputum 
culture are warranted to be able to connect plasma drug concentrations with outcome. 
In the meantime, Therapeutic Drug Monitoring (TDM) can be performed and dose 
adjustments can be made when plasma drug concentrations are very low (for example 
Cmax < 4 mg/L for rifampicin) and patients are not responding to therapy, or, very 
high and dose-dependent toxicity is known for the drug and toxicity in the patient 
is suspected. Nonetheless, in the clinic, therapeutic drug monitoring should never 
be a substitute for sound clinical judgement [55]. In our lab, methods for analysis of 
rifampicin, pyrazinamide, ethambutol and moxifloxacin have been developed so far.  
Type 2 diabetes
Recent studies show that between 10 and 30% of tuberculosis patients may also 
have type 2 diabetes [56-61]. Presence of type 2 diabetes seems to affect the outcome 
of tuberculosis treatment adversely [62]. In a study in Indonesia, more than twice 
as many diabetic patients had a sputum culture positive for M.	 tuberculosis	at six 
months, and diabetes remained a strong and independent prognostic factor for 
positive cultures after adjustment for possible confounders [62]. Others also reported 
significant negative findings on treatment outcome [63-66], such as cavities and lower 
lung field lesions on chest radiographs and a higher mortality rate [67]. However, one 
study in Saudi Arabia found no effect of diabetes on tuberculosis cure rates [58]. It 
should be acknowledged that, except for the Indonesian study, none of these studies 
used sputum culture after treatment as study endpoint.
If diabetes indeed would have a negative effect on the outcome of TB treatment, 
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one starts wondering about the possible cause. A higher rate of non-adherence or 
resistance among diabetics was excluded in the study by Alisjahbana et al. Therefore, 
pharmacokinetic aspects of tuberculosis treatment could be relevant. In Chapter 5, we 
showed that the exposure (AUC0-6h) of rifampicin was approximately two-fold lower 
in tuberculosis patients with diabetes, compared to tuberculosis patients without 
diabetes. A higher body weight and the presence of diabetes seemed to contribute to 
lower rifampicin exposure. In addition, more profound hyperglycemia was associated 
with lower plasma rifampicin concentrations. If these results are confirmed in a 
follow-up study in Bandung in which a full pharmacokinetic curve (samples up to 24 
h post dose) is recorded, it may imply that patients with a higher body weight and 
diabetes require a higher dose of rifampicin. Since diabetes was poorly controlled 
in our study, plasma glucose was significantly higher in tuberculosis patients with 
diabetes, and we hypothesized about an negative influence of high plasma glucose on 
the absorption of rifampicin. 
By means of the follow-up study which is currently being performed in Indonesia, 
we will also attempt to unmask the mechanisms of lower exposure to rifampicin in 
diabetes patients. Within patients, we will compare the difference in exposure after 
oral or intravenous administration of rifampicin in order to ascertain indisputably 
whether it is decreased absorption in diabetes patients that causes the lower exposure. 
Besides, to test whether exposure to rifampicin increases when blood glucose is 
normalized, exposure to rifampicin will also be assessed after regular self-treatment 
with antidiabetics and after controlled plasma glucose by the use of insulin within the 
same patient. Moreover, a comparable study in TB patients from another race, namely 
African patients, is being started at the moment. The outcomes of these studies will 
dictate the direction of future research. 
Combined treatment of tuberculosis-HIV 
Several problems are associated with the drug treatment of TB-HIV co-infection: first, 
non-adherence, because many different drugs have to be used. Second, the adequacy 
of TB drug absorption among patients with advanced HIV disease and the complex 
pharmacokinetic drug-drug interactions between the rifamycins and two widely used 
classes of antiretroviral drugs – the protease inhibitors (PIs) and the non nucleoside 
reverse transcriptase inhibitors (NNRTIs). These interactions lead to decreased plasma 
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concentrations of a number of antiretroviral drugs, potentially leading to loss of 
antiretroviral efficacy and stepwise accumulation of resistance mutations [68-72]. 
Third, the simultaneous administration of antituberculosis and antiretroviral drugs to 
patients is associated with frequent adverse events. Determining the etiology of these 
adverse events is challenging, because the adverse effect profiles of antituberculosis 
drugs overlap with those of antiretroviral drugs [73]. Fourth, the development of an 
immune reconstitution syndrome in patients with a recovering immune system on 
ART therapy may cause a revival of TB symptoms. 
With regard to the drug absorption among HIV patients, currently available studies 
are not consistent. It appears that HIV-infected patients achieve somewhat lower 
concentrations of the orally administered first-line antituberculosis drugs (rifampicin, 
isoniazid, pyrazinamide, and ethambutol) [2, 74-76]. Whether the somewhat lower 
concentrations of antituberculosis drugs in patients with advanced HIV infection 
affect treatment outcomes, is not likely [73]. 
With regard to the drug-drug interactions in TB-HIV co-infection, these are mainly 
caused by rifampicin.  Rifampicin is a prominent inducer of the expression of many 
enzymes and drug-transporting molecules as well. The interactions between rifampicin 
and the NNRTIs are particularly important, because NNRTIs are recommended as a 
component of initial ART both in western countries as in countries with a high burden 
of HIV infection [77]. Fortunately, the modest decrease in efavirenz concentration is 
not expected to be clinically relevant [78, 79]. Because of the teratogenic potential of 
efavirenz, nevirapine is widely used in many developing countries as well. Although 
the effect of rifampicin on nevirapine is greater than its effect on efavirenz 
concentrations, nevirapine is considered to be an alternative in rifampicin-based 
TB treatment [80-82]. An important disadvantage of the NNRTIs as a group is their 
low genetic barrier for the development of resistance. In the long term, resistance 
will develop, also in Sub Saharan Africa, and a second-line treatment will have to be 
available.  The effectivity of the newer integrase inhibitors and CCR5-inhibitors also 
seem to be hampered by rifampicin, either by its UGT inducing (raltegravir) [83] or 
CYP3A4 inducing properties (maraviroc) [84].
Obviously, the second-line antiretroviral treatment options when combination 
with rifampicin is necessary, are limited. Triple NRTI regimens are inferior to the 
combination of two NRTIs plus an NNRTI or PI. PIs, however, are all substrate to CYP 
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3A4 and P-glycoprotein. Therefore, the plasma concentrations of nearly all of the 
currently available PIs are profoundly reduced by rifampicin, and because of this, 
their simultaneous use is contraindicated [85]. Increasing the dose of the PI could 
possibly overcome this interaction. Another option would be to increase the dose of 
the booster, usually ritonavir. In a study in healthy volunteers, both these alternatives 
have been evaluated for the first-line PI lopinavir/ritonavir when combined with 
rifampicin. Increasing the dose of ritonavir seemed to be less tolerable than 
increasing the dose of lopinavir [86]. Therefore, we performed a study that aimed to 
evaluate the pharmacokinetics of two adjusted dose regimens of lopinavir/ritonavir 
tablets in combination with rifampicin in healthy volunteers (Chapter 6). Due to an 
unexpectedly high incidence of adverse events, this study was terminated prematurely 
[87]. Studies by others [88, 89] have also shown that combined use of PIs and 
rifampicin can lead to an acute intoxication and adverse events, nausea, vomiting and 
transaminase elevations. Surprisingly, toxicity seems to be intricately linked to the 
design of the study. According to our study with lopinavir/ritonavir and studies with 
two other ritonavir boosted PIs, saquinavir and recent findings concerning atazanavir, 
rifampicin lead-in seems to incontrovertibly favor toxicity [88-90]. Participants who 
had been receiving the PIs before the introduction of rifampicin had a lower risk of 
hepatitis. The explanation for this phenomenon is not unraveled yet. Pre-induction of 
CYP 3A4 may generate a PI metabolite, or inhibition of CYP 3A4 may block clearance 
of a rifampicin metabolite which mediates toxicity [91]. A time-dependent effect 
by lopinavir/ritonavir on P-gp [92] could also have caused high plasma lopinavir 
concentrations and therefore to toxicity. Alternative explanations for the hepatitis 
in our study would be either the absence of a dose escalation for lopinavir/ritonavir 
resulting in too high lopinavir concentrations, although five days of rifampicin in 
advance should have given sufficient enzyme induction [86]. 
The question arises how to combine TB and second-line HIV treatment effectively. 
Since rifampicin causes all drug-drug interactions described above, three possible 
approaches are imaginable. First, to treat TB or HIV separately, since combination of TB 
and HIV drugs will inevitably lead to either toxicity or the development of resistance. 
Obviously, this is only an option in a selected patient group. In general, TB will be 
treated first in order to prevent spread of the bacteria. This is only possible in HIV 
patients with relatively high CD4 counts. Second, to use a non-rifamycin regimen. This 
option is not desirable considering the efficacy of rifamycins. However, two cases in 
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which moxifloxacin successfully replaced rifamycins, were recently described [93]. 
Third, to use alternative rifamycins, which cause less enzyme induction. Rifapentine 
is currently not recommended for use in HIV-infected patients, owing to relapses of 
TB with rifamycin monoresistant strains when it was used once weekly during the 
continuation phase of TB treatment [94]. Of the currently available rifamycins, rifabutin 
has the least potential for enhancing the metabolism of antiretrovirals. Unfortunately, 
this approach is not feasible for most TB control programs in most countries, since 
rifabutin is very expensive. Besides, protease inhibitors influence the pharmacokinetic 
profile of rifabutin [95, 96].   
Application of therapeutic drug monitoring (TDM), could guide physicians who treat 
complicated TB-HIV co-infected cases. With regard to patient care, it is woeful that 
TDM usually is unavailable in the most burdened regions. Therapeutic monitoring 
in this patient class needs to be investigated further in terms of improved treatment 
outcomes.
The retrospective study in chapter 7, evaluating the clinical experience with the 
combined use of lopinavir/ritonavir and rifampicin in the Netherlands, illustrates 
the difficulties encountered when combining rifampicin and PI-based antiretroviral 
treatment. Omitting dose adjustments of lopinavir/ritonavir when combined with 
rifampicin will lead to subtherapeutic plasma concentrations of lopinavir/ritonavir 
and suboptimal efficacy. However, adjustment of the dose of lopinavir/ritonavir 
seems to lead to a higher incidence of adverse events and premature termination of 
combined use of the drugs. It seems choosing the lesser of two evils.
Apparently, more studies are warranted, but a question of ethical consideration arises: 
is it ethically justified to expose healthy volunteers to these highly toxic TB plus HIV 
drug combinations? Considering the serious liver enzyme elevations, nausea and 
vomiting, that occurred in previous studies in healthy volunteers, future studies with 
rifampicin and PIs should be performed in patients. On the other hand, performing the 
studies in patients contains the risk of resistance to vital drugs and this is undesirable 
as well. However, this impasse obviously needs to be overcome. Studies assessing the 
pharmacokinetics of this drug combination should be highly balanced in terms of risks 
and benefit. From studies in the past with healthy volunteers and the combination of 
a PI and rifampicin, it was observed that especially the study phase in which the dose 
of the PI was increased, was problematic for the safety of the healthy study subjects. 
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This phase would not give problems of drug resistance development in TB and HIV 
co-infected patients. In other words, the assessment whether a pharmacokinetic 
interaction occurs might have to be established in healthy volunteers. Once a 
pharmacokinetic interaction has been established, dose increments of the PI when 
combined with rifampicin might have to be tested in patients. The necessity of 
intensively monitoring the safety of the healthy volunteers and the development of 
drug resistance (low plasma drug concentrations) cannot be stressed enough.
Research in developing countries 
The huge gap between industrialized countries and developing countries regarding 
standards of living and especially access to healthcare is an example of the inequalities 
in our world. Research in developing countries should avoid widening this gap, but 
contribute to reducing it [97]. 
The positive impact of performing a clinical trial in developing countries is the local 
acquisition of new knowledge, the accessibility of new treatments (over time) and 
the capacity-building induced by the implementation of the clinical trial. Especially 
the latter was one of the major goals of the consortium within which the studies in 
this dissertation were performed. A potential negative impact may also occur: the 
implementation of the clinical trial can disturb the local pre-existing healthcare. 
Several other issues that deserve attention when performing clinical studies in 
developing countries and other cultures were encountered during the studies 
described in this thesis, including: 
Stigma. For example, HIV infection/AIDS is highly stigmatized in Indonesia. HIV – 
testing before participating in a trial is therefore difficult to achieve in Indonesia. A 
recent study performed in Yogyakarta found that unlinked anonymous HIV testing 
is well accepted and can be implemented with modest additional efforts [98].
Obtaining informed consent. The way information is given to patients and the – 
procedure of obtaining consent may vary according to the specific situation of the 
country and its inhabitants, the level of literacy, the level of scientific understanding 
and the organization of the community; different views regarding privacy and 
personal data may exist and should be coped with. 
Financial compensation for involvement in a clinical study is another sensitive – 
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issue, it should be benevolent in order to avoid exploitation. On the other hand, 
inconvenience or travel costs, caused by involvement should be compensated. 
Liability insurance of patients. The standards of insurance, liability and indemnity – 
insurance for the participants in a clinical trial and their families must provide the 
same kind of protection wherever a trial takes place [97]. This issue often seems to be 
inadequately arranged and overshadowed by enthusiasm to start the clinical trial.
Free supply of a proven beneficial new drug to all the participants of a trial after – 
the trial has ended is the rule, as long as it is not yet available through the regular 
health care [97]. In developing countries, the same rule must be applicable even 
if this implies supplying the drug for a lifetime if necessary. Within the scope of 
our research, we have adopted TB patients and compensated for the costs of their 
treatment, regular visits and diagnostic tests. 
Next to these fundamental problems which form a threat for the success of research - 
in developing countries, trivial problems, such as lack of space and time, are just as 
threatening. Lack of space gives rise to creative solutions, but these are not often the 
most sensible ones. Inclusion screening of potentially infectious TB patients next to 
the ambulant HIV clinic with a shared corridor, for example, might not be prudent. 
Furthermore, suboptimal quality of equipment in developing countries makes 
research even more complex. For example, lack of high quality drug-susceptibility 
testing or lack of fine HPLC apparatus, compels to send samples to European countries. 
Recently, the Indonesian government  issued new legislation and banned transport of 
all biological samples to foreign countries. This legislation may stimulate  that high-
quality material will be established and personnel will be trained adequately. 
Study setting 
In order to achieve our objectives, the studies were performed in both the Netherlands 
and Indonesia.
Around 1910, a shocking 15% of the Dutch people suffered from tuberculosis. The first 
sanatoria were established of which two still exist and are still in use; University Lung 
Centre Dekkerswald and Center for Tuberculosis, Beatrixoord. Over time, tuberculosis 
prevalence has decreased spectacularly and currently, around 1000 patients are treated 
for tuberculosis each year in the Netherlands. The majority of the patients is treated at the 
municipal health service under directly observed therapy. A small part of these patients 
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will be admitted to the hospital, or whenever indicated, to one of the two tertiary referral 
centres. Infectious patients will be confined and whenever unwilling patients refuse, 
adequate legislation [99] foresees in forced isolation for the duration of the infectious 
period. If confinement is warranted longer than the infectious period, for example in case 
of non-adherence, confinement after the infectious period is allowed as well [100]. 
As mentioned before, overpopulated and resource-limited countries encounter the 
largest burden of tuberculosis. Besides, limited information on the clinical pharmacology 
of TB drugs is available in these settings. The majority of the studies presented in this 
dissertation were performed in Indonesia within the context of  the PRIOR (Poverty 
Related Infection Oriented Research) network. PRIOR is a research network which 
connects academic institutes from the Netherlands, Indonesia, and Tanzania to 
facilitate joint-research on poverty-related diseases, such as tuberculosis, malaria, and 
HIV/AIDS. PRIOR was founded through a grant from the Netherlands Foundation for 
the Advancement of Tropical Research (NWO-WOTRO) and the Netherlands Foundation 
for Health Research and Development (ZONMW). It focuses on capacity building and 
the establishment of independent centers of excellence in Indonesia and Tanzania to 
ensure the continuation of research and care in the future. 
Indonesia ranks third in the list of countries with highest TB burden with an estimated 
incidence of 539,189 per year. In the larger cities and on Java, tuberculosis patients are 
mainly diagnosed and treated in specialized TB centres. Patients with adverse reactions, 
TB-HIV co-infection or extensive and complicated disease are treated in a teaching 
hospital. In smaller cities and villages, TB centres may not be present, and patients are 
treated by the local health centre (puskesmas). Access to treatment is reasonably well 
arranged in Indonesia, although free drug treatment is not secured for children and in some 
hospitals expensive brand drugs are available instead of free generic drugs. Moreover, the 
prevention of transmission of TB and the implementation and exertion of DOTS clinics 
remains a focus of attention. Treatment is sometimes initiated without bacteriological 
confirmation. Besides, diagnosing TB is based on sputum microscopy, not culture, in 
the DOTS strategy. Due to resource limitations, drug-susceptibility testing is normally 
not performed at treatment initiation. The study by Cox [101], which was performed in 
Uzbekistan, shows high mortality and recurrence numbers in a patient group with high 
resistance rates. These patients joined a functioning DOTS programme. Apparently, drug 
susceptibility testing, access to second-line drugs and DOTS are instruments that are 
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only successful in TB treatment and control when they are used jointly. These factors 
should be addressed in order to be able to actually fight tuberculosis. 
Future perspectives
It is ironic that many dedicated agencies exist to tackle AIDS-related issues,  while 
control of TB, for which breathing is the only risk factor, has only few powerful 
advocates at the governmental and international levels. Unless there is a 10-fold 
increase in spending on TB research much of the success stemming from improved 
HIV therapies may prove to have been temporal [42]. 
An important  short-term goal for TB treatment is to optimize the dose of existing 
TB drugs for drug-susceptible TB. Mortality numbers show that improved treatment 
is needed urgently, especially for certain subgroups of TB patients. From a study in 
Indonesian tuberculosis meningitis in admitted patients, in which 124 out of 154 
were diagnosed with tuberculous meningitis, the one-month mortality was 40.1%. 
HIV dramatically decreased the survival rate of TBM patients [102]. Shortened TB 
treatment would significantly improve global control efforts. Availability of new 
drugs for this purpose on the short term seems unrealistic. Therefore, better use of 
existing drugs could be the answer to shortening TB treatment. More studies are 
warranted to investigate the additional value of higher dosages of rifampicin for an 
improved treatment outcome of TB. Daily dosing of rifapentine in combination with 
moxifloxacin has demonstrated promising results in mice [103], although recent 
results show that rifapentine, just as rifampicin, also induces the metabolism of 
moxifloxacin [51]. Research is warranted to investigate the possible addition of 
rifapentine and moxifloxacin for the shortening of TB treatment.
Furthermore, drug-resistant TB, such as MDR-TB, due to strains of M.	 tuberculosis 
resistant to at least rifampicin and isoniazid, is increasingly common in parts of Asia, 
Russia and other states of the ex-Sovjet Union [104]. A new, even more deadly form 
has emerged among AIDS patients in South Africa and has been termed extensively 
drug-resistant TB (XDR-TB) [105]. New drugs are needed to stop this threat from 
expanding. Seven drugs are currently under investigation for their abilities to improve 
TB treatment, although not all of them are active to drug-resistant strains. 
Respiratory drug delivery systems certainly have the potential for antitubercular 
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inhaled therapy, based on experimental data [106]. However, the possibility of variable 
deposition of an inhaled formulation in the lungs needs to be considered and is a 
matter of concern because it could result in suboptimal drug concentrations in certain 
lung regions which could lead to impaired response.
More research is needed to seize the complicated relationship between plasma drug 
concentrations and outcome of treatment and the pharmacokinetic determinants of 
the existing drugs, since the belief that new drugs will become available all over the 
world is unrealistic. For very complicated or resistant cases of TB, all efforts should be 
employed in order to ensure that new and safe drugs will become readily available. 
Nonetheless, more research alone will not suffice. Worldwide coordination of research 
and development of new drugs is required to efficiently supervise the development of 
effective and safe new drugs for TB. Compatibility with HIV drugs might have to be a 
special point of attention for these new drugs. To stress this necessity, in sub-Saharan 
Africa, over 75% of cases of TB are HIV associated [107]. Unfortunately, until now only 
few patients have access to antiretroviral treatment in sub-Saharan Africa, but access 
to HIV drugs will undoubtedly increase. Anticipation on the future is not optional, but 
compulsory. TB research in the most burdened areas is crucial, therefore research and 
capacity-building should go hand in hand.  
In any case, our actions and reactions to tuberculosis in the coming years will be 
decisive for the fate of present and future tuberculosis patients all over the world. 
However, control of TB epidemic does not depend on the development of new drugs 
solely. The socio-economic situation and general health status (nutrition, HIV infection) 
of patients is essential to the impact of TB infection. The quality and quantity of the 
diagnostic and therapeutic facilities of health care centers in the most burdened 
settings are crucial to fight TB successfully. 
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Introduction
The overall objective of this thesis was to contribute to the optimization of 
tuberculosis (TB) drug treatment, more specifically to optimize the dose of TB drugs. 
The central principle underlying the studies in this dissertation was that adequate 
plasma drug concentrations are pivotal for a good treatment response and play a 
central role in optimizing TB treatment. 
Part I of the thesis includes pharmacokinetic studies that contribute to shortening TB 
treatment. Part II focuses on suboptimal response to tuberculosis treatment. Certain 
patient groups are prone to a more problematic course of tuberculosis treatment, 
such as patients who are admitted to a tertiary referral hospital and patients who 
also have type 2 diabetes. Part III describes the challenges of combined treatment 
with lopinavir/ritonavir and rifampicin for HIV-TB co-infection. 
Part I
Pharmacokinetic contributions to shortening tuberculosis treatment
The treatment of TB is complicated by the length and complexicity of currently 
available drug regimens and invites problems of nonadherence, inadequate response 
and resistance development. A long-term goal for TB control has been to shorten the 
duration of treatment. This may possibly be achieved by increasing the dose of the 
pivotal drug rifampicin. 
In Chapter 1 we investigated the effect of increasing the dose of rifampicin in terms 
of pharmacokinetics and tolerability. Previously, low peak plasma concentrations 
(below 4 mg/L) were found in Indonesian TB patients. Indonesian TB patients were 
randomized to either a high (600 mg) or standard (450 mg, i.e. 10 mg/kg) dose of 
rifampicin. High and standard doses of rifampicin were administered every day in 
the intensive phase and three times weekly in the continuation phase of treatment. 
Single blood samples were collected two hours after witnessed intake of TB drugs on 
an empty stomach, patients were questioned actively for possible adverse events and 
liver transaminases were monitored. This trial in Indonesia showed that a higher 
dose of rifampicin significantly increased the proportion of patients with rifampicin 
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peak plasma concentrations above the reference value of 8 mg/L, whereas no 
differences were noted in terms of tolerability. Since the study in Chapter 1 
only evaluated a single time point and was non-blinded, a follow-up study was 
designed.
 
Chapter 2 describes this double-blind randomized clinical trial with intensive 
pharmacokinetic sampling to compare the steady-state pharmacokinetics and 
tolerability of a higher (600 mg) and the standard (450 mg) dose of rifampicin. 
Twenty-five patients were allocated to each of the two study arms. Exposure to 
rifampicin (AUC0-24) was 65% higher and the peak plasma concentration (Cmax) 
was increased by 49% in the higher-dose arm, which reflects a more than dose-
proportional increase of the exposure upon increasing the dose. The percent of 
patients who reached a reference peak plasma concentration of at least 8 mg/L was 
96% in the higher dose group and 79% in the standard-dose group. No significant 
differences were found between the high and standard dose group in the incidence 
of nausea, vomiting, abdominal pain, and hepatotoxicity grade 3. Hepatotoxicity 
grade 1 or 2 was more common in the higher dose group, but none of the patients 
developed serious hepatotoxicity and no action had to be taken. This phase II clinical 
study showed that increasing the dose of rifampicin is feasible and effective from a 
pharmacokinetic point of view. This calls for follow-up phase II studies that evaluate 
an even higher 15 or 20 mg/kg dose of rifampicin. Available evidence shows that TB 
treatment duration could possibly be shortened to 4 months by using higher doses 
of rifampicin. This should be tested in larger numbers of patients, within the context 
of a phase III trial.  
In Chapter 3, the possible interaction between moxifloxacin and rifampicin was 
investigated. New TB drugs may help to shorten the treatment duration. Moxifloxacin 
has shown the potential to shorten TB treatment with two months when used as 
a subsititute for isoniazid in the murine model. However, the pharmacokinetic 
interaction between moxifloxacin and rifampicin had not been investigated before. 
This possible interaction was investigated in nineteen Indonesian TB patients in the 
last month of the continuation phase of TB treatment. Next to regular treatment 
with rifampicin and isoniazid, subjects were given 400 mg of moxifloxacin QD 
during five days. After finishing TB treatment and a one month wash-out phase, 
patients received 400 mg of moxifloxacin for another five days. The AUC and 
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Cmax  of moxifloxacin were decreased by 31 and 32% respectively when combined 
with rifampicin. This interaction is expected to result from an increase in phase 
II metabolism caused by rifampicin as moxifloxacin does not undergo phase I 
oxidative metabolism. The clinical relevance of the findings in this study have 
yet to be elucidated. On the basis of the current study, we would propose that 
follow-up pharmacokinetic studies are performed to assess the pharmacokinetics, 
pharmacodynamics and tolerability of a dose increase to 600 or 800 mg moxifloxacin 
when combined with rifampicin or other rifamycin derivatives.   
Part II
Pharmacokinetic determinants of suboptimal response to tuberculosis 
treatment
To optimize TB treatment, a better understanding of the pharmacokinetics of TB 
drugs is required. More descriptive pharmacokinetic data from TB patients should 
be obtained, determinants associated with the pharmacokinetics of TB drugs should 
be identified, and interventions to improve plasma drug concentrations should be 
carried out. 
 
In Chapter 4, the pharmacokinetics of rifampicin, isoniazid, pyrazinamide, 
ethambutol and moxifloxacin were described in a cohort of tuberculosis patients 
who were admitted to the two Dutch tuberculosis referral centers and possible 
determinants of pharmacokinetic parameters in these patients were evaluated. 
 
Forty-one patients were included in the study. Rifampicin showed the highest 
interindividual variation in pharmacokinetics and approximately 30% of 
the patients using the regular dose of rifampicin (10 mg/kg) did not achieve 
the minimum reference peak concentration. Our results further suggest that 
pyrazinamide is able to reduce the plasma concentrations of rifampicin. The 
interaction between moxifloxacin and rifampicin (Chapter 3) was confirmed in this 
cohort of Dutch patients. Ethambutol was associated with an increased exposure to 
pyrazinamide and smoking was associated with reduced exposure to ethambutol. 
The concentration at 2 h post dose (C2h) of rifampicin, pyrazinamide, moxifloxacin, 
but not ethambutol correlated with Cmax and AUC, enabling limited sampling to 
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estimate exposure to the TB drugs.  The significance of these descriptive findings 
and determinants should be studied in pharmacokinetic and pharmacodynamic 
studies in larger patient populations.  
In Chapter 5, the plasma concentrations of rifampicin in Indonesian tuberculosis 
patients with and without type 2 diabetes were compared. The global type 2 diabetes 
incidence is increasing, especially in developing countries, where tuberculosis 
is highly endemic. Diabetes compromises the response to TB treatment and we 
examined if this might be due to lower plasma concentrations of rifampicin. Indeed, 
exposure to rifampicin was 53% lower in Indonesian tuberculosis patients with 
diabetes, compared to tuberculosis patients without diabetes. Similarly, Cmax of 
rifampicin was above the target concentration of 8 mg/L in only one out of seventeen 
(6%) tuberculosis patients with diabetes, compared to eight of seventeen (47%) 
patients without diabetes. Multivariate analysis revealed that a higher body weight 
and the presence of diabetes contributed to lower rifampicin exposure. In addition, 
more profound hyperglycemia was associated with lower plasma rifampicin 
concentrations. The findings of this study suggest that the unfavorable response 
of patients with type 2 diabetes may at least partially be explained by differences 
in pharmacokinetics. Tuberculosis patients with concomitant type 2 diabetes and 
a higher body weight may possibly need a higher dose of rifampicin. Additional 
studies should assess the influence of diabetes, as well as the possible benefit of 
active treatment of diabetes on the pharmacokinetics of TB drugs and the outcome 
of tuberculosis treatment. 
Part III
Drug-drug interactions in the treatment of TB-HIV co-infection
Approximately one-third of the 40 million people living with HIV/AIDS worldwide 
are co-infected with M.	 tuberculosis. The World Health Organization (WHO) 
recommends to combine rifampicin-based TB treatment with antiretroviral therapy 
based on non-nucleoside reverse transcriptase inhibitors (NNRTIs) in these TB-
HIV-co-infected patients. For patients with NNRTI-resistant HIV or those unable to 
take NNRTIs due to adverse events, antiretroviral protease inhibitors (PIs) such as 
lopinavir/ritonavir may be an alternative. Previous research in healthy volunteers 
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has demonstrated that increased doses of lopinavir/ritonavir soft gel capsules 
compensate for the interaction with rifampicin. The pharmacokinetic interaction 
study in Chapter 6 showed a high incidence of adverse events in 11 healthy 
volunteers treated with a higher than standard dose of the new lopinavir/ritonavir 
tablets in combination with rifampicin. In fact, the study had to be terminated 
prematurely after addition of 600/150 or 800/200 mg lopinavir/ritonavir twice 
daily to rifampicin. Eight subjects suffered from both nausea and vomiting, one from 
nausea only. Moreover, increases in AST/ALT levels were reported in all subjects. All 
levels returned to normal within six weeks. The observed toxicity may be explained 
by three means. Firstly, rifampicin was introduced prior to lopinavir/ritonavir, a 
sequence which has been associated with drug discontinuation in a similar trial 
with healthy volunteers; secondly, the adjusted dose of lopinavir/ritonavir was 
not escalated; and thirdly, the new lopinavir/ritonavir tablet formulation was used 
instead of the capsule formulation. It was advised that further studies investigating 
the interaction between rifampicin and lopinavir/ritonavir tablets be performed 
in the actual target population of HIV-TB co-infected patients rather than healthy 
volunteers. Extreme caution and close monitoring of liver enzymes are warranted 
when lopinavir/ritonavir and rifampicin are combined in HIV-TB co-infected 
patients.
Chapter 7 describes the clinical experience with the combined use of lopinavir/
ritonavir and rifampicin in the Netherlands. Thirty-four adult HIV-infected 
individuals were selected from the Dutch ATHENA cohort for retrospective analysis. 
Overall, only 15% used a recommended increased dose of lopinavir/ritonavir. 
Lopinavir trough plasma concentrations during combined use were available for 6 
of 23 (26%) patients on a non-adjusted dose of lopinavir/ritonavir, none of 6 patients 
on a slightly adjusted dose and 2 of 5 (40%) patients on a recommended dose. Four of 
6 (67%) patients on a non-adjusted dose of lopinavir/ritonavir had a subtherapeutic 
lopinavir trough plasma concentration (< 1.0 mg/L), whereas the 2 patients on a 
recommended dose had a therapeutic concentration. Overall, 7 of 34 (21%) patients 
prematurely stopped the combination within 4 weeks because of acute adverse 
events; this was 4 of 23 (17%) on a non-adjusted dose, 1 of 6 (17%) on a slightly adjusted 
dose and 2 of 5 (40%) on a recommended dose of lopinavir/ritonavir. It was concluded 
that a small minority of HIV-infected patients in the Netherlands has been treated 
with the recommended increased dose of lopinavir/ritonavir in combination with 
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rifampicin. This was associated with inferior exposure to lopinavir and, possibly, 
virological failure. Concomitant use of lopinavir/ritonavir and rifampicin remains 
challenging. 
General discussion 
In the general discussion, our clinical pharmacokinetic studies on the long duration 
of current TB treatment (Part I), the pharmacokinetic determinants of suboptimal 
response (Part II) and  the combined treatment of TB and HIV infection (Part III) were 
placed in perspective. Recent developments and studies performed by others are 
described and future directives are discussed.  
Since the majority of studies in this thesis were performed in Indonesia, the 
discussion paid attention to research in developing countries. It was noticed that 
research in developing countries should contribute to reducing the gap between 
industrialized and developing countries regarding standards of living and especially 
access to healthcare. The implementation of clinical trials should avoid to disturb 
the local pre-existing healthcare.  Moreover, several other issues, such as stigma, 
financial compensation and liability insurance deserve attention when performing 
clinical studies in developing countries and other cultures. 
Global mortality numbers show that improved tuberculosis treatment is needed 
urgently. Availability of new drugs for this purpose on the short term seems 
unrealistic. Better use of existing drugs could be the answer to shortening TB 
treatment. 
In any case, our actions and reactions to tuberculosis in the coming years will be 
decisive for the fate of present and future tuberculosis patients all over the world. 
Quality and quantity of the diagnostic and therapeutic facilities of health care 
centers in the most burdened settings are crucial to fight TB successfully. 
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Inleiding
De doelstelling van dit proefschrift was om bij te dragen aan de optimalisatie 
van de tuberculose (TB) behandeling, preciezer gezegd: om de dosis van de TB 
geneesmiddelen te optimaliseren. Het centrale principe van dit proefschrift was 
dat adequate plasma geneesmiddelconcentraties essentieel zijn voor een goede 
respons op de behandeling en een belangrijke rol spelen in de verbetering van de 
tuberculosebehandeling. 
Deel I van dit proefschrift bevat farmacokinetische studies die bijdragen aan de 
verkorting van de tuberculosebehandeling.  Deel II focust op suboptimale respons 
op de tuberculosebehandeling. Bepaalde patiëntgroepen zijn ontvankelijker voor 
een problematische tuberculosebehandeling, zoals patiënten die opgenomen zijn in 
een tertiaire verwijskliniek en patiënten die ook type 2 diabetes hebben. Deel III 
beschrijft de uitdagingen van gecombineerde behandeling van HIV-TB co-infectie 
met lopinavir/ritonavir en rifampicine.
Deel I
Farmacokinetische bijdragen aan verkorting van de tuberculose-
behandeling 
De behandeling van tuberculose wordt bemoeilijkt door de duur en complexiteit 
van de momenteel beschikbare geneesmiddel regimes, en leidt tot problemen met 
therapietrouw, onvoldoende respons en resistentieontwikkeling. Een lange termijn 
doel van tuberculosecontrole is om de behandeling te verkorten. Dit doel zou bereikt 
kunnen worden door de verhoging van de dosis van het belangrijke geneesmiddel 
rifampicine.
In Hoofdstuk 1 onderzochten we het effect van de dosisverhoging van rifampicine 
op het gebied van farmacokinetiek en verdraagbaarheid. Eerder werden al 
lage plasma piekconcentraties (lager dan 4 mg/L) gevonden in Indonesische TB 
patiënten. Indonesische TB patiënten werden gerandomiseerd naar een hoge (600 
mg) of standaard (450 mg, 10 mg/kg) dosis rifampicine. Hoge en standaard doses 
rifampicine werden in de intensieve fase elke dag toegediend en driemaal per 
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week in de vervolgfase van de behandeling. De bloedmonsters werden twee uur na 
geobserveerde inname van TB geneesmiddelen op een nuchtere maag verzameld. 
De patiënten werden actief ondervraagd over mogelijke bijwerkingen en 
leverenzymen werden gemonitored. Dit onderzoek in Indonesië liet zien dat 
een hogere dosis rifampicin het aantal patiënten met een rifampicine plasma 
piekconcentratie hoger dan 8 mg/L significant verhoogde, terwijl geen verschillen in 
verdraagzaamheid werden opgemerkt.  Aangezien dit onderzoek slechts een enkel 
tijdspunt (de plasma piekconcentratie) onderzocht en niet geblindeerd was, werd 
een vervolgonderzoek opgezet. 
Hoofdstuk 2 beschrijft dit dubbelblind gerandomiseerde klinische onderzoek. 
De steady-state farmacokinetiek en verdraagzaamheid van een hoge (600 mg) en 
standaard (450 mg) dosis rifampicine werd vergeleken. Vijfentwintig patiënten 
werden aan elk van de twee studiearmen toegewezen en de patiënten werden 
intensief bemonsterd. Blootstelling aan rifampicine (AUC0-24) was 65% hoger en de 
plasma piekconcentratie was toegenomen met 49% in de groep die de hoge dosering 
ontving, wat een meer dan dosisproportionele toename van de blootstelling 
weerspiegelt. Het percentage patiënten dat een referentie plasma piekconcentratie 
bereikte van tenminste 8 mg/L was 96% in de groep die de hoge dosering ontving 
en 79% in de groep die de standaard dosering ontving. Geen significante verschillen 
tussen de hoge en standaard dosis rifampicin werden gevonden met betrekking tot 
de incidentie van misselijkheid, braken, maagpijn en graad 3 hepatotoxiciteit. Graad 
1 of 2 hepatotoxiciteit kwam meer voor in de groep die de hoge dosering ontving, 
maar geen van de patiënten ontwikkelde ernstige hepatotoxiciteit en er hoefde geen 
actie ondernomen te worden. Dit fase II klinische onderzoek liet zien dat verhoging 
van de dosis rifampicine haalbaar is en in farmacokinetisch opzicht effectief is. Dit 
resultaat nodigt uit tot follow-up fase II onderzoek dat een nog hogere 15 of 20 mg/kg 
dosis rifampicine onderzoekt. Huidig bewijs laat zien dat de tuberculosebehandeling 
mogelijk tot vier maanden verkort kan worden door het gebruik van een hogere dosis 
rifampicine. Dit zou getoetst moeten worden in een fase III onderzoek met grotere 
patiëntaantallen. 
In Hoofdstuk 3 werd de mogelijke interactie tussen moxifloxacine en rifampicine 
onderzocht. Nieuwe geneesmiddelen tegen tuberculose zouden ingezet kunnen 
worden om de tuberculosebehandeling te verkorten. In het muis-model heeft 
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moxifloxacine haar potentie laten zien de tuberculosebehandeling met twee 
maanden te verkorten wanneer het in plaats van isoniazide werd ingezet. De 
farmacokinetische interactie tussen moxifloxacine en rifampicine was echter nog 
niet eerder onderzocht. Deze mogelijke interactie werd onderzocht in negentien 
Indonesische tuberculosepatiënten in de laatste maand van de vervolgfase van 
de tuberculosebehandeling. Naast de reguliere behandeling met rifampicine 
en isoniazide, ontvingen de deelnemers 400 mg moxifloxacine eenmaal daags 
gedurende vijf dagen. Na de beëindiging van de tuberculosebehandeling en 
een maand wash-out, ontvingen de patiënten wederom 400 mg moxifloxacine 
gedurende vijf dagen. De AUC en Cmax van moxifloxacine werden verlaagd met 
respectievelijk 31 en 32% wanneer het werd gecombineerd met rifampicine. De 
verwachting is dat deze interactie teweeg gebracht werd door een toename in fase II 
metabolisme veroorzaakt door rifampicine - moxifloxacin ondergaat namelijk geen 
fase I metabolisme. De klinische relevantie van de resultaten van dit onderzoek 
moet verduidelijkt worden. Op basis van dit onderzoek zouden wij voorstellen dat 
follow-up onderzoek uitgevoerd wordt om de farmacokinetiek, farmacodynamiek 
en verdraagzaamheid te beoordelen van een dosisverhoging tot 600 of 800 mg 
moxifloxacine wanneer het gecombineerd wordt met rifampicine of andere 
rifamycinederivaten.
Deel II
Farmacokinetische determinanten van suboptimale respons op 
tuberculosebehandeling
Om de tuberculosebehandeling te optimaliseren is een beter begrip van de 
farmacokinetiek van de tuberculosegeneesmiddelen benodigd. Meer beschrijvende 
farmacokinetische data van tuberculosepatiënten zouden verkregen moeten 
worden, determinanten die geassocieerd zijn met de farmacokinetiek van 
tuberculosegeneesmiddelen zouden geïdentificeerd moeten worden en 
interventies moeten worden uitgevoerd om plasma geneesmiddelconcentraties te 
optimaliseren. 
In Hoofdstuk 4 werd de farmacokinetiek van rifampicin, isoniazide, pyrazinamide, 
ethambutol en moxifloxacine beschreven in een cohort van tuberculosepatiënten 
die opgenomen waren in de twee tuberculose verwijsklinieken in Nederland. 
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Daarnaast werden mogelijke determinanten van farmacokinetische parameters 
geëvalueerd. Eenenveertig patiënten werden geïncludeerd in het onderzoek. 
Rifampicine liet de grootste interindividuele variatie in farmacokinetiek zien. 
Ongeveer 30% van de patiënten die de reguliere dosis van rifampicine (10 mg/
kg) innam, behaalde de minimum referentie plasma piekconcentratie niet. 
Onze resultaten suggereren verder dat pyrazinamide de plasmaconcentraties 
van rifampicine kan verlagen. De interactie tussen moxifloxacin en rifampicine 
(Hoofdstuk 3) werd bevestigd in dit cohort van Nederlandse patiënten. Ethambutol 
werd geassocieerd met een verhoogde blootstelling aan pyrazinamide en roken werd 
geassocieerd met gereduceerde blootstelling aan ethambutol. De concentratie op twee 
uur na geneesmiddelinname (C2u) van rifampicine, pyrazinamide, moxifloxacine, 
maar niet van ethambutol correleert met Cmax en AUC. Dit betekent dat de 
laatste farmacokinetische parameters met een enkele monstername kunnen 
worden geschat. De betekenis van deze beschrijvende bevindingen en 
determinanten zou in in grotere patiëntenaantallen in farmacokinetische en 
farmacodynamische studies onderzocht moeten worden.
In Hoofdstuk 5 werden de plasma concentraties van rifampicine in Indonesische 
tuberculosepatiënten met en zonder type 2 diabetes vergeleken. Wereldwijd neemt 
type 2 diabetes  toe, met name in ontwikkelingslanden waar tuberculose endemisch 
is. Diabetes compromitteert de respons op de tuberculosebehandeling en wij 
onderzochten of dit aan lagere concentraties rifampicine te wijten zou kunnen zijn. 
De blootstelling aan rifampicin bleek inderdaad 53% lager te zijn in Indonesische 
tuberculosepatiënten met diabetes, vergeleken met tuberculosepatiënten zonder 
diabetes. Op dezelfde manier was de Cmax van rifampicin boven de doelconcentratie 
van 8 mg/l in slechts één van de zeventien (6%) tuberculosepatiënten met diabetes, 
in vergelijking met acht van zeventien (47%) patiënten zonder diabetes. Multivariate 
analyse openbaarde dat een hoger lichaamsgewicht en de aanwezigheid van diabetes 
tot lagere blootstelling aan rifampicine bijdroegen. Bovendien werd hyperglycemie 
geassocieerd met de lagere plasma concentraties van rifampicine. De bevindingen 
van deze studie suggereren dat de ongunstige respons van patiënten met type 2 
diabetes op zijn minst gedeeltelijk door verschillen in farmacokinetiek verklaard kan 
worden. Tuberculosepatiënten met type 2 diabetes  en een hoger lichaamsgewicht 
hebben mogelijk een hogere dosis rifampicin nodig. Aanvullend onderzoek zou de 
invloed van diabetes of de  behandeling van diabetes op de farmacokinetiek van 
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de tuberculosegeneesmiddelen en op het resultaat van de tuberculosebehandeling 
inzichtelijk moeten maken.  
Deel III
Geneesmiddelinteracties in de behandeling van TB-HIV co-infectie 
Ongeveer één derde van de 40 miljoen mensen die wereldwijd met HIV/AIDS 
leven, is ook besmet met de tuberculosebacterie. De Wereldgezondheidsorganisatie 
(de WHO) adviseert om in TB-HIV gecoinfecteerde patiënten de op rifampicine 
gebaseerde tuberculosebehandeling te combineren met antiretrovirale therapie 
die op non-nucleoside reverse transcriptase inhibitors (NNRTIs) is gebaseerd. Voor 
patiënten met NNRTI-resistente HIV of patiënten die in verband met bijwerkingen 
geen NNRTIs kunnen nemen, kunnen de antiretrovirale proteaseremmers (PIs), zoals 
lopinavir/ritonavir, een alternatief zijn. Eerder onderzoek in gezonde vrijwilligers 
heeft aangetoond dat een verhoogde dosering van lopinavir/ritonavir zachte 
gelcapsules de interactie met rifampicin kan compenseren. De farmacokinetische 
interactiestudie in Hoofdstuk 6 liet een hoge incidentie van bijwerkingen zien in 11 
gezonde vrijwilligers die met een hogere dosis dan de standaarddosis van de nieuwe 
lopinavir/ritonavir tabletten in combinatie met rifampicin werden behandeld. De 
studie moest vroegtijdig worden beëindigd na toevoeging van 600/150 of 800/200 
mg lopinavir/ritonavir tweemaal dagelijks aan rifampicine. 
Acht deelnemers hadden zowel last van misselijkheid als braken, één deelnemer 
was alleen misselijk. Bovendien werden leverenzymverhogingen bij alle deelnemers 
gerapporteerd. Alle verhogingen waren binnen zes weken genormaliseerd. Deze 
toxiciteit kan door drie mogelijke hypothesen worden verklaard. Ten eerste werd 
rifampicine voorafgaand aan lopinavir/ritonavir geïntroduceerd - deze volgorde 
werd in een vergelijkbaar onderzoek in gezonde vrijwilligers ook geassocieerd met 
vroegtijdige beëindiging van het onderzoek; ten tweede, de hogere dosering van 
lopinavir/ritonavir werd niet langzaam opgebouwd, maar ineens toegepast; en ten 
derde, werd de nieuwe lopinavir/ritonavir tabletformulering gebruikt in plaats van 
de capsuleformulering. Wij adviseerden dat verdere studies die de interactie tussen 
rifampicin en tabletten lopinavir/ritonavir onderzoeken beter in de daadwerkelijke 
doelgroep van TB-HIV besmette patiënten dan in gezonde vrijwilligers kunnen 
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worden uitgevoerd. Extreme voorzichtigheid en intensief toezicht op leverenzymen 
zijn noodzakelijk wanneer lopinavir/ritonavir en rifampicin in TB-HIV geco-
infecteerde patiënten worden gecombineerd.
Hoofdstuk 7 beschrijft de klinische ervaring met het gecombineerde gebruik van 
lopinavir/ritonavir en rifampicine in Nederland. Vierendertig volwassen HIV 
besmette patiënten werden geselecteerd uit het Nederlandse ATHENA cohort voor 
retrospectieve analyse. In totaal gebruikte slechts 15% een aanbevolen verhoogde 
dosis lopinavir/ritonavir. De plasmadalconcentraties van lopinavir tijdens het 
gecombineerd gebruik waren beschikbaar voor 6 van 23 (26%) patiënten op een niet-
aangepaste dosis lopinavir/ritonavir, voor geen van de 6 patiënten op een lichtjes 
aangepaste dosis en 2 van 5 (40%) patiënten op een geadviseerde dosis. Vier van 
de 6 (67%) patiënten op een niet-aangepaste dosis lopinavir/ritonavir hadden een 
subtherapeutische lopinavir plasmadalconcentratie (< 1.0 mg/l), terwijl de 2 patiënten 
op een geadviseerde dosis een therapeutische plasmaconcentratie hadden. In totaal 
werd bij 7 van de 34 (21%) patiënten de geneesmiddelcombinatie vroegtijdig gestopt 
wegens acute bijwerkingen; dit was bij 4 van 23 (17%) op een niet-aangepaste dosis, 
1 van 6 (17%) op een licht verhoogde dosis en 2 van 5 (40%) op een geadviseerde dosis 
lopinavir/ritonavir. Op basis van dit onderzoek werd geconcludeerd dat een kleine 
minderheid van de HIV-besmette patiënten in Nederland werd behandeld met de 
geadviseerde verhoogde dosis lopinavir/ritonavir in combinatie met rifampicin. 
Dit werd geassocieerd met inferieure blootstelling aan lopinavir en misschien 
virologisch falen. Gecombineerd gebruik van lopinavir/ritonavir en rifampicin blijft 
een uitdaging. 
Algemene discussie
In de algemene discussie worden onze klinisch farmacokinetische studies over de 
lange duur van de huidige tuberculosebehandeling (Deel I), de farmacokinetische 
determinanten van suboptimale respons (Deel II) en de gecombineerde behandeling 
van TB-HIV co-infectie (Deel III) in perspectief geplaatst. De recente ontwikkelingen 
en studies die door anderen zijn uitgevoerd worden beschreven en het perspectief 
voor de toekomst wordt besproken. 
Aangezien de meerderheid van de onderzoeken in dit proefschrift in Indonesië 
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werd uitgevoerd, wordt in de discussie aandacht besteed aan onderzoek in 
ontwikkelingslanden. Er werd opgemerkt dat het onderzoek in ontwikkelingslanden 
zou moeten bijdragen tot het dichten van de kloof tussen geïndustrialiseerde 
en ontwikkelingslanden betreffende levensstandaard en met name toegang tot 
gezondheidszorg. De implementatie van klinisch onderzoek zou de lokale reeds 
bestaande gezondheidszorg niet moeten verstoren. Voorts verdienen verscheidene 
andere kwesties, zoals stigma, financiële compensatie en aansprakelijk heids-
verzekering aandacht bij het uitvoeren van klinische studies in ontwikkelingslanden 
en in andere culturen. 
De wereldwijde mortaliteit ten gevolge van tuberculose laat zien dat optimalisering 
van tuberculosebehandeling dringend nodig is. Het lijkt onrealistisch dat er op korte 
termijn nieuwe geneesmiddelen beschikbaar komen die dit doel zouden kunnen 
verwezenlijken. Verbeterd gebruik van bestaande geneesmiddelen zou kunnen 
leiden tot verkorting van de tuberculosebehandeling. 
In de komende jaren zullen al onze acties en reacties op tuberculose beslissend 
zijn voor het lot van de huidige en toekomstige tuberculosepatiënten wereldwijd. 
Kwaliteit en kwantiteit van de diagnostische en therapeutische faciliteiten 
van gezondheidszorgcentra in de meest belaste gebieden zijn cruciaal voor een 
succesvolle strijd tegen tuberculose. 
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Dankwoord
Dit promotie-onderzoek, en daarmee dit proefschrift, is het product van de 
succesvolle samenwerking van een heel aantal mensen, welke ik hierbij graag 
zou willen bedanken. Bijzonder aan dit promotie-onderzoek is dat voorgenoemde 
mensen zich zowel in Nederland als in Indonesië bevinden. 
Dit onderzoek was niet mogelijk geweest zonder alle deelnemers aan de verschillende 
onderzoeken, de patiënten in zowel Indonesië als Nederland, en de gezonde 
vrijwilligers. Daarom wil ik hen als eerste danken voor hun trouwe deelname en 
medewerking aan de onderzoeken.
Een aantal mensen wil ik ook persoonlijk bedanken voor hun bijdrage. Allereerst 
mijn promotor, prof. dr. Hekster. Beste Chiel, dank voor je creatieve benadering en je 
laagdrempeligheid. Een overleg met jou leverde altijd nieuwe en verfrissende ideeën 
op en ik ben je daar zeer erkentelijk voor. 
Dr. R.E. Aarnoutse, copromotor, beste Rob, dank voor je begeleiding. Je grondigheid 
is absoluut onovertroffen en hebben de artikelen stuk voor stuk verfraaid. Ik heb je 
als een erg fijne begeleider ervaren. 
Dr. R. van Crevel, copromotor, beste Reinout, je bevlogenheid en enthousiasme voor 
het onderzoek en met name het onderzoek in Indonesië is bewonderenswaardig. Ik 
wens je (nog) heel veel succes en plezier in Indonesië de komende tijd. 
Rovina Ruslami, dear Nina, thank you for being my ‘twin-partner’ from Indonesia. 
I cherish many good memories of us working (and having fun at the same time) 
at your table in your house at Jalan Eykman. Thank you and your family for your 
hospitality. You have taught me a lot about the Indonesian culture, and I think 
your flexibility to adapt anywhere in the world is admirable. I hope we will keep 
in touch!
Dr. D.M. Burger, beste David, als copromotor van Rafaëlla en tijdens het schrijven van 
de HIV-TB artikelen, heb ik je leren kennen als een echte onderzoeker en inspirerend 
begeleider.
dankwoord
Nijland.1046-Proefschrift.indd   186 07-04-2009   15:41:57
187
Oud-collega onderzoekers: Jackie, Manon, jullie gingen me voor in het promotie-
traject. Veel dank voor alle interesse, ervaringen en tips!
Rafaëlla, wij zijn gedurende onze promotie-tijd kamergenoten geweest en hoewel jij 
HIV onderzoek in Tanzania deed, en ik natuurlijk TB onderzoek in Indonesië, bleek 
het onbetaalbaar prettig om al het promotie lief en leed met elkaar te kunnen delen! 
Heel veel geluk met jullie jonge gezinnetje en in je nieuwe baan in Maastricht. 
Roger, Matthijs, jullie kwamen wat later in beeld als promovendus in de apotheek 
en brachten de man-vrouw verhouding in het onderzoeksgroepje weer een beetje 
in evenwicht. Dank voor de gezelligheid en ik wens jullie veel succes met jullie 
promoties!
Quirine, erg geestig dat wij elkaar in Indonesië via via hebben leren kennen en dat 
jij nu aan ‘mijn’ bureau zit in de apotheek. Nu ga je een ander continent ontdekken; 
heel veel succes met je onderzoek op het HIV gebied in Afrika!
Remco de Jong, afdelingshoofd Apotheek/ Klinische Farmacie: promoveren op een 
armoedegerelateerde ziekte is op zichzelf al erg bijzonder en daarbij kwamen de 
regelmatige werkbezoeken aan Indonesië waar ik enorm van genoten heb. Dank 
voor deze bijzondere en leerzame ervaring.
De analisten van het Laboratorium Klinische Farmacie ben ik zeer erkentelijk voor 
de vele metingen van alle PK monsters. Peter Diebels, hartelijk dank voor het fijne 
en snelle inplannen van de metingen van de onderzoeksmonsters. Marga en Elly, 
veel dank voor jullie enthousiasme voor het TB onderzoek en het opzetten van de 
analysemethode voor rifampicine en moxifloxacine! 
Anita Huisman, dank voor je hulp bij het opzetten van het Daktari onderzoek. 
Het was erg prettig samenwerken met jou. 
Alle collega’s uit de apotheek wil ik graag danken voor de interesse in mijn onderzoek! 
Andre van der Ven, directeur van PRIOR, wil ik danken voor de mogelijkheid om zo 
een bijzonder promotietraject in te gaan. 
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De PRIOR-office in Nederland, Henri van Asten wil ik danken en (destijds) Clara 
Blaauw, Mieke Daalderop en Carla Ysenbrandt in het bijzonder voor de fijne 
organisatie van mijn werkbezoeken aan Indonesië. 
Bachti Alisjahbana, dear Bachti, besides a very involved almost all-round researcher, 
you are also a fantastic people manager. I wish you all the best in all your activities, 
including in your NGO. 
Ida Parwati, dear Ida, thank you very much for your help and assistance in all our 
studies in Bandung. Your activities in both Indonesia and the Netherlands are 
admirable. 
Dr. Hedy Sampoerno from the Bandung Lung Clinic, also known as BP4, thank you 
very much for your support for all research we were able to conduct in your clinic. 
Hopefully, the patients are the ones who will finally profit from all our efforts.
Dr. Hadi Yusuf, PRIOR contact person from the very beginning, terima kasih. Thank 
you for your warm welcomes to Indonesia, I still remember your attentive small 
presents (oleh-oleh) at my first visit to Bandung. 
The studies presented in this thesis and performed in Indonesia could not have taken 
place without the help of many. I would especially like to thank Dewi, Ita and Lika: 
thanks to your involvement we could perform all studies during the weekends. 
Terima kasih banyak. 
Prof. Nelwan, Janneke Stalenhoef en Erni Nelwan, dankzij jullie doortastendheid 
konden we in onvoorstelbaar korte tijd de TB-DM PK-substudie (hoofdstuk 5) 
opzetten en uitvoeren in Jakarta. Het was een vermoeiende, maar onvergetelijke 
periode, en het is een hoofdstuk geworden om trots op te zijn!
Dr. Arto Juwono Suroto and Regina Loprang, I am very happy we met in Bandung 
and I honestly hope we, together with my friends Janneke Stalenhoef and Marie-
Chantal Canoy, can collaborate and improve access to TB treatment by means of the 
TIBI foundation! 
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Wiel de Lange, Martin Boeree en Cecile Magis, dank voor al jullie hulp en 
inspanningen met betrekking tot de Dekkerswald-Beatrixoord studie (Hoofdstuk 4). 
Martin, ik heb erg genoten van je immer positieve instelling en je gave om elke 
bijeenkomst een vrolijke noot mee te geven! Cecile, het was fijn met jou te kunnen 
overleggen en ik wens je heel veel succes met je promotie-onderzoek! 
Richard van Altena, dank voor je duizendpoot-achtige inzet in de studie in 
Beatrixoord. Ik heb bewondering voor de manier waarop je je zowel in medisch als 
sociaal opzicht, samen met Tjip van der Werf en alle verpleegkundigen, inzet voor de 
patiënten in Beatrixoord. Tjip en Gieneke, veel dank voor jullie gastvrijheid tijdens 
de Beatrixoord studiedagen. 
Janita Kuijper, veel dank voor je hulp tijdens voorgenoemd onderzoek!  
De medewerkers van het Clinical Research Centre Nijmegen wil ik danken voor hun 
bijdrage aan de uitvoering van het onderzoek in gezonde vrijwilligers (Hoofdstuk 6).
Alle andere co-auteurs die ik nog niet genoemd heb, wil ik danken voor hun bijdragen 
aan de opzet, uitvoering en publicatie van de verschillende onderzoeken.
De financiering van dit onderzoek, vallend onder PRIOR project 2, werd mogelijk 
gemaakt door NWO-WOTRO (WB  98-158), ZonMW (907-00-100) en de Stichting 
Klinisch Farmaceutische Dienstverlening. 
Verder wil ik de leden van de manuscriptcommissie, prof. dr. J.W.M. van der Meer, 
prof. dr. H.J. Guchelaar, prof. dr. T.S. van der Werf, bedanken voor het bestuderen en 
beoordelen van dit proefschrift. 
Bij deze wil ik ook mijn collega’s bij de Inspectie voor de Gezondheidszorg bedanken 
voor hun medeleven en begrip voor het afronden van het promotietraject!
Familie en vrienden, dank voor al jullie interesse in mijn promotie-onderzoek en 
mijn Indonesische verhalen. 
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Paranimfen Janneke en Jan Martijn. Janneke, wij hebben elkaar ontmoet in 
Indonesië en bleken naast onze bijna identieke voornamen veel meer te delen, 
waardoor een heel bijzondere vriendschap is ontstaan die ik zeer waardeer. 
Jan Martijn, lieve broer, ik vind het heel fijn te weten dat je op een bijzondere dag 
als vandaag achter mij staat!  
Papa en mama, jullie hebben me altijd gestimuleerd en gesteund in zaken waarvan ik 
vond dat ik ze moest doen, ook al leken die soms bijna niet mogelijk. Ik ben erg blij met 
jullie positieve instelling, die ik van jullie geërfd lijk te hebben. Dankzij jullie was alles 
mogelijk, zolang je maar wilt, en daar ben ik jullie ontzettend dankbaar voor. 
Jan Martijn, broer, dank voor je nuchterheid en ondersteuning! De volgende keer dat 
ik naar Indonesië reis, ga je mee!
Mijn schoonouders wil ik danken voor hun interesse en support, ik heb geboft met 
jullie! 
Lieve Jan-Willem, dank voor je onvoorwaardelijke steun, je realisme en je eerlijkheid. 
We gaan nu samen aan een nieuw avontuur beginnen, ze trappelen al van ongeduld 
in mijn buik…! 
dankwoord
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Hanneke Martine Jolande Later-Nijland werd op 10 december 1977 te Zwolle 
geboren. Ze groeide op in Zwolle en behaalde in 1997 het VWO diploma aan de 
Thorbecke Scholengemeenschap. Aansluitend aan haar eindexamen startte zij 
met de studie Farmacie (nu: Farmaceutische Wetenschappen) aan de Universiteit 
Utrecht. In 1999 begon zij met de studie Rechtsgeleerdheid aan dezelfde universiteit. 
Ter afsluiting van de doctoraalopleiding Farmacie volgde Hanneke een 
wetenschappelijke stage aan ‘The Biotechnology Centre of Oslo’ (BiO) te Oslo, 
Noorwegen. Op 29 januari 2003 behaalde ze het doctoraalexamen Farmacie. Ter 
afsluiting van de apothekersopleiding volgde ze een stage in ‘The Diocesan Hospital 
Pharmacy’ in Kumasi, Ghana. Het apothekersexamen werd behaald op 26 augustus 
2004. In oktober 2004 startte zij met haar promotie-onderzoek op het gebied van 
tuberculosebehandeling (promotor: Prof. Dr. Y.A. Hekster) bij de afdeling Apotheek/
Klinische Farmacie van het UMC St Radboud te Nijmegen en binnen het Indonesisch-
Tanzaniaans-Nederlandse onderzoeksnetwerk ‘PRIOR’ (Poverty Related Infection 
Oriented Research). 
Op 31 augustus 2006 behaalde Hanneke het doctoraalexamen Rechtsgeleerdheid. 
In april 2008 startte zij als Inspecteur Klinisch onderzoek en Farmacovigilantie bij 
de Inspectie voor de Gezondheidszorg (IGZ) in Den Haag. Hanneke is getrouwd met 
Jan-Willem, zij wonen in Den Haag en verwachten in maart 2009 een tweeling. 
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